NZ756260B2 - Liquid protein formulations containing viscosity-lowering agents - Google Patents
Liquid protein formulations containing viscosity-lowering agentsInfo
- Publication number
- NZ756260B2 NZ756260B2 NZ756260A NZ75626014A NZ756260B2 NZ 756260 B2 NZ756260 B2 NZ 756260B2 NZ 756260 A NZ756260 A NZ 756260A NZ 75626014 A NZ75626014 A NZ 75626014A NZ 756260 B2 NZ756260 B2 NZ 756260B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- viscosity
- protein
- formulation
- liquid pharmaceutical
- pharmaceutical formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 296
- 239000007788 liquid Substances 0.000 title claims abstract description 85
- 102000004169 proteins and genes Human genes 0.000 title description 261
- 108090000623 proteins and genes Proteins 0.000 title description 261
- 102000004965 antibodies Human genes 0.000 claims abstract description 74
- 108090001123 antibodies Proteins 0.000 claims abstract description 74
- 229960003495 thiamine Drugs 0.000 claims abstract description 30
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011721 thiamine Substances 0.000 claims abstract description 17
- 235000019157 thiamine Nutrition 0.000 claims abstract description 17
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 12
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 5
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 5
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 237
- 238000009472 formulation Methods 0.000 claims description 127
- 239000003814 drug Substances 0.000 claims description 106
- -1 poly(ethylene glycol) Polymers 0.000 claims description 85
- 239000011780 sodium chloride Substances 0.000 claims description 73
- 239000007924 injection Substances 0.000 claims description 71
- 238000002347 injection Methods 0.000 claims description 59
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 55
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 47
- 150000002500 ions Chemical class 0.000 claims description 25
- 239000000546 pharmaceutic aid Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 229920000136 polysorbate Polymers 0.000 claims description 9
- 230000003003 lyoprotectant Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002335 preservative Effects 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229950008882 Polysorbate Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229940071643 Prefilled Syringe Drugs 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 229940090047 Auto-Injector Drugs 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 230000001082 cryoprotectant Effects 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 210000002966 Serum Anatomy 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 101700082413 tant Proteins 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 57
- 238000001802 infusion Methods 0.000 abstract description 33
- 235000018102 proteins Nutrition 0.000 description 260
- 239000000243 solution Substances 0.000 description 105
- 239000008363 phosphate buffer Substances 0.000 description 88
- 239000007864 aqueous solution Substances 0.000 description 75
- 235000002639 sodium chloride Nutrition 0.000 description 65
- 229940120638 Avastin Drugs 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 55
- 229940082789 Erbitux Drugs 0.000 description 49
- 230000001225 therapeutic Effects 0.000 description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- 230000000694 effects Effects 0.000 description 40
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 39
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 34
- 230000001603 reducing Effects 0.000 description 34
- 229940116176 Remicade Drugs 0.000 description 31
- 101710004602 SLC11A1 Proteins 0.000 description 29
- 238000006722 reduction reaction Methods 0.000 description 28
- 229940079593 drugs Drugs 0.000 description 27
- 230000001965 increased Effects 0.000 description 27
- 210000004027 cells Anatomy 0.000 description 26
- 230000035492 administration Effects 0.000 description 25
- 230000027455 binding Effects 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 238000003860 storage Methods 0.000 description 23
- 239000002253 acid Substances 0.000 description 22
- 238000007920 subcutaneous administration Methods 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- 239000004475 Arginine Substances 0.000 description 19
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 19
- 229960003121 arginine Drugs 0.000 description 19
- 235000012970 cakes Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 239000012530 fluid Substances 0.000 description 17
- 230000002829 reduced Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229940022353 Herceptin Drugs 0.000 description 16
- 239000000825 pharmaceutical preparation Substances 0.000 description 16
- 108010053490 Infliximab Proteins 0.000 description 15
- 108010010691 Trastuzumab Proteins 0.000 description 15
- 229960000575 trastuzumab Drugs 0.000 description 15
- 108010022830 Cetuximab Proteins 0.000 description 14
- 229940068968 Polysorbate 80 Drugs 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000038129 antigens Human genes 0.000 description 14
- 108091007172 antigens Proteins 0.000 description 14
- 229960005395 cetuximab Drugs 0.000 description 14
- 229960000598 infliximab Drugs 0.000 description 14
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 14
- 229920000053 polysorbate 80 Polymers 0.000 description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- 229960003589 Arginine hydrochloride Drugs 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
- 229940003641 Rituxan Drugs 0.000 description 12
- 229940079023 Tysabri Drugs 0.000 description 12
- 229960000074 biopharmaceuticals Drugs 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 230000003247 decreasing Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 11
- 229960000106 biosimilars Drugs 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 229940110584 Arzerra Drugs 0.000 description 10
- 229940088598 Enzyme Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 10
- 229960002450 Ofatumumab Drugs 0.000 description 10
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 229960003646 lysine Drugs 0.000 description 10
- 235000018977 lysine Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108010052070 ofatumumab Proteins 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229940109239 Creatinine Drugs 0.000 description 9
- 241001527806 Iti Species 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 9
- 206010025135 Lupus erythematosus Diseases 0.000 description 9
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 9
- 108010001645 Rituximab Proteins 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 229940058865 Vectibix Drugs 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 229960004919 procaine Drugs 0.000 description 9
- 239000012460 protein solution Substances 0.000 description 9
- 229960004641 rituximab Drugs 0.000 description 9
- 239000012064 sodium phosphate buffer Substances 0.000 description 9
- 230000036912 Bioavailability Effects 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 108010035649 Natalizumab Proteins 0.000 description 8
- 108010061219 Panitumumab Proteins 0.000 description 8
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 230000035514 bioavailability Effects 0.000 description 8
- 230000002354 daily Effects 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037240 fusion proteins Human genes 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 229960005027 natalizumab Drugs 0.000 description 8
- 229960001972 panitumumab Drugs 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 230000003442 weekly Effects 0.000 description 8
- 108010005144 Bevacizumab Proteins 0.000 description 7
- 102100010782 EGFR Human genes 0.000 description 7
- 101700039191 EGFR Proteins 0.000 description 7
- 230000035693 Fab Effects 0.000 description 7
- 229960002885 Histidine Drugs 0.000 description 7
- 102000002265 Human Growth Hormone Human genes 0.000 description 7
- 108010000521 Human Growth Hormone Proteins 0.000 description 7
- 239000000854 Human Growth Hormone Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004429 atoms Chemical group 0.000 description 7
- 229960000397 bevacizumab Drugs 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 108091006028 chimera Proteins 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 229950008597 drug INN Drugs 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 7
- 230000002209 hydrophobic Effects 0.000 description 7
- 239000002050 international nonproprietary name Substances 0.000 description 7
- 229960000060 monoclonal antibodies Drugs 0.000 description 7
- 230000003204 osmotic Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 101710027066 ALB Proteins 0.000 description 6
- 108010004463 Abciximab Proteins 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 6
- 229960002363 Thiamine Pyrophosphate Drugs 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- 229960000446 abciximab Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 229910052798 chalcogen Inorganic materials 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 230000002427 irreversible Effects 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000009522 phase III clinical trial Methods 0.000 description 6
- 239000011678 thiamine pyrophosphate Substances 0.000 description 6
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 6
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 6
- 229960005267 tositumomab Drugs 0.000 description 6
- 108010026410 Ado-Trastuzumab Emtansine Proteins 0.000 description 5
- 206010003816 Autoimmune disease Diseases 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 229920002574 CR-39 Polymers 0.000 description 5
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 5
- 108010084740 Daclizumab Proteins 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 229960001375 Lactose Drugs 0.000 description 5
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010019613 Palivizumab Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 229940068977 Polysorbate 20 Drugs 0.000 description 5
- 229910006069 SO3H Inorganic materials 0.000 description 5
- 102100015249 VEGFA Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000000975 bioactive Effects 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001787 chalcogens Chemical class 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 229960002806 daclizumab Drugs 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000002608 ionic liquid Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229960000402 palivizumab Drugs 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 230000035533 AUC Effects 0.000 description 4
- 206010072599 Amyloid related imaging abnormality Diseases 0.000 description 4
- 229960001950 Benzethonium Chloride Drugs 0.000 description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N Cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 4
- 210000000170 Cell Membrane Anatomy 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 206010011401 Crohn's disease Diseases 0.000 description 4
- 229940073621 Enbrel Drugs 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 4
- 229960003727 Granisetron Drugs 0.000 description 4
- 230000036499 Half live Effects 0.000 description 4
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- SYPJAQDFAJIVOU-ZSCHJXSPSA-N NCCCC[C@H](N)C(O)=O.CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2 Chemical compound NCCCC[C@H](N)C(O)=O.CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2 SYPJAQDFAJIVOU-ZSCHJXSPSA-N 0.000 description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 4
- 108091005990 PEGylated Proteins Proteins 0.000 description 4
- 229960001376 Pegloticase Drugs 0.000 description 4
- 108010068701 Pegloticase Proteins 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 229940068638 Simponi Drugs 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229960002833 aflibercept Drugs 0.000 description 4
- 108010081667 aflibercept Proteins 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960002328 chloroquine phosphate Drugs 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 230000002132 lysosomal Effects 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 108010042024 pertuzumab Proteins 0.000 description 4
- 229960002087 pertuzumab Drugs 0.000 description 4
- 230000003285 pharmacodynamic Effects 0.000 description 4
- 230000036231 pharmacokinetics Effects 0.000 description 4
- 229960002292 piperacillin Drugs 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 231100000161 signs of toxicity Toxicity 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 108010078548 tocilizumab Proteins 0.000 description 4
- 229960003989 tocilizumab Drugs 0.000 description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- 210000003719 B-Lymphocytes Anatomy 0.000 description 3
- 229940022836 Benlysta Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 3
- 229960001139 Cefazolin Drugs 0.000 description 3
- 108010070202 Certolizumab Pegol Proteins 0.000 description 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- JMANVNJQNLATNU-UHFFFAOYSA-N Cyanogen Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 3
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 3
- 108010043242 Denosumab Proteins 0.000 description 3
- 102100010813 EGF Human genes 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 102000027760 ERBB2 Human genes 0.000 description 3
- 101700025368 ERBB2 Proteins 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108091006004 Fc-tagged proteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 206010018987 Haemorrhage Diseases 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- 229950003818 Itolizumab Drugs 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 3
- YKQOSKADJPQZHB-QNPLFGSASA-N N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2- Chemical class CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-QNPLFGSASA-N 0.000 description 3
- QJNLOHOBGVRMHV-LKZWMPDMSA-N N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.OC(=O)C=1C(O)=CC=C(S(=O)(=O)O)C1 Chemical compound N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.OC(=O)C=1C(O)=CC=C(S(=O)(=O)O)C1 QJNLOHOBGVRMHV-LKZWMPDMSA-N 0.000 description 3
- 229950010203 Nimotuzumab Drugs 0.000 description 3
- 229910018828 PO3H2 Inorganic materials 0.000 description 3
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229950003238 Rilotumumab Drugs 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229940036185 Synagis Drugs 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 241000822135 Ula Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 108091008116 antibody drug conjugates Proteins 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000008228 bacteriostatic water for injection Substances 0.000 description 3
- 108010051561 belimumab Proteins 0.000 description 3
- 229960003270 belimumab Drugs 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 230000000740 bleeding Effects 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004432 carbon atoms Chemical group C* 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960003115 certolizumab pegol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229960001251 denosumab Drugs 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 108010063231 eculizumab Proteins 0.000 description 3
- 229960002224 eculizumab Drugs 0.000 description 3
- 238000002641 enzyme replacement therapy Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 229940031098 ethanolamine Drugs 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 229960004222 factor IX Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 229960004859 glucarpidase Drugs 0.000 description 3
- 108010049491 glucarpidase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108010056290 itolizumab Proteins 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 3
- 229960002409 mepivacaine Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229960003702 moxifloxacin Drugs 0.000 description 3
- 108010043585 nimotuzumab Proteins 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000000069 prophylaxis Effects 0.000 description 3
- 201000004681 psoriasis Diseases 0.000 description 3
- 108010011457 rilotumumab Proteins 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- YOBPSXOHCHDCMU-IXIFSOOLSA-M sodium;(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical class [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(O)=NN1C YOBPSXOHCHDCMU-IXIFSOOLSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 229960001612 trastuzumab emtansine Drugs 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- ARHYWWAJZDAYDJ-UHFFFAOYSA-N 1,2-dimethylpiperazine Chemical compound CC1CNCCN1C ARHYWWAJZDAYDJ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-Methylimidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- IPWKIXLWTCNBKN-UHFFFAOYSA-N 1-[3-Chloro-2-hydroxypropyl]-2-methyl-5-nitroimidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 description 2
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 2
- QWOLGQYXAQSNAE-UHFFFAOYSA-N 2-[[7-bromo-3-(2-fluorophenyl)-1,2-benzoxazol-6-yl]oxy]acetic acid Chemical compound N=1OC2=C(Br)C(OCC(=O)O)=CC=C2C=1C1=CC=CC=C1F QWOLGQYXAQSNAE-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N 52232-67-4 Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710034857 ATIC Proteins 0.000 description 2
- 229940022663 Acetate Drugs 0.000 description 2
- 229940119059 Actemra Drugs 0.000 description 2
- 229950004283 Actoxumab Drugs 0.000 description 2
- 229940035938 Adcetris Drugs 0.000 description 2
- 102000009914 Adenosine deaminases Human genes 0.000 description 2
- 108091022188 Adenosine deaminases Proteins 0.000 description 2
- 108010090838 Alemtuzumab Proteins 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 Aztreonam Drugs 0.000 description 2
- 229950002584 BROCRINAT Drugs 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229950008086 Bezlotoxumab Drugs 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 2
- 229960000455 Brentuximab vedotin Drugs 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229940112129 Campath Drugs 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229960002682 Cefoxitin Drugs 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 Cimetidine Drugs 0.000 description 2
- 229940090100 Cimzia Drugs 0.000 description 2
- 229960003324 Clavulanic Acid Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- 102000013831 Coagulation factor IX Human genes 0.000 description 2
- 206010009887 Colitis Diseases 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 229940079157 Eloctate Drugs 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 2
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 2
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 2
- 229950009760 Epratuzumab Drugs 0.000 description 2
- 108010066668 ErbB-2 Receptor Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229940051306 Eylea Drugs 0.000 description 2
- 102100000368 F8 Human genes 0.000 description 2
- 101700070229 F8 Proteins 0.000 description 2
- 102100006624 F9 Human genes 0.000 description 2
- 101710009074 FLT3 Proteins 0.000 description 2
- 229940014516 Fabrazyme Drugs 0.000 description 2
- 201000005603 Fabry disease Diseases 0.000 description 2
- 229960000301 Factor VIII Drugs 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960003082 Galactose Drugs 0.000 description 2
- 206010018048 Gaucher's disease Diseases 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 208000005017 Glioblastoma Diseases 0.000 description 2
- 229940097043 Glucuronic Acid Drugs 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 206010020243 Hodgkin's disease Diseases 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 2
- 108010079451 IMC-18F1 Proteins 0.000 description 2
- 108010024848 IMC-3G3 Proteins 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010089187 Ipilimumab Proteins 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 229940003703 Kuvan Drugs 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N Levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- 229940091827 Lumizyme Drugs 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 2
- 206010024579 Lysosomal storage disease Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000035888 Maximum plasma concentration Effects 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 229950010006 Olokizumab Drugs 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 229950004327 Ozoralizumab Drugs 0.000 description 2
- 102100005352 PCSK9 Human genes 0.000 description 2
- 101700000651 PCSK9 Proteins 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 229960001373 Pegfilgrastim Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229940039551 Perjeta Drugs 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 Phenylephrine Drugs 0.000 description 2
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 241000048284 Potato virus P Species 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O Pyridinium Chemical group C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 229960004910 Raxibacumab Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229950010316 Rontalizumab Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229950010077 Sifalimumab Drugs 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229940055944 Soliris Drugs 0.000 description 2
- 102100009493 TNFSF13B Human genes 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- CBPNZQVSJQDFBE-HGVVHKDOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N Tetrahydrobiopterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 2
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 2
- 229950000835 Tralokinumab Drugs 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 229940116269 Uric Acid Drugs 0.000 description 2
- 108091007928 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 229940014556 Xgeva Drugs 0.000 description 2
- 229940055760 Yervoy Drugs 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108010080226 actoxumab Proteins 0.000 description 2
- 229940089792 ado-trastuzumab emtansine Drugs 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229960004593 alglucosidase alfa Drugs 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 108010067114 bezlotoxumab Proteins 0.000 description 2
- 201000002393 blood protein disease Diseases 0.000 description 2
- 108010011709 brodalumab Proteins 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 2
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 229940105774 coagulation factor IX Drugs 0.000 description 2
- 201000011231 colorectal cancer Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 108010007604 epratuzumab Proteins 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical group C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002027 evolocumab Drugs 0.000 description 2
- 108010075853 evolocumab Proteins 0.000 description 2
- 201000003542 factor VIII deficiency Diseases 0.000 description 2
- 108010054491 factor VIII-Fc fusion protein Proteins 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108010086781 golimumab Proteins 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 201000005569 gout Diseases 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001024 immunotherapeutic Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 229940099563 lactobionic acid Drugs 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 2
- 229960001093 lixisenatide Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 2
- 230000001394 metastastic Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 201000005962 mycosis fungoide Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010082216 olokizumab Proteins 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229960002313 ornidazole Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960001045 piperocaine Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108010087730 raxibacumab Proteins 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 108010024190 rontalizumab Proteins 0.000 description 2
- 229960004617 sapropterin Drugs 0.000 description 2
- 108010037957 sifalimumab Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- FCPVYOBCFFNJFS-UHFFFAOYSA-M sodium;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].O=C1N2C(C([O-])=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003068 static Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108010037465 tralokinumab Proteins 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 108010035693 vedolizumab Proteins 0.000 description 2
- 229960004914 vedolizumab Drugs 0.000 description 2
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- HFQKBOPMAOTAIR-TZSVBWBLSA-N α-D-galactosyl-(1->4)-β-D-galactosyl-(1->4)-β-D-glucosylceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LSPHULWDVZXLIL-LDWIPMOCSA-N (1R,3S)-1,2,2-trimethylcyclopentane-1,3-dicarboxylic acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 1
- PQEJXGNZBLONLG-XJDOXCRVSA-N (2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O PQEJXGNZBLONLG-XJDOXCRVSA-N 0.000 description 1
- UGQOPAJHKRJXBG-ADKAHSJRSA-N (2R)-2-amino-3-[1-[3-[3-[2,3-bis(2-methoxyethoxy)propoxy]propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCOCC(OCCOC)COCCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O UGQOPAJHKRJXBG-ADKAHSJRSA-N 0.000 description 1
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- DAMLYUHJAAMPKB-FUCKFSFUSA-N (2R,3S)-N-[[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3-[(E)-hexadec-3-enyl]-2-hydroxytetracosanamide Chemical compound O[C@@H]1[C@@H](O)[C@H](OCNC(=O)[C@H](O)[C@H](CC\C=C\CCCCCCCCCCCC)CCCCCCCCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 DAMLYUHJAAMPKB-FUCKFSFUSA-N 0.000 description 1
- BXTJCSYMGFJEID-XMTADJHZSA-N (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-[3-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- PMOOKBAYUNEHOF-IKHMJLPLSA-N (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)OC1CC[C@]2(C)[C@H]3CCC=4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(CC1=4)(C)C)C(O)=O)C(O)=O)[C@@H]1CC[C@@H](O)[C@H](O)[C@H]1O PMOOKBAYUNEHOF-IKHMJLPLSA-N 0.000 description 1
- WMUIYURBHSELFV-NZODMTSUSA-N (3S)-4-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-4-amino-1-[[2-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 WMUIYURBHSELFV-NZODMTSUSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3S,3aR,6R,6aR)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- NWXMGUDVXFXRIG-PMXORCKASA-N (4R,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-PMXORCKASA-N 0.000 description 1
- GXXLUDOKHXEFBQ-YJFSRANCSA-N (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 GXXLUDOKHXEFBQ-YJFSRANCSA-N 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- LXLDMYXULSBRCX-HZEONMFJSA-N (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N1SC(N)=N\C1=C(\N=O)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(\C=C/3C(N([C@H]4CNCC4)CC\3)=O)CS[C@@H]21 LXLDMYXULSBRCX-HZEONMFJSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 1
- SQZCAOHYQSOZCE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N=C(N)N=C(N)N SQZCAOHYQSOZCE-UHFFFAOYSA-N 0.000 description 1
- WYTRYIUQUDTGSX-UHFFFAOYSA-N 1-phenylpropan-2-ol Chemical compound CC(O)CC1=CC=CC=C1 WYTRYIUQUDTGSX-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-N 2,3-dimethylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-N 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-Dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- CHZLVSBMXZSPNN-UHFFFAOYSA-N 2,4-dimethylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C(C)=C1 CHZLVSBMXZSPNN-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- AXFGWXLCWCNPHP-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound COCCNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCOC AXFGWXLCWCNPHP-UHFFFAOYSA-N 0.000 description 1
- DJQJFMSHHYAZJD-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,6-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC=CC(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O DJQJFMSHHYAZJD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GKWLIQDHWRWNRS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC(N)(CO)CO.OCCN1CCN(CCS(O)(=O)=O)CC1 GKWLIQDHWRWNRS-UHFFFAOYSA-N 0.000 description 1
- AKTFIQYVASYRMU-UHFFFAOYSA-N 2-aminoethanol;2,5-dihydroxybenzoic acid Chemical compound NCCO.OC(=O)C1=CC(O)=CC=C1O AKTFIQYVASYRMU-UHFFFAOYSA-N 0.000 description 1
- LBORPQYMABOVPW-UHFFFAOYSA-N 2-benzoyl-3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=CC=CC=C1 LBORPQYMABOVPW-UHFFFAOYSA-N 0.000 description 1
- MOEFFSWKSMRFRQ-UHFFFAOYSA-N 2-ethoxyphenol Chemical compound CCOC1=CC=CC=C1O MOEFFSWKSMRFRQ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- KQDVAKBJCMTTQE-UHFFFAOYSA-N 2H-thiopyran;hydrochloride Chemical compound Cl.C1SC=CC=C1 KQDVAKBJCMTTQE-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- SLYZGQVSYAQHRW-UHFFFAOYSA-N 3-[2-(2-propoxyethoxy)ethoxy]propan-1-amine Chemical compound CCCOCCOCCOCCCN SLYZGQVSYAQHRW-UHFFFAOYSA-N 0.000 description 1
- WWVAPFRKZMUPHZ-UHFFFAOYSA-N 3-[3-[2-[2-[2-[3-(3-carboxy-2,4,6-triiodoanilino)-3-oxopropoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-2,4,6-triiodobenzoic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I WWVAPFRKZMUPHZ-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N 3-acetyl-6-methylpyran-2,4-dione Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- WQPMYSHJKXVTME-UHFFFAOYSA-N 3-hydroxypropane-1-sulfonic acid Chemical compound OCCCS(O)(=O)=O WQPMYSHJKXVTME-UHFFFAOYSA-N 0.000 description 1
- 108010063357 3K3A-APC protein Proteins 0.000 description 1
- 101700019104 3SPM Proteins 0.000 description 1
- 101700016269 3SPT Proteins 0.000 description 1
- GICMHQJTKXNMGB-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)aniline Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N)C=C1 GICMHQJTKXNMGB-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-Aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- YEGPVWSPNYPPIK-UHFFFAOYSA-N 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O YEGPVWSPNYPPIK-UHFFFAOYSA-N 0.000 description 1
- JVZPYJSJSQIEOG-UHFFFAOYSA-N 4-imidazol-1-ylbutan-1-amine Chemical compound NCCCCN1C=CN=C1 JVZPYJSJSQIEOG-UHFFFAOYSA-N 0.000 description 1
- OSRVYZUNOKHKID-UHFFFAOYSA-N 4-imidazol-1-ylbutan-1-amine;dihydrochloride Chemical compound Cl.Cl.NCCCCN1C=CN=C1 OSRVYZUNOKHKID-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- IYYUWAULZBEIST-UHFFFAOYSA-N 4-pyridin-1-ium-1-ylpyridine Chemical compound C1=CC=CC=[N+]1C1=CC=NC=C1 IYYUWAULZBEIST-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- LMFAFFIRCNUJJO-UHFFFAOYSA-N 5-(4-azidophenyl)-8-iodo-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(I)=C(O)C=C2C1C1=CC=C(N=[N+]=[N-])C=C1 LMFAFFIRCNUJJO-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-α-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N 8-Hydroxyquinoline Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- 108091002522 AGS-16C3F Proteins 0.000 description 1
- 108010057854 ALT-801 Proteins 0.000 description 1
- 108010059766 AMG 139 Proteins 0.000 description 1
- 108091001400 AMG 557 Proteins 0.000 description 1
- 108010005567 AMG 595 Proteins 0.000 description 1
- 108010079335 AMG 745 Proteins 0.000 description 1
- 108010013271 AMG 811 Proteins 0.000 description 1
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 description 1
- 108010093583 ART123 Proteins 0.000 description 1
- 108091021646 ATX-MS-1467 Proteins 0.000 description 1
- 108010083275 AV-203 Proteins 0.000 description 1
- 108091000214 Abituzumab Proteins 0.000 description 1
- 229950005008 Abituzumab Drugs 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 229940099983 Activase Drugs 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 229940060205 Adagen Drugs 0.000 description 1
- 108010007562 Adalimumab Proteins 0.000 description 1
- 206010001150 Adenocarcinoma gastric Diseases 0.000 description 1
- 229940022705 Aldurazyme Drugs 0.000 description 1
- 229940071626 Alprolix Drugs 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 229950001537 Amatuximab Drugs 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N Aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N Ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002224 Anaplastic astrocytoma Diseases 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 229950006588 Anetumab ravtansine Drugs 0.000 description 1
- 229950010117 Anifrolumab Drugs 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 229950005794 Anrukinzumab Drugs 0.000 description 1
- 229940077770 Anthim Drugs 0.000 description 1
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 description 1
- 229960005475 Antiinfectives Drugs 0.000 description 1
- 229950006372 Antithrombin gamma Drugs 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- 241000006966 Areva Species 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 229960003554 Asfotase alfa Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229950009925 Atacicept Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 Atropine Drugs 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940003504 Avonex Drugs 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 108010025582 BAN2401 Proteins 0.000 description 1
- 108010019949 BAX 855 Proteins 0.000 description 1
- 108010089449 BAY 79-4620 Proteins 0.000 description 1
- 108010026955 BAY 94-9027 Proteins 0.000 description 1
- 108010049700 BHQ880 Proteins 0.000 description 1
- 108010007900 BIIB022 Proteins 0.000 description 1
- 108010038094 BIW-8962 Proteins 0.000 description 1
- 108091004904 BMN 250 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229950001863 Bapineuzumab Drugs 0.000 description 1
- 108010067213 Basiliximab Proteins 0.000 description 1
- 229950007843 Bavituximab Drugs 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N Benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229950000321 Benralizumab Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 206010061590 Blood disease Diseases 0.000 description 1
- 229950005042 Blosozumab Drugs 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 102100017562 C5AR1 Human genes 0.000 description 1
- 101700049499 C5AR1 Proteins 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 102100013077 CD4 Human genes 0.000 description 1
- 101700022938 CD4 Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100003729 CD40LG Human genes 0.000 description 1
- 102100008191 CD8A Human genes 0.000 description 1
- 101700054655 CD8A Proteins 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- 229960000466 CEFPIROME Drugs 0.000 description 1
- DNKYDHSONDSTNJ-XJVRLEFXSA-N CHEMBL1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 description 1
- 108091022090 CNTO3157 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 108091003505 CT-P6 Proteins 0.000 description 1
- 102100002212 CXCR4 Human genes 0.000 description 1
- 101710003734 CXCR4 Proteins 0.000 description 1
- 229950005072 Calaspargase pegol Drugs 0.000 description 1
- 102000004414 Calcitonin gene-related peptide Human genes 0.000 description 1
- 108090000932 Calcitonin gene-related peptide Proteins 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229940043202 Calcium Cyclamate Drugs 0.000 description 1
- 229950006450 Calcobutrol Drugs 0.000 description 1
- 229950009749 Caloxetic acid Drugs 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N Canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- 108010066889 Capromab Pendetide Proteins 0.000 description 1
- 229940034605 Capromab Pendetide Drugs 0.000 description 1
- 241001060848 Carapidae Species 0.000 description 1
- 229960003669 Carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- 229960005361 Cefaclor Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N Cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 Cefamandole Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004261 Cefotaxime Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 Cefotetan Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N Cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960000484 Ceftazidime Drugs 0.000 description 1
- 229950004259 Ceftobiprole Drugs 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- 229960001668 Cefuroxime Drugs 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 229940106164 Cephalexin Drugs 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
- 229940106195 Cephalothin Drugs 0.000 description 1
- 229940049197 Cerezyme Drugs 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229960001884 Chlorhexidine diacetate Drugs 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 229960000724 Cidofovir Drugs 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovirum Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N Cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229940088949 Cinryze Drugs 0.000 description 1
- 229950006647 Cixutumumab Drugs 0.000 description 1
- 229950001565 Clazakizumab Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108009000280 Complement Activation Proteins 0.000 description 1
- 229950009735 Concizumab Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000008260 Crohn's colitis Diseases 0.000 description 1
- 208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N DL-lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229950007372 Damoctocog alfa pegol Drugs 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- XYWBJDRHGNULKG-OUMQNGNKSA-N Desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N Diazolidinyl urea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229940061607 Dibasic Sodium Phosphate Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229950003468 Dupilumab Drugs 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229940098753 Dysport Drugs 0.000 description 1
- 108030001588 EC 3.4.24.25 Proteins 0.000 description 1
- 102000027776 ERBB3 Human genes 0.000 description 1
- 101700041204 ERBB3 Proteins 0.000 description 1
- 102100009851 ERBB4 Human genes 0.000 description 1
- 101700023619 ERBB4 Proteins 0.000 description 1
- 229950000006 Ecromeximab Drugs 0.000 description 1
- 229940012882 Elaprase Drugs 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 229940053603 Elitek Drugs 0.000 description 1
- 229960004137 Elotuzumab Drugs 0.000 description 1
- TYEXNVNUZXJNBN-UHFFFAOYSA-N Eltrombopag Chemical compound O=C1C(NN=C2C(C(=CC=C2)C=2C=C(C=CC=2)C(O)=O)=O)=C(C)NN1C1=CC=C(C)C(C)=C1 TYEXNVNUZXJNBN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229950001752 Enoticumab Drugs 0.000 description 1
- 229950010640 Ensituximab Drugs 0.000 description 1
- 229950009493 Entolimod Drugs 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 229940051398 Erwinaze Drugs 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- CBOQJANXLMLOSS-UHFFFAOYSA-N Ethylvanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 1
- 229960003976 Etidocaine Drugs 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229950004912 Etrolizumab Drugs 0.000 description 1
- 208000004526 Exfoliative Dermatitis Diseases 0.000 description 1
- 108060003023 F Proteins 0.000 description 1
- 101700074227 F9 Proteins 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 102100014838 FCGRT Human genes 0.000 description 1
- 108010042984 FG 3019 Proteins 0.000 description 1
- 102100013182 FLT4 Human genes 0.000 description 1
- 101710030894 FLT4 Proteins 0.000 description 1
- 101700036477 FOLH1 Proteins 0.000 description 1
- 102100008453 FOLH1 Human genes 0.000 description 1
- 229940012414 Factor VIIa Drugs 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 241000272190 Falco peregrinus Species 0.000 description 1
- 229950009929 Farletuzumab Drugs 0.000 description 1
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N Faropenem Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 1
- 229950000335 Fasinumab Drugs 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 229950002846 Ficlatuzumab Drugs 0.000 description 1
- 229950010320 Flanvotumab Drugs 0.000 description 1
- 229960004273 Floxacillin Drugs 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229950011078 Foravirumab Drugs 0.000 description 1
- 229950004003 Fresolimumab Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N Fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 102100018083 GBA Human genes 0.000 description 1
- 101710042131 GCG Proteins 0.000 description 1
- 102100003818 GCG Human genes 0.000 description 1
- 229940116922 GENTISIC ACID ETHANOLAMIDE Drugs 0.000 description 1
- 101700031223 GLP2 Proteins 0.000 description 1
- 108010079503 GSK1070806 Proteins 0.000 description 1
- 108010009473 GSK1995057 Proteins 0.000 description 1
- 108010070653 GSK2862277 Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 229950004896 Ganitumab Drugs 0.000 description 1
- 229940054499 Gazyva Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229950003717 Gevokizumab Drugs 0.000 description 1
- 229950002026 Girentuximab Drugs 0.000 description 1
- 229950009672 Glembatumumab vedotin Drugs 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N Glucono δ-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 229960003681 Gluconolactone Drugs 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229950010864 Guselkumab Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 208000005209 Hematologic Disease Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000009429 Hemophilia B Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 229940048921 Humira Drugs 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100008356 IDS Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100008185 IL6R Human genes 0.000 description 1
- 229940113174 IMIDUREA Drugs 0.000 description 1
- 229960002182 IMIPENEM Drugs 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 108010035620 INGAP peptide Proteins 0.000 description 1
- 108010043766 IRX2 Proteins 0.000 description 1
- 229950010245 Ibalizumab Drugs 0.000 description 1
- 108010004082 Icrucumab Proteins 0.000 description 1
- 229950006359 Icrucumab Drugs 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 229940071829 Ilaris Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N Imipenem Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 229950011428 Indatuximab ravtansine Drugs 0.000 description 1
- 208000000509 Infertility Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 108010027059 Inotuzumab Ozogamicin Proteins 0.000 description 1
- 229950004101 Inotuzumab ozogamicin Drugs 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 229960002869 Insulin Glargine Drugs 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 family Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 231100000601 Intoxication Toxicity 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 229940001952 Iprivask Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N Isomalt Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 229960005435 Ixekizumab Drugs 0.000 description 1
- 241000981924 Juniperus oxycedrus Species 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 229940089787 KADCYLA Drugs 0.000 description 1
- 229940120535 Krystexxa Drugs 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 241001185603 Labrys Species 0.000 description 1
- 229950000482 Lampalizumab Drugs 0.000 description 1
- 229940060975 Lantus Drugs 0.000 description 1
- 229940047834 Lemtrada Drugs 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 229940087875 Leukine Drugs 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 229950011263 Lirilumab Drugs 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- 241000211815 Livia Species 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229950000151 Luspatercept Drugs 0.000 description 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 description 1
- 108010075841 MEDI3617 Proteins 0.000 description 1
- 108010048793 MEDI4212 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229950007254 Mavrilimumab Drugs 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N Medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 229960003074 Medronic acid Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- ANZJBCHSOXCCRQ-UHFFFAOYSA-N Mertansine Chemical compound CN1C(=O)CC(OC(=O)C(C)N(C)C(=O)CCS)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-UHFFFAOYSA-N 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N Methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 108010013295 Microbial Collagenase Proteins 0.000 description 1
- 229950010895 Midostaurin Drugs 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 229940045641 Monobasic Sodium Phosphate Drugs 0.000 description 1
- 210000000865 Mononuclear Phagocyte System Anatomy 0.000 description 1
- 229950000720 Moxetumomab pasudotox Drugs 0.000 description 1
- 206010028093 Mucopolysaccharidosis Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidosis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 229960003816 Muromonab-CD3 Drugs 0.000 description 1
- 108090000393 Muromonab-CD3 Proteins 0.000 description 1
- 229940117040 Myalept Drugs 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- 229940103023 Myozyme Drugs 0.000 description 1
- ZUXUNWLVIWKEHB-UHFFFAOYSA-N N',N'-dimethylhexane-1,6-diamine Chemical compound CN(C)CCCCCCN ZUXUNWLVIWKEHB-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- RWRYJKPCPRFYOZ-VOXJJDTJSA-N N[C@@H](CCCCN)C(=O)O.N[C@@H](CCCCN)C(=O)O.OC(=O)C=1C(O)=CC=C(S(=O)(=O)O)C1 Chemical compound N[C@@H](CCCCN)C(=O)O.N[C@@H](CCCCN)C(=O)O.OC(=O)C=1C(O)=CC=C(S(=O)(=O)O)C1 RWRYJKPCPRFYOZ-VOXJJDTJSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229940068704 Naglazyme Drugs 0.000 description 1
- 229950009793 Naptumomab estafenatox Drugs 0.000 description 1
- 229950008353 Narnatumab Drugs 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 229950002697 Nesvacumab Drugs 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229940017335 Nulojix Drugs 0.000 description 1
- 229950005751 Ocrelizumab Drugs 0.000 description 1
- 229960003921 Octisalate Drugs 0.000 description 1
- 229950001570 Octocog alfa Drugs 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Octyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940099990 Ogen Drugs 0.000 description 1
- 229950000846 Onartuzumab Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229950002610 Otelixizumab Drugs 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229950009723 Ozanezumab Drugs 0.000 description 1
- 102100005994 PAH Human genes 0.000 description 1
- 108091001447 PEGPH20 Proteins 0.000 description 1
- 108010069655 PF-04605412 Proteins 0.000 description 1
- 108010071250 PF-05280014 Proteins 0.000 description 1
- 101700037337 PIGA Proteins 0.000 description 1
- 102100012341 PIGA Human genes 0.000 description 1
- 102100006759 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 108010089484 PRM-151 Proteins 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 101700008337 PSMA Proteins 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 229950011346 Panipenem Drugs 0.000 description 1
- 229950003522 Pateclizumab Drugs 0.000 description 1
- 229950006957 Peginterferon lambda-1a Drugs 0.000 description 1
- 229940056360 Penicillin G Drugs 0.000 description 1
- 229940056367 Penicillin V Drugs 0.000 description 1
- 229960003330 Pentetic Acid Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 108091022057 Phenylalanine Ammonia-Lyase Proteins 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229950010074 Pinatuzumab vedotin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229940007060 Plegridy Drugs 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229950003486 Ponezumab Drugs 0.000 description 1
- 229940029359 Procrit Drugs 0.000 description 1
- 229940092597 Prolia Drugs 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229950007142 Prosultiamine Drugs 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229960000856 Protein C Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 229940048084 Pyrophosphate Drugs 0.000 description 1
- UKHVLWKBNNSRRR-TYYBGVCCSA-M Quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C/C=C/Cl)C3 UKHVLWKBNNSRRR-TYYBGVCCSA-M 0.000 description 1
- 229950003033 Quilizumab Drugs 0.000 description 1
- OSUHJPCHFDQAIT-UHFFFAOYSA-N Quizalofop-ethyl Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 OSUHJPCHFDQAIT-UHFFFAOYSA-N 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 229950000381 RAZUPENEM Drugs 0.000 description 1
- 101700067545 REGN Proteins 0.000 description 1
- 108010056922 RG7212 Proteins 0.000 description 1
- 108010077454 RG7356 Proteins 0.000 description 1
- 108010015286 RG7652 Proteins 0.000 description 1
- 101700016196 RNP30 Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 229950011613 Racotumomab Drugs 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229950007649 Ranpirnase Drugs 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- XFGOMLIRJYURLQ-GOKYHWASSA-N Razupenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(SC=1)=NC=1C1=C[C@H](C)NC1 XFGOMLIRJYURLQ-GOKYHWASSA-N 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- DTLOVISJEFBXLX-REAFJZEQSA-N Relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 229950010968 Romosozumab Drugs 0.000 description 1
- 108010064989 SAR252067 Proteins 0.000 description 1
- MNGBJGFSOBSOSR-MEWBUHPBSA-N SAR3419 Chemical compound CNC(=O)CCCSSC(C)(C)CCC(=O)N(C)C(C)C(=O)OC([C@@]1(O[C@H]1C1C)C)CC(=O)N(C)C(C(=C(OC)C=2)Cl)=CC=2C\C(C)=C\C=C\C(OC)[C@]2(O)NC(=O)O[C@H]1C2 MNGBJGFSOBSOSR-MEWBUHPBSA-N 0.000 description 1
- 108010056463 SAR342434 Proteins 0.000 description 1
- 108010028116 SAR650984 Proteins 0.000 description 1
- 102100017041 SLC40A1 Human genes 0.000 description 1
- 108091006892 SLC40A1 Proteins 0.000 description 1
- 229940075562 SODIUM PHOSPHATE DIHYDRATE Drugs 0.000 description 1
- 229940050865 SODIUM PHOSPHATE,MONOBASIC,MONOHYDRATE Drugs 0.000 description 1
- 229960004542 Sebelipase alfa Drugs 0.000 description 1
- 108010082455 Sebelipase alfa Proteins 0.000 description 1
- DLSWIYLPEUIQAV-CCUURXOWSA-N Semaglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DLSWIYLPEUIQAV-CCUURXOWSA-N 0.000 description 1
- 229950011186 Semaglutide Drugs 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229950009513 Simtuzumab Drugs 0.000 description 1
- 229940115586 Simulect Drugs 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229950006094 Sirukumab Drugs 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H Sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M Sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M Sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 229950007874 Solanezumab Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 229950002894 Sotatercept Drugs 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 229950002135 Sprifermin Drugs 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229940071598 Stelara Drugs 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N Sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 Sulbactam Drugs 0.000 description 1
- 229960002673 Sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N Sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960000551 Sulfacetamide Sodium Drugs 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 101700077912 T801 Proteins 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N TBHQ Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 101000103679 TNF Proteins 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 101710037530 TRX4 Proteins 0.000 description 1
- 229950010265 Tabalumab Drugs 0.000 description 1
- 229950008160 Tanezumab Drugs 0.000 description 1
- 229950007435 Tarextumab Drugs 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- UMHMOGFSSCTSNY-XSJWQOAGSA-N Tecemotide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]2N(CCC2)C(=O)[C@H](C)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](C)NC(=O)[C@H]2N(CCC2)C(=O)[C@H]2N(CCC2)C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CCC1 UMHMOGFSSCTSNY-XSJWQOAGSA-N 0.000 description 1
- 229950001399 Tecemotide Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N Temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229950010259 Teprotumumab Drugs 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004659 Ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229950004742 Tigatuzumab Drugs 0.000 description 1
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 1
- 230000035852 Tmax Effects 0.000 description 1
- 229950001210 Trebananib Drugs 0.000 description 1
- 229950007217 Tremelimumab Drugs 0.000 description 1
- 229940026454 Tresiba Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229960004418 Trolamine Drugs 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N Tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N Tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- VQLPLYSROCPWFF-QZTJIDSGSA-N U50488 Chemical compound N1([C@@H]2CCCC[C@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 VQLPLYSROCPWFF-QZTJIDSGSA-N 0.000 description 1
- 108091011587 UB-421 Proteins 0.000 description 1
- 229950004593 Ublituximab Drugs 0.000 description 1
- 229950005972 Urelumab Drugs 0.000 description 1
- 108010077389 Ustekinumab Proteins 0.000 description 1
- 102100009661 VTN Human genes 0.000 description 1
- 102100019017 VWF Human genes 0.000 description 1
- 229950008718 Vantictumab Drugs 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 229950002148 Vatelizumab Drugs 0.000 description 1
- 229950000815 Veltuzumab Drugs 0.000 description 1
- 229950005018 Vericiguat Drugs 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229940103766 Vimizim Drugs 0.000 description 1
- 241000625014 Vir Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 229950001212 Volociximab Drugs 0.000 description 1
- 229940110548 Vpriv Drugs 0.000 description 1
- 229940018782 Wilate Drugs 0.000 description 1
- 229940018272 Xeomin Drugs 0.000 description 1
- 229940022743 Xiaflex Drugs 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- 108010010452 Xultophy Proteins 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 108010088502 ZMapp Proteins 0.000 description 1
- 229950009002 Zanolimumab Drugs 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N [amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]-[6-[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]azaniumylhexyl]azanium;diacetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001239 agalsidase alfa Drugs 0.000 description 1
- 108010049936 agalsidase alfa Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 108010009237 alirocumab Proteins 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 108091020210 amatuximab Proteins 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010003824 anetumab ravtansine Proteins 0.000 description 1
- 108010012837 anifrolumab Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 108091021984 anrukinzumab Proteins 0.000 description 1
- 108010049535 anti-IgE antibodies Proteins 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010016526 asfotase alfa Proteins 0.000 description 1
- 229940102797 asparaginase Erwinia chrysanthemi Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000006647 atypical hemolytic-uremic syndrome Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 108010047242 bapineuzumab Proteins 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 108010001114 bavituximab Proteins 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- 108010055391 benralizumab Proteins 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 108090000514 blinatumomab Proteins 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 108010017735 blosozumab Proteins 0.000 description 1
- ZTHQBROSBNNGPU-UHFFFAOYSA-N butyl hydrogen sulfate Chemical compound CCCCOS(O)(=O)=O ZTHQBROSBNNGPU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 108010033937 calaspargase pegol Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- GCLKDXFGQNCFQW-UHFFFAOYSA-L calcium;2-[4-(carboxylatomethyl)-10-(carboxymethyl)-7-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetate Chemical compound [Ca+2].OCC(O)C(CO)N1CCN(CC(O)=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GCLKDXFGQNCFQW-UHFFFAOYSA-L 0.000 description 1
- GWFCZKWFPVVILX-LMOVPXPDSA-L calcium;2-[[(2S)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;hydron Chemical compound [H+].[H+].[H+].[Ca+2].CCOC1=CC=C(C[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)N(CC([O-])=O)CC([O-])=O)C=C1 GWFCZKWFPVVILX-LMOVPXPDSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960003525 cefalexin Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 108091005269 cixutumumab Proteins 0.000 description 1
- 108010055841 clazakizumab Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 229940105778 coagulation factor VIII Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- 229960005099 collagenase Clostridium histolyticum Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091004848 concizumab Proteins 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 108010070608 daclizumab HYP Proteins 0.000 description 1
- 229940006976 dalfampridine Drugs 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 108010020644 dalotuzumab Proteins 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 108010031324 daratumumab Proteins 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 229920005994 diacetyl cellulose Polymers 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 201000010870 diseases of metabolism Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GQPXYJNXTAFDLT-UHFFFAOYSA-L disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Chemical compound [Na+].[Na+].O=C1N(COP([O-])(=O)[O-])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 GQPXYJNXTAFDLT-UHFFFAOYSA-L 0.000 description 1
- BJTHMUJCKBTCFR-UHFFFAOYSA-L disodium;ethane-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCS([O-])(=O)=O BJTHMUJCKBTCFR-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108091003598 dupilumab Proteins 0.000 description 1
- 108010069578 ecromeximab Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010061937 elotuzumab Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108091007634 enoticumab Proteins 0.000 description 1
- 108010060104 ensituximab Proteins 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091003080 etrolizumab Proteins 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 108010087285 farletuzumab Proteins 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 108010076847 fasinumab Proteins 0.000 description 1
- 102000003977 fibroblast growth factor 18 Human genes 0.000 description 1
- 108090000370 fibroblast growth factor 18 Proteins 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- 108010028445 ficlatuzumab Proteins 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229960005394 flucloxacillin Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010073818 fresolimumab Proteins 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 108091000790 ganitumab Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108010072141 gevokizumab Proteins 0.000 description 1
- 108010085319 glembatumumab vedotin Proteins 0.000 description 1
- 230000002518 glial Effects 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 201000011626 grade III astrocytoma Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 108010020157 guselkumab Proteins 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003558 hepcidin family Proteins 0.000 description 1
- 102000018511 hepcidin family Human genes 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 102000023609 human TNF protein Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 108010004953 ibalizumab Proteins 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 108010074944 indatuximab ravtansine Proteins 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229960002487 iodoxamic acid Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000000622 irritating Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 108010063443 ixekizumab Proteins 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 108010032674 lampalizumab Proteins 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 229950001712 lidofenin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 108010091736 luspatercept Proteins 0.000 description 1
- 230000002535 lyotropic Effects 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 108010089383 mavrilimumab Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 108010062313 mepolizumab Proteins 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QZFHIXARHDBPBY-UHFFFAOYSA-N methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate Chemical compound N1=C(N)C(NC(=O)OC)=C(N)N=C1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F QZFHIXARHDBPBY-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- GTGQRSIMEUWHPA-ZBJAFUORSA-M mezlocillin sodium Chemical compound [Na+].N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O GTGQRSIMEUWHPA-ZBJAFUORSA-M 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 108060005018 mobB Proteins 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 108010071242 naptumomab estafenatox Proteins 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 101700041618 nhr-4 Proteins 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 108010045555 obinutuzumab Proteins 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 108010030900 ocrelizumab Proteins 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 108010092946 onartuzumab Proteins 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 229940000673 orphan drugs Drugs 0.000 description 1
- 108010009925 otelixizumab Proteins 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 108010031295 ozanezumab Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 108010086188 pateclizumab Proteins 0.000 description 1
- 108010005691 peginterferon lambda-1a Proteins 0.000 description 1
- 108010026276 pembrolizumab Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 description 1
- 108010031155 pergoveris Proteins 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229960004331 phenoxymethylpenicillin Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 201000011252 phenylketonuria Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 125000004437 phosphorous atoms Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 108010004845 pinatuzumab vedotin Proteins 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 108010058215 ponezumab Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003405 preventing Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 101700015794 pro Proteins 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 229960002862 pyridoxine Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940096792 quaternium-15 Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 108010020302 racotumomab Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010026911 ramucirumab Proteins 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 108091003300 romosozumab Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 108010074113 simtuzumab Proteins 0.000 description 1
- 108010012416 sirukumab Proteins 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045919 sodium polymetaphosphate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 108010079667 solanezumab Proteins 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 108010029352 tabalumab Proteins 0.000 description 1
- 108010010186 talactoferrin alfa Proteins 0.000 description 1
- 229960000231 talactoferrin alfa Drugs 0.000 description 1
- 108010038329 tanezumab Proteins 0.000 description 1
- 108010032361 tarextumab Proteins 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- 108091015329 teprotumumab Proteins 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 150000003866 tertiary ammonium salts Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic Effects 0.000 description 1
- 108010092179 tigatuzumab Proteins 0.000 description 1
- 229950010206 tigemonam Drugs 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 108010072993 tremelimumab Proteins 0.000 description 1
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N trimethylphenylammonium Chemical class C[N+](C)(C)C1=CC=CC=C1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 1
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 108010071767 ublituximab Proteins 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 108010053952 urelumab Proteins 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 108010063727 veltuzumab Proteins 0.000 description 1
- 229960002569 versetamide Drugs 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 108010031272 volociximab Proteins 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 229960001134 von Willebrand factor Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 108010052251 zanolimumab Proteins 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Abstract
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of antibodies comprising thiamine have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intra-venous infusion.
Description
LIQUID PROTEIN FORMULATIONS CONTAINING
VISCOSITY-LOWERING AGENTS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to and the benefit of U.S. Provisional
Application No. ,521, filed July 29, 2014, entitled “Low- Viscosity
Protein Formulations Containing Hydrophobic Salts; ” U.S. Provisional
Application No. 62/026,497, filed July 18, 2014, entitled “LowwViscosity
n Formulations Containing GRAS Viscosity-Reducing Agents; ” U.S.
Provisional Application No. 62/008,050, filed June 5, 2014, entitled “Low-
Viscosity Protein Formulations Containing Ionic s; ” U.S. Provisional
Application No. 61/988,005, filed May 2, 2014, entitled “Low-Viscosity
ProteinllFormulations Containing plzosphatesf’ U.S. Provisional
Application No. 61/946,436, filed February 28, 2014, entitled
“Concentrated, Low-Viscosity Infliximab Formulations; ” US Provisional
ation No. 61/943,197, filed February 21, 2014, entitled
“Concentrated, Low~Viscosity, olecular—Weight—Protein
Formulations; ” U.S. Provisional ation No. 61/940,227, filed February
14, 2014, entitled ”Concentrated, Low— Viscosity High~Molecular~ Weight
Protein Formulations; ” and U.S. Provisional Application No. 61,876,621,
filed September 11, 2013, entitled “Concentrated scosity, High—
Molecular- Weight Protein Formulations, ” the disclosures ofwhich are
expressly incorporated hereby by nce.
FIELD OF THE INVENTION
The invention is generally in the field of inj ectable low-viscosity
pharmaceutical formulations of highly concentrated proteins and methods of
making and using thereof.
BACKGROUND OF THE INVENTION
Monoclonal antibodies (mAbs) are important protein-based
therapeutics for treating s human diseases such as cancer, infectious
diseases, inflammation, and mune diseases. More than 20 mAb
products have been approved by the U.S. Food and Drug Administration
(FDA), and imately 20% of all biopharrnaceuticals currently being
evaluated in al trials are mAbs (Daugherty et al. , Adv. Drug Deliv. Rev.
58:686-706, 2006; and Buss et al., Curr. Opinion in Pharmacol. 12:615-622,
2012).
mAb-based therapies are y stered repeatedly over an
extended period oftime and require l mg/kg dosing. Antibody
solutions or sions can be administered via parenteral routes, such as
by intravenous (IV) infusions, and subcutaneous (SC) or intramuscular (1M)
injections. The SC or IM routes reduce the treatment cost, increase patient
compliance, and improve ience for patients and healthcare providers
during administration compared to the IV route. To be effective and
phannaceutically able, parenteral formulations should preferably be
sterile, stable, inj ectable (e.g., via a syringe), and non-irritating at the site of
injection, in compliance with FDA guidelines. Because ofthe small volumes
required for subcutaneous (usually under about 2 mL) and intramuscular
(usually under about 5 mL) injections, these routes of administration for
high-dose protein therapies require concentrated protein solutions. These
high concentrations often result in very viscous formulations that are difficult
to administer by injection, cause pain at the site of injection, are often
imprecise, andfor may have decreased chemical and/or physical stability.
These characteristics result in manufacturing, storage, and usage
requirements that can be challenging to achieve, in particular for
formulations having high eonCentrations ofhigh—molecular-weight proteins,
such as mAbs. All protein therapeutics to some extent are subject to physical
and chemical instability, such as aggregation, denaturation, inking,
deamidation, isomerization, oxidation, and clipping (Wang et all, J Pharm.
Sci. 96:1-26, 2007). Thus, optimal formulation development is paramount in
the development of commercially viable n pharmaceuticals.
High protein trations pose challenges relating to the physical
and chemical ity of the protein, as well as difficulty with manufacture,
storage, and delivery of the protein formulation. One m is the tendency
ofproteins to aggregate and form particulates during processing and/or
storage, which makes manipulations during further sing and/or
delivery difficult. Concentration-dependent degradation and/or aggregation
are major challenges in developing protein formulations at higher
concentrations. In addition to the potential for non-native protein ation
and particulate formation, reversible ssociation in aqueous solutions
2014/055254
may occur, which butes to, among other things, increased viscosity that
complicates delivery by injection. (See, for example, Steven J. Shire er al, .1
Pharm. Sci. 93:1390—1402, 2004.) Increased viscosity is one of the key
challenges encountered in concentrated protein compositions affecting both
production processes and the ability to readily r such compositions by
conventional means. (See, for e, J. Jezek et (.11., Advanced Drug
Delivery Reviews 63:1107—1117, 2011.)
Highly viscous liquid formulations are difficult to manufacture, draw
into a syringe, and inject subcutaneously or intramuscularly. The use of force
in manipulating the viscous ations can lead to excessive frothing,
which may further denature and inactivate the therapeutically active protein.
High viscosity solutions also require larger diameter needles for injection
and produce more pain at the injection site.
Currently available commercial mAb products administered by SC
or IM injection are. usually formulated in aqueous buffers, such as a
phosphate or L-histidine buffer, with excipients or tants, such as
mannitol, sucrose, lactose, trehalose, POLOXAMER® (nonionic triblock
copolyrners composed of a central hydrophobic chain ofpolyoxypropylene
(poly(propylene ) flanked by two hydrophilic chains of
polyoxyethylene (poly(ethylene )) or POLYSORBATE® 80
(PEG(80)sorbitan monolaurate), to prevent aggregation and improve
stability. Reported antibody concentrations formulated as described above
are typically up to about 100 mg/mL (Wang et al, J. Pharm. Sci. 96: l-26,
2007).
US. Patent No. 7,758,860 describes reducing the viscosity in
formulations of low-molecular-weight proteins using a buffer and a
Viscosity-reducing inorganic salt, such as m de or magnesium
de. These same salts, however, showed little effect on the viscosity of a
high-molecular-weight antibody (IMA—63 8) formulation. As described in
US. Patent No. 7,666,413, the viscosity of aqueous formulations of high-
molecular-weight proteins has been reduced by the addition of such salts as
arginine hydrochloride, sodium thiocyanate, ammonium thiocyanate,
ammonium sulfate, ammonium de, calcium chloride, zinc chloride, or
sodium acetate in a tration of greater than about 100 mM or, as
described in US. Patent No. 7,740,842, by addition of organic or inorganic
acids. However, these salts do not reduce the ity to a desired level and
in some cases make the formulation so acidic that it is likely to cause pain at
the site of injection.
US. Patent No. 7,666,413 describes reduced-viscosity formulations
containing specific salts and a tituted anti-lgE mAb, but with a
maximum antibody concentration of only up to about 140 mg/mL. US.
Patent No. 7,740,842 describes E25 anti-IgE mAb ations containing
acetate/acetic acid buffer with antibody concentrations up to 257 mg/mL.
The addition of salts such as NaCl, CaClg, or MgCiz was demonstrated to
decrease the dynamic Viscosity under high-shear conditions; however, at
low-shear the salts produced an undesirable and dramatic increase in the
c viscosity. Additionally, inorganic salts such as NaCl may lower
solution ity and/0r decrease aggregation (EP 1981824).
Non-aqueous antibody or protein formulations have also been
described. /071693 bes a non-aqueous suspension of up to
100 mg/mL mAb in a formulation having a Viscosity enhancer
(polyvinyipyrrolidone, PVP) and a solvent (benzyl benzoate or PEG 400).
W02004/089335 describes 100 mg/mL non-aqueous lysozyme suspension
formulations ning PVP, glycofurol, benzyl benzoate, benzyl alcohol, or
PEG 400. /0226689A1 describes 100 mg/mL human growth
hormone (hGH) single phase, three vehicle component (polymer, surfactant,
and a solvent), non-aqueous, Viscous formulations. U.S. Patent No.
6,730,328 describes non-aqueous, hydrophobic, lar vehicles of low
reactivity, such as perfluorodecalin, for protein formulations. These
formulations are non-optimal and have high viscosities that impair
processing, manufacturing and injection; lead to the presence of multiple
vehicie components in the formulations; and present ial regulatory
nges associated with using polymers not yet approved by the FDA.
Alternative non—aqueous protein or antibody formulations have been
described using organic solvents, such as benzyl benzoate (Miller er £11.,
Langmuir 26:1067-1074, 2010), benzyl acetate, ethanol, or methyl ethyl
ketone (Srinivasan er LIL, Pharm. Res. 30: 1749-1757, 2013). In both
instances, viscosities of less than 50 centipoise (cP) were achieved upon
2014/055254
formulation at protein concentrations of at least about 200 mg/mL. U.S.
Patent No. 6,252,055 describes mAb formulations with concentrations
ranging from 100 mg/mL up to 257 mg/mL. Formulations with
concentrations greater than about 189 mg/mL demonstrated dramatically
increased Viscosities, low recovery rates, and difficulty in processing. US.
Patent ation ation No. 20 1 2/0230982 describes dy
formulations with concentrations of 100 mg/rnL to 200 mg/mL. None of
these formulations are low enough viscosity for ease of injection.
Du and Klibanov (Biotechnology and Bioengineering 108:632—636,
2011) described reduced ity of concentrated aqueous solutions of
bovine serum albumin with a maximum concentration up to 400 mg/mL and
bovine gamma globulin with a maximum concentration up to 300 mg/mL.
Guo er al. (Pharmaceutical ch 29231026109, 2012) described low-
ity aqueous solutions of four model rnAbs achieved using hydrophobic
salts. The mAb formulation employed by Guo had an initialviscosity, prior
to adding salts, no greater than 73 CF. The Viscosities of many
pharmaceutically ant mAbs, on the other hand, can exceed 1,000 cP at
therapeutically relevant concentrations.
It is not a trivial matter to l aggregation and viscosity in high—
concentration mAb solutions (EP 253 8973). This is evidenced by the few
mAb products currently on the market as high—concentration formulations (>
100 mg/rnL) (EP 253 8973).
The references cited above demonstrate that while many groups have
attempted to prepare low-viscosity formulations of mAbs and other
eutically important proteins, a truly usefiil formulation for many
proteins has not yet been achieved. y, many ofthe above reports
employ agents for which safety and toxicity profiles have not been fully
established. These formulations would therefore face a higher regulatory
burden prior to approval than formulations containing compounds known to
be safe. Indeed, even if a compound were to be shown to substantially
reduce viscosity, the compound may ultimately be unsuitable for use in a
formulation intended for injection into a human.
Many pharmaceutically important high-molecular-weight proteins,
such as rnAbs, are currently administered via IV infusions in order to deliver
therapeutically effective amounts of n due to problems with high
viscosity and other properties of concentrated solutions of large proteins.
For example, to provide a therapeutically effective amount ofmany high-
molecular-«weight proteins, such as mAbs, in volumes less than about 2 mL,
n concentrations greater than 150 mg/mL are often required.
It is, therefore, an object of the present ion to provide
concentrated, low-viscosity liquid formulations of pharmaceutically
important proteins, especially high-molecular—weight proteins, such as
mAbs.
It is a further object of the present invention to e concentrated
low—Viscosity liquid formulations of proteins, especially high-molecular"
weight proteins, such as mAbs, capable of ring eutically
effective amounts of these proteins in volumes useful for SC and 1M
injections.
It is a further object of the present invention to provide the
concentrated liquid formulations of proteins, especially olecular-
weight proteins, such as mAbs, with low viscosities that can improve
inj ectability and/or patient compliance, convenience, and comfort.
It is also an object of the present invention to provide methods for
making and storing concentrated, low-viscosity formulations of proteins,
especially high-moiecular-vveight proteins, such as mAbs.
It is an additional obj ect of the t invention to provide methods
of administering iow-viscosity, concentrated liquid formulations of proteins,
especially high-«molecular—weight proteins, such as mAbs. It is an additional
object of the present invention to provide methods for processing reduced-
viscosity, high-concentration biologics With tration and ion
techniques known to those skilled in the art.
SUMMARY OF THE INVENTION
Concentrated, low-viscosity, low-volume liquid pharmaceutical
formulations of proteins have been developed. Such formulations can be
rapidly and conveniently administered by subcutaneous (SC) or
intramuscular (1M) ion, rather than by lengthy intravenous infiision.
These formulations include lecular-weight and/or olecular-
Weight proteins, such as mAbs, and viscosity-lowering agents that are
typically bulky polar organic compounds, such as many of the GRAS (US
Food and Drug Administration’s list of nds generally regarded as
safe), inactive inj ectable ingredients and FDA-approved therapeutics.
The concentration ofproteins is between about 10 mg/mL and about
,000 mg/mL, more preferably from about 100 mg/mL to about 2,000
mg/mL. In some embodiments, the concentration ofproteins is between
about 100 mg/mL to about 500 mg/mL, more preferably from about 300
mg/mL to about 500 mg/mL. Formulations containing proteins and
Viscosity-lowering agents are stable when stored at a temperature of 4° C, for
a period of at least one month, preferably at least two months, and most
preferably at least three months. The ity of the formulation is less than
about 75 CF, preferably below 50 CF, and most preferably below 20 cP at
about 25° C. In some embodiments, the viscosity is less than about 15 cP or
even less than or about 10 C]? at about 25° C. In certain embodiments, the
viscosity of the ation is about 10 cP. Formulations containing proteins
and ity-lowering agents typically are measured at shear rates from
about 0.6 s'1 to about 450 3'1, and preferably from about 2 s'1 to about 400 s",
when ed using a cone and plate viscometer. Formulations containing
ns and Viscosity—lowering agents typically are measured at shear rates
from about 3 s'1 to about 55,000 5'}, and preferably from about 20 s"1 to about
2,0005'1,when measured using a microfluidic viscometer.
The viscosity of the protein formulation is reduced by the ce of
one or more viscosity—lowering agents. Unless specifically stated otherwise,
the term “viscosity-lowering agen ” includes both single compounds and
es of two or more compounds. It is preferred that the viscosity-
lowering agent is present in the formulation at a concentration less than
about 1.0 M, preferably less than about 0.50 M, more preferably less than
about 0.30 M, and most preferably less than about 0.15 M. In some
embodiments, the viscosity-lowering agent is present in the formulation in
concentrations as low as 0.01 M. The formulations can have a viscosity that '
is at least about 30% less, ably at least about 50% less, most preferably
at least about 75% less, than the viscosity of the corresponding formulation
under the same ions except for replacement of the Viscosity-lowering
agent with an appropriate buffer or salt of about the same concentration. In
some embodiments, a low-viscosity formulation is provided where the
viscosity of the corresponding formulation without the viscosity—lowering
agent is greater than about 200 cP, greater than about 500 GP, or even above
about 1,000 cP. In a preferred embodiment, the shear rate of the formulation
is at least about 0.5 5‘1, when measured using a cone and plate viscometer or
at least about 1.0 s'l, when ed using a microfluidic viscometer.
For embodiments in which the protein is a “high-molecular-weight
protein”, the high molecular weight protein may have a molecular weight
between about 100 kDa and about 1,000 kDa, preferably between about 120
kDa and about 500 kDa, and most preferably n about 120 kDa and
about 250 kDa. The high-molecular-weight protein can be an antibody, such
as a mAb, or a PEGylated, or otherwise a derivatized form thereof. Preferred
mAbs include natalizumab (TYSABRI®), cetuximab (ERBITUX®),
bevacizumab (AVASTIN®), trastuzumab (HERCEPTIN®), infliximab
(REMICADE®), rituxiinab AN®), paniturnumab (VECTIBIX®),
ofatumumab (ARZERRA®), and biosimilars thereof. The olecular-
weight protein, optionally PEGylated, can be an enzyme. Other proteins and
es ofproteins may also be formulated to reduce their viscosity.
In some ments, the protein and viscosity—lowering agent are
ed in a lyophilized dosage unit, sized for reconstitution with a sterile
aqueous pharmaceutically acceptable vehicle, to yield the concentrated low-
viscosity liquid formulations. The presence of the viscosity-lowering
agent(s) facilitates and/or accelerates the titution of the iyophilized
dosage unit compared to a lyophiiized dosage unit not containing a Viscosity-
lowering agent.
Methods are ed herein for preparing concentrated, low-
viscosity liquid ations of high-molecular—weight proteins such as
mAbs, as well as methods for g the low~viscosity, high—concentration
protein formulations, and for stration thereof to patients. In another
embodiment, the viscosity-lowering agent is added to facilitate processing
(e.g., pumping, concentration, and/or filtration) by reducing the viscosity of
the protein solutions.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the ity in cP as a n of the protein
concentration (in mg/mL) for solutions of biosimilar cetuximab
(ERBITUX®) in 0.25 M phosphate buffer (PB; diamonds) and a solution
containing 0.25 M camphorsulfonic acid L—lysine (CSAL; squares) at 25°C
and final pH of 7.0. The data points incorporate standard deviations which,
r, are often smaller than the symbols.
Figure 2 depicts the viscosity in CF as a on of the protein
concentration (in mg/mL) for solutions of biosimilar bevacizumab
(AVASTIN®) in 0.25 M phosphate buffer (PB; diamonds) and 0.25 M CSAL
(squares) at 25°C and final pH of 7.0. The data points incorporate standard
deviations which, however, are often smaller than the symbols.
Figure 3 is a graph of the Viscosity (cP) of aqueous solutions of 200 i
9 mg/mL biosimilar zumab (AVASTIN®) as a flinction ofpH along
the x—axis containing either ate-citrate buffer or camphorsulfonic acid
arginine (CSAA) at a concentration of 0.25 M.
Figure 4 is a bar graph comparing the fold reduction in Viscosity as a
function ofpH for aqueous solutions containing biosimilar zumab
(AVASTIN®; at approximately 200 mg/mL or 226 mg/mL) and 0.25 M
camphorsulfonic acid arginine (CSAA). The fold ion is computed as
the ratio of the viscosity (CF) in phosphate-citrate buffer to the viscosity (cP)
in the 0.25 M CSAA solution.
Figure 5 is a graph of the viscosity (cP) of aqueous solutions of
biosimiiar cetuximab (ERBITUX®; at 202 :t 5 mg/mL, 229 d: 5 mg/mL, or
253 :1: 4 mg/mL) containing 0.25 M CSAA as a function ofpH along the X-
axis at 25°C.
Figure 6 is a size—exclusion chromatography trace depicting
absorbance intensity (at 280 nm) as a function of n time (in minutes)
for a 220 mg/InL aqueous solution of REMICADE® stored at 4°C for up to
100 days, ed to freshly reconstituted connnercial drug product.
Figure 7 depicts the Viscosity (cP) as a function of protein
concentration (mg/mL) of aqueous solutions of biosimilar zumab
(AVASTIN®) in 0.25 M phosphate buffer, 0.10 M or 0.25 M APMI*2HC1
((1—(3 -arninopropyl)—2—methy1—1H~imidazole bis-HCI).
Figure 8 s the Viscosity (GP) as a function of protein
tration ) of aqueous solutions of biosimilar bevacizumab
(AVASTIN®) in 0.25 M phosphate buffer, 0.10 M thiamine pyrophosphate
(TPP), or 0.10 M TPP1-(3-aminopropyl)—2—methyl—lH-imidazole (APMI).
Figure 9 depicts the Viscosity (0P) of aqueous solutions of golimumab
NI ARIA®) as a on ofprotein concentration (mg/mL) with
0.15 M phosphate buffer or 0.15 M thiamine HCl.
DETAILED PTION OF THE INVENTION
I. DEFINITIONS
The term "protein," as generally used , refers to a polymer of
amino acids linked to each other by peptide bonds to form a polypeptide for
which the chain length is sufficient to produce at least a detectable tertiary
structure. Proteins having a moleculm weight (expressed in kDa wherein
“Da” stands for “Daltons” and 1 kDa = 1,000 Da) greater than about 100
kDa may be ated “high-molecular-weight proteins,” whereas ns
having a molecular weight less than about 100 kDa may be designated “low-
molecular-weight proteins.” The term “low-molecular-weight protein”
excludes small peptides lacking the requisite of at least tertiary structure
necessary to be considered a protein. Protein molecular weight may be
determined using standard methods known to one skilled in the art,
including, but not limited'to, mass spectrometry (e.g., ESI, MALDI) or
calculation from known amino acid sequences and glycosylation. Proteins
can be naturally occurring or non—naturally occurring, synthetic, or semi—
synthetic.
“Essentially pure protein(s)” and "substantially pure protein(s)” are
used interchangeably herein and refer to a composition comprising at least
about 90% by weight pure protein, preferably at least about 95% pure protein
by weight. “Essentially homogeneous” and antially homogeneous” are
used interchangeably herein and refer to a composition wherein at least about 90% by weight
of the protein present is a combination of the monomer and ible di- and oligo-meric
associates (not irreversible aggregates), preferably at least about 95%.
The term “monoclonal antibody” or “mAb,” as generally used herein, refers to an
antibody obtained from a population of substantially homogeneous antibodies, i.e., the
individual dies comprising the population are identical, except for possible naturally
occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly
specific, being directed against a single epitope. These are lly synthesized by culturing
hybridoma cells, as described by Kohler et al. (Nature 256: 495, 1975), or may be made by
recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567), or ed from phage
antibody libraries using the ques described in Clackson et al. (Nature 352: 624-628,
1991) and Marks et al. (J. Mol. Biol. 222: 7, 1991), for example. As used herein,
“mAbs” ically include derivatized antibodies, antibody-drug conjugates, and
“chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or
homologous to corresponding sequences in antibodies derived from a particular species or
belonging to a particular antibody class or subclass, while the remainder of the chain(s) is
(are) identical with or homologous to corresponding sequences in antibodies derived from
r species or belonging to another antibody class or subclass, as well as nts of
such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No.
4,816,567; on et al., Proc. Natl. Acad. Sci. USA 1-6855, 1984).
An “antibody fragment” comprises a portion of an intact antibody, including the
antigen binding and/or the variable region of the intact
antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv
fragments; diabodies; linear antibodies (see U.S. Patent No. 5,641,870;
Zapata et al., Protein Eng. 8:1057-1062, 1995); single-chain antibody
molecules; multivalent single domain antibodies; and multispecifie
antibodies formed from antibody fragments.
“Humanized” forms ofnon-human (e.g., murine) dies are
chimeric immunoglobulins, immunoglobulin chains, or fragments thereof
(such as Fv, Fab; Fah', F(ab’)2, or other antigen-binding subsequences of
antibodies) of mostly human ces, which contain minimal sequences
derived from non-human immunoglobulin. (See, e.g.; Jones et al. , Nature
2-525, 1986; Reichmann at £11., Nature 332:323-329, 1988; and Presta,
Curr. 0p. Struct. Biol. 2:593-596, 1992.)
“Rheology” refers to the study of the deformation and flow of matter.
“Viscosity" refers to the resistance of a substance (typically a liquid)
to flow. Viscosity is d to the concept of shear force; it can be
understood as the effect of different layers of the fluid exerting shearng
force on each other, or on other surfaces, as they move against each other.
There are several measures of Viscosity. The units of viscosity are Ns/rnz,
known as Pascal-seconds (Pa-s). Viscosity can be "kinematic” or "absolute".
Kinematic viscosity is a measure of the rate at which momentum is
transferred h a fluid. It is measured in Stokes (St). The kinematic
viscosity is a measure of the ive flow of a fluid under the ce of
gravity. When two fluids of equal volume and differing Viscosity are placed
in identical capillary viscometers and allowed to flow by gravity; the more
viscous fluid takes longer than the less viscous fluid to flow h the
capillary. If, for example, one fluid takes 200 seconds (s) to te its
flow and another fluid takes 400 s, the second fluid is called twice as viscous
as the first on a kinematic viscosity scale. The dimension ofkinematic
viscosity is lengch/time. Commonly, kinematic viscosity is expressed in
tokes (cSt). The S1 unit of kinematic viscosity is mmzls, which is equal
to 1 cSt. The "absolute viscosity,“ sometimes called ”dynamic viscosity" or
”simple Viscosity," is the product of tic Viscosity and fluid density.
Absolute ity is expressed in units of centipoise (CF). The SI unit of
absolute viscosity is the milliPascal-second (mPa—s), where 1 OP = 1 mPa—s.
ity may be measured by using, for example, a viscometer at a
given shear rate or multiple shear rates. An “extrapolated zero-shear”
viscosity can be determined by creating a best fit line of the four highest-
shear points on a plot of absolute viscosity versus shear rate, and linearly
extrapolating viscosity back to zero-shear. Alternatively, for a Newtonian
fluid, viscosity can be ined by averaging viscosity values at multiple
shear rates. Viscosity can aiso be measured using a microfluidic viscometer
at single or multiple shear rates (also called flow , wherein absolute
viscosity is derived from a change in pressure as a liquid flows through a
channel. Viscosity equals shear stress over shear rate. Viscosities measured
with microfluidic viscometers can, in some embodiments, be ly
compared to extrapolated zero-shear viscosities, for example those
extrapolated from viscosities measured at multiple shear rates using a cone
and plate viscometer.
“Shear rate" refers to the rate of change of velocity at- which one layer
of fluid passes over an adjacent layer. The ty gradient is the rate of
change of velocity with ce from the plates. This simple case shows the
uniform velocity gradient with shear rate (v1 - V2)/h in units of (cm/sec)/(cm)
= llsec. Hence, shear rate units are reciprocal s or, in general,
reciprocal time. For a microfluidic viscometer, change in pressure and flow
rate are related to shear rate. "Shear rate" is to the speed with which a
material is ed. ations containing ns and viscosity-
lowering agents are typically measured at shear rates ranging from about 0.5
s‘1 to about 200 s'1 when measured using a cone and plate viscometer and a
spindle appropriately chosen by one skilled in the art to accurately measure
viscosities in the viscosity range of the sample of interest (i.e., a sample of 20
cP is most accurately measured on a CPE40 spindle affixed to a DV2T
viscometer (Brookfield)); greater than about 20 s'1 to about 3,000 5'1 when
measured using a microfluidic viscometer.
For classical nian” fluids, as generally used herein, viscosity
is essentially independent of shear rate. For “non-Newtonian ”
however, viscosity either decreases or increases with increasing shear rate,
e.g., the fluids are "shear thinning" or "shear thickening", respectively. In the
case of concentrated (i.e., high—concentration) protein solutions, this may
manifest as plastic shear-thinning behavior, i.e., a decrease in
viscosity with shear rate.
The term "chemical stability," as generally used herein, refers to the
ability of the protein ents in a formulation to resist degradation via
chemical pathways, such as ion, ation, or hydrolysis. A protein
formulation is typically considered chemically stable if less than about 5% of
the components are degraded after 24 months at 4° C.
The term "physical stability," as generally used herein, refers to the
y of a n formulation to resist physical deterioration, such as
aggregation. A ation that is physically stable forms only an acceptable
percentage of irreversible aggregates (e.g., dimers, trimers, or other
aggregates) of the bioactive protein agent. The ce of ates may
be assessed in a number ofways, including by measuring the e particle
size of the proteins in the formulation by means of dynamic light scattering.
A formulation is considered physicaily stable if less than about 5%
irreversible aggregates are formed after 24 months at 4°C. Acceptable levels
of aggregated contaminants ideally would be less than about 2%. Levels as
low as about 0.2% are achievable, although approximately 1% is more
typical.
The term "stable formulation," as generally used herein, means that a
formulation is both chemically stable and physically stable. A stable
formulation may be one in which more than about 95% of the bioactive
protein molecules retain bioactivity in a formulation after 24 months of
storage at 4° C, or equivalent solution conditions at an elevated temperature,
such as one month storage at 40° C. Various analytical techniques for
measuring protein stability are available in the art and are reviewed, for
example, in Peptide and Protein Drug Delivery, 247—301, Vincent Lee, Ed,
Marcel , Inc, New York, NY. (1991) and Jones, A., Adv. Drug
Delivery Revs. 10:29-90, 1993. Stability can be measured at a selected
temperature for a certain time period. For rapid screening, for example, the
formulation may be kept at 40°C, for 2 weeks to one month, at which time
2014/055254
al biological activity is measured and compared to the initial condition
to assess stability. When the formulation is to be stored at 2°C -8°C,
generally the formulation should be stable at 30°C or 40°C for at least one
month and/0r stable at 2°C -8°C for at least 2 years. When the formulation is
to be stored at room temperature, about 25°C, generally the formulation
should be stable for at least 2 years at about 25°C and/or stable at 40°C for at
least about 6 months. The extent of aggregation following lyophilization and
storage can be used as an indicator of protein stability. In some
embodiments, the ity is assessed by measuring the le size of the
proteins in the formulation In some embodiments, stability may be assessed
by measuring the activity of a formulation using standard biological activity
or binding assays well within the abilities of one ordinarily skilled in the art.
The term n cle size," as generally used herein, means the
average diameter of the predominant population of bioactive molecule
particulates, or particle size distributions thereof, in a formulation as
determined by using well known particle sizing instruments, for e,
dynamic light scattering, SEC (size ion chromatography), or other
methods known to one ordinarily d in the art.
The term “concentrated” or "high—concentration", as generally used
herein, describes liquid formulations having a final concentration of protein
greater than about 10 mg/mL, preferably greater than about 50 mg/mL, more
preferably greater than about 100 mg/rnL, still more preferably greater than
about 200 mg/mL, or most preferably greater than about 250 mg/mL.
A “reconstituted formulation,” as generally used , refers to a
formulation which has been prepared by dissolving a dry ,
lyophilized, spray-dried or solvent-precipitated protein in a diluent, such that
the protein is dissolved or dispersed in aqueous solution for administration.
A “lyoprotectant” is a substance which, when combined with a
protein, cantly reduces chemical and/or physical instability of the
protein upon lyophilization and/or subsequent storage. Exemplary
lyoprotectants include sugars and their corresponding sugar alcohols, such as
sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, and
mannitol; amino acids, such as arginine or histidine; lyotropic salts, such as
magnesium sulfate; s, such as propylene glycol, glycerol,
poly(ethylene glycol), or poly(propylene glycol); and combinations thereof.
Additional exemplary lyoprotectants include gelatin, ns, modified
starch, and carboxymethyl cellulose. Preferred sugar ls are those
compounds obtained by reduction of mono- and di-saccharides, such as
e, trehalose, maltose, ose, and maltulose. onal examples of
sugar alcohols are glucitol, maltitol, lactitol and isomaltulose. The
lyoprotectant is generally added to the pre-lyophilized formulation in a
“lyoprotecting amount.” This means that, following lyophilization of the
protein in the presence of the lyoprotecting amount of the lyoprotectant, the
protein essentially retains its physical and chemical stability and integrity.
A “diluent” or “carrier,” as generally used herein, is a
pharmaceutically acceptable (i.e., safe and non-toxic for administration to a
human or another mammal) and useful ingredient for the preparation of a
liquid formulation, such as an aqueous formulation reconstituted after
lyophilization. Exemplary diluents include sterile water, bacteriostatic water
for injection , a pH ed solution (e.g., phosphate-buffered
saline), steriie saline on, Ringer's solution or dextrose solution, and
combinations f.
A “preservative” is a compound which can be added to the
formulations herein to reduce contamination by and/or action of bacteria,
fungi, or another infectious agent. The addition of a preservative may, for
example, facilitate the production of a multi-use (multiple-dose) formulation.
es ofpotential preservatives include
cyldimethylbenzylammonium chloride, thonium chloride,
benzalkonium chioride (a mixture of enzyldimethylammonium
chlorides in which the aikyl groups are long-chained), and benzethonium
chloride. Other types of preservatives include aromatic alcohols such as
phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl
paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
A “bulking agent,” as generally used , is a compound which
adds mass to a lized mixture and contributes to the physical structure
ofthe lyophilized cake (e.g. facilitates the production of an essentially
uniform lyophilized cake which maintains an open pore structure).
Exemplary bulking agents include mannitol, glycine, lactose, modified
starch, poly(ethylene glycol), and sorbitol.
A “therapeutically effective amoun ” is the least tration
required to effect a measurable improvement or prevention of any symptom
or a particular condition or disorder, to effect a measurable enhancement of
life expectancy, or to generally improve patient y of life. The
therapeutically effective amount is dependent upon the specific biologically
active molecule and the specific condition or disorder to be treated.
Therapeutically effective amounts ofmany proteins, such as the mAbs
described herein, are well known in the art. The eutically ive
amounts ofproteins not yet established or for treating specific disorders with
known proteins, such as mAbs, to be clinically d to treat additional
disorders may be determined by standard techniques which are well within
the craft of a skilled artisan, such as a physician.
The term tability" or “syringeability,” as generally used herein,
refers to the injection performance of a pharmaceutical formulation through an.
syringe equipped with an 18-32 gauge needle, optionally thin walled.
Inj ectability depends upon factors such as pressure or force required for
injection, evenness of flow, aspiration qualities, and fieedom from clogging.
Injectabiiity of the liquid pharmaceutical formulations may be ed by
comparing the injection force of a reduced-Viscosity fomiulation to a
standard formulation t added viscosity-lowering . The reduction
in the injection force of the formulation containing a Viscosity-lowering
agent reflects improved injectability of that formulation. The reduced
Viscosity formulations have improved inj ectability when the injection force is
reduced by at least 10%, preferably by at least 30%, more preferably by at
least 50%, and most preferably by at least 75% when compared to a standard
formulation having the same concentration ofprotein under ise the
same conditions, except for replacement of the viscosity-lowering agent with
an riate buffer of about the same concentration. Alternatively,
inj ectability of the liquid pharmaceutical formulations may be assessed by
comparing the time ed to inject the same volume, such as 0.5 mL, or
more preferably about 1 mL, of different liquid protein formulations when
the e is depressed with the same force.
The term “inj ecti0n force," as generally used herein, refers to the
force ed to push a given liquid formulation through a given syringe
equipped with a given needle gauge at a given injection speed. The injection
force is typically reported in s. For example, the injection force may
be measured as the force required to push a liquid formulation through a 1
mL plastic syringe having a 0.25 inch inside diameter, equipped with a 0.50
inch 27 gauge needle at a 250 nun/min ion speed. g equipment
can be used to measure the ion force. When measured under the same
conditions, a formulation with lower Viscosity will generally e an
overall lower injection force.
The “viscosity gradient,” as used herein, refers to the rate of change
ofthe viscosity of a protein solution as protein concentration increases. The
viscosity gradient can be approximated from a plot of the Viscosity as a
function of the protein concentration for a series of formulations that are
otherwise the same but have different protein concentrations .u. The viscosity
increases approximately exponentially with increasing protein concentration.
The viscosity gradient ata specific protein concentration can be
approximated from the slope ‘of a line tangent to the plot of viscosity as a
function of protein concentration. The viscosity gradient can be
approximated from a linear approximation to the plot of ity as, a
function of any protein concentration or over a narrow window of protein
concentrations. In some ments a formulation is said to have a
decreased viscosity gradient if, when the viscosity as a function of protein
concentration is approximated as an ntial function, the exponent of
the exponential function is smaller than the exponent obtained for the
otherwise same formulation without the viscosity~lowering agent. In a
similar manner, a formulation can be said to have a lower/higher ity
gradient when compared to a second formulation if the exponent for the
formulation'is lower/higher than the exponent for the second formulation.
The viscosity gradient can be numerically approximated from a plot of the
ity as a function of protein concentration by other methods known to
the skilled formulation researchers.
The term ed-visco sity ation,” as generally used herein,
refers to a liquid formulation having a high concentration of a high-
molecular—weight protein, such as a mAb, or a low-«molecular-weight n
that is modified by the presence of one or more additives to lower the
viscosity, as compared to a corresponding formulation that does not contain
the viscosity-lowering additive(s).
The term “osmolarity,” as generally used , refers to the total
number of dissolved components per liter. rity is similar to ty
but includes the total number of moles of dissolved Species in solution. An
osmolarity of l Osm/L means there is 1 mole of dissolved components per L
of solution. Some solutes, such as ionic solutes that dissociate in solution,
will contribute more than 1 mole of dissolved components per mole of solute
in the solution. For example, NaCl dissociates into Na+ and CT in solution
and thus provides 2 moles of ved components per 1 mole of ved
NaCl in solution. Physiological osmolarity is typically in the range of about
280 mOsm/L to about 310 mOsrn/L.
The term “tonicity,” as generally used herein, refers to the osmotic
re gradient resulting from the separation oftwo solutions by a semi-
permeable membrane. In particular, tonicity is used to describe the osmotic
pressure created across a cell membrane when a cell is exposed to an external
on. Solutes that can cross the cellular membrane do not contribute to
the final osmotic pressure nt. Only those dissolved species that do not
cross the cell membrane will contribute to osmotic pressure differences and
thus tonicity.
The term “hypertonic,” as generally used herein, refers to a solution
with a higher concentration of solutes than is present on the inside of the cell.
When a cell is immersed into a hypertonic solution, the tendency is for water
to flow out ofthe cell in order to balance the concentration of the solutes.
The term “hypotonic,” as generally used herein, refers to a solution
with a lower tration of solutes than is present on the inside of the cell.
When a cell is immersed into a hypotonic solution, water flows into the cell
in order to balance the concentration of the solutes.
The term “isotonic,” as generally used herein, refers to a solution
wherein the osmotic re gradient across the cell membrane is essentially
balanced. An ic formulation is one which has essentially the same
osmotic pressure as human blood. Isotonic formulations will generally have
an osmotic re from about 250 mOsm/kg to 350 mOsm/kg.
The term “liquid formulation,” as used herein, is a protein that is
either ed in an acceptable pharmaceutical diluent or one that is
reconstituted in an acceptable pharmaceutical diluent prior to stration
to the patient.
The terms “branded” and “reference,” when used to refer to a protein
or biologic, are used interchangeably herein to mean the single biological
product licensed under section 351(a) of the US. Public Health Service Act
(42 use. § 262).
The term “biosimilar,” as used herein, is generally used
interchangeably with “a generic equivalent” or “follow-on.” For example, a
“biosimilar'mAb” refers to a subsequent version of an innovator’s mAb
typically made by a different company. “Biosimilar” When used in reference
to a branded protein or branded biologic can refer to a biological product
ted against the branded protein or branded biologic and licensed under
section 351(k) of the US. Public Health e Act (42 U.S.C. § 262). A
biosimilar mAb can be one that satisfies one or more guidelines adopted May
, 2012 by the Committee for Medicinal Products for Human Use (CHMP)
ofthe an Medicines Agency and published by the European Union as
“Guideline on similar biological medicinal products containing monoclonal
antibodies — non—clinical and clinical issues" (Document Reference
EMA/CHMP/BMWP/403 543/2010).
Biosimilars can be produced by ial cells (prokaryotic,
eukaryotic), cell lines of human or animal origin (e.g., mammalian, avian,
insect), or tissues derived from animals or plants. The expression construct
for a proposed biosimilar t will generally encode the same primary
amino acid sequence as its reference product. Minor modifications, such as
N- or C— terminal truncations that will not have an effect on safety, purity, or
potency, may be present.
A biosimilar mAb is r to the reference mAb physiochemically
or biologically both in terms of safety and efficacy. The biosimilar mAb can
be ted against a reference mAb using one or more in vitro studies
including assays ing g to target antigen(s); binding to isoforms of
the Fc gamma receptors (Fm/R1, Fc'yRII, and FcyRIII), FcRn, and
complement (Clq); Fab-associated functions (e.g. neutralization of a e
ligand, receptor activation or blockade); or Fc-associated functions (6.g.
antibody-dependent cell-mediated cytotoxicity, complement-dependent
cytotoxicity, complement activation). In vitro comparisons may be combined
with in vivo data demonstrating similarity of cokinetics,
pharmacodynamics, and]or safety. Clinical evaluations of a biosimilar mAb
against a nce mAb can include comparisons ofpharmacokinetic
properties (e.g. AUCO_inf, AUCM, Cum, tmax, ; codynamic
endpoints; or similarity of clinical efficacy (e.g. using randomized, parallel
group ative clinical trials). The quality comparison between a
biosimilar mAb anda reference mAb can be evaluated using established
procedures, ing those described in the “Guideline on similar biological
nal products containing biotechnology—derived ns as active
substance: Quality issues” (EMEA/CHMP/BWP/49348/2005), and the
“Guideline on development, production, characterization and specifications
for monoclonal antibodies and related substances”
(EMEA/CHMP/BWP/l 2007).
Differences between a biosimilar mAb and a reference mAb can
include post-translational modification, 6.g. by attaching to the mAb other
biochemical groups such as a phosphate, various lipids and carbohydrates; by
proteolytic cleavage following translation; by changing the chemical nature
of an amino acid (cg, formyiation); or by many other mechanisms. Other
post—translational ations can be a consequence ofmanufacturing
process operations — for example, glycation may occur with exposure ofthe
product to reducing sugars. In other cases, storage conditions may be
permissive for certain ation pathways such as oxidation, deamidation,
or aggregation. As all of these product-related variants may be included in a
biosimilar mAb.
The term “viscosity-lowering agent,” as used herein, refers to a
nd which acts to reduce the viscosity of a solution relative to the
Viscosity of the solution absent the Viscosity~lowering agent. The viscosity—
lowering agent may be a single compound, or may be a mixture of one or
more nds. When the viscosity—lowering agent is a mixture of two or
more compounds, the listed concentration refers to each individual agent,
WO 38818
unless otherwise specified. By way of example, a formulation containing
about 0.25 M camphorsulfonic acid arginine as the viscosity-lowering agent
is a solution having rsulfonic acid at a concentration of 0.25 M, and
arginine at a concentration of 0.25 M.
Certain Viscosity-lowering agents contain acidic or basic onal
groups. Whether or not these funCtional groups are fillly or partiaily ionized
depends on the pH ofthe formulation they are in. Unless otherwise
specified, reference to a formulation ning a ity-lowering agent
having an ionizable functional group includes both theparent compound and
any possible ionized states.
As used herein, the term “hydrogen bond donor” refers to a hydrogen
atom connected to a vely electronegative atom, which creates a partial
positive charge on the hydrogen atom.
As used , the term “hydrogen bond acceptor” refers to a
relatively electronegative atom or functional group capable of cting
with a hydrogen atom bearing a partial positive charge.
As used herein, the term “fieely rotating bond” refers to any singly
bonded pair of non-hydrogen atoms.
As used herein, the term “molecular polar surface area” refers to the
total exposed polar area on the surface of the molecule of interest.
As used herein, the term “molar volume” refers to the total volume
that one mole of the molecule of st occupies in its native state (i.e.
solid, liquid).
As used herein, the term “polarizability” refers to the induced dipole
moment when the le of interest is placed in an electric field of unit
strength.
As used herein, the term “pharmaceutically acceptable salts” refers to
salts prepared from pharmaceutically acceptable non-toxic acids and bases,
ing inorganic acids and bases, and organic acids and bases. Suitable
non-toxic acids include inorganic and organic acids such as ,
benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric,
gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic,
malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic,
phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like.
Suitable positively charged counterions include sodium, potassium, lithium,
calcium and magnesium.
As used herein, the term "ionic liquid” refers to a crystalline or
amorphous salt, zwitterion, or mixture thereof that is a liquid at or near
temperatures where most conventional salts are solids: at less than 200°C,
preferably less than 100°C or more preferably less than 80°C. Some ionic
liquids have melting temperatures around room temperature, e.g. between
' 10°C and 40°C,
or between 15°C and 35°C. The term erion" is used
herein to describe an overall lly charged le which carries formal
positive and negative s on different chemical groups in the molecule.
Examples of ionic liquids are described in Riduan er al., Chem. Soc. Rev.,
42:9055-9070, 2013; Rantwijk et at, Chem. Rev., 107:2757-2785, 2007;
Earle er al, Pure Appl. Chem, 72(7): 1391-1398, 2000; and Sheldon et all,
Green Chem, 4:147—151, 2002.
As used herein, the term “organophosphate” refers to a nd
containing one or more phosphoryl groups at least one of which is covalently
ted to an organic group through a phosphoester bond.
As used herein, a “water soluble organic dye” is an organic molecule
having a molar solubility of at least 0.001 M at 25°C and pH 7, and that
s certain wavelengths of light, preferably in the visible-to-infrared
portion of the electromagnetic spectrum, While possibly transmitting or
reflecting other wavelengths of light.
As used herein, the term ogen” refers to Group 16 elements,
including oxygen, sulfur and selenium, in any oxidation state. For instance,
unless specified otherwise, the term “chalcogen” also includes 802.
As used herein, term “alkyl group” refers to straight-chain, branched-
chain and cyclic hydrocarbon groups. Unless specified otherwise, the term
alkyl group embraces hydrocarbon groups ning one or more double or
triple bonds. An alkyl group containing at least one ring system is a
“cycloalkyl” group. An alkyl group containing at least one double bond is an
“alkenyl group,” and an alkyl group ning at least one triple bond is an
“alkynyl group.”
The term as used herein, “Ary ” refers to aromatic carbon ring
systems, including fused ring systems. In an “ary ” group, each of the atoms
that form the ring are carbon atoms.
The term as used herein “Heteroaryl” refers to aromatic ring systems,
ing fused ring systems, wherein at least one of the atoms that forms the
ring is a heteroatom.
The term as used herein “Heterocycle” refers to ring systems that,
including fused ring systems, are not aromatic, n at least one of the
atoms that forms the ring is a heteroatorn.
The term as used herein, “heteroatom” is any non-carbon or non-
hydrogen atom. Preferred atoms include , sulfur, and en.
Exemplary aryl and heterocyclyl rings include: benzimidazolyl,
benzofilranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, ,
benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH. carbazolyl, inyl,
nyl, chromenyl, cinnolinyl, decahydroquinolinyl, 1,5,2-
dithiazinyl, dihydrofuro [2,3 b]tetrahydrofuran, furanyl, furazanyl,
imidazolidinyl, imidazolinyl, imidazolyl, lHnindazolyl, indolenyl, indolinyl,
indolizinyl, indolyl, 3H—indolyl, isatinoyl, isobenzofuranyl, isochrornanyl,
isoindazolyl, olinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl,
methylenedioxyphenyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3—oxadiazolyl, 1,2,4-oxadiazolyl,
1,2,5-oxadiazolyl, 1,3,4-oxadiazoly1, oxazolidinyl, oxazolyl, oxindolyl,
pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl,
phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl,
piperidonyl, 4-piperidonyl, nyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, zinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-
quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl,
ydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H—1,2,5-
thiadiazinyl, 1,2,3—thiadiazolyl, 1,2,4-thiadiazoly1, 1,2,5-thiadiazolyl, 1,3,4-
thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl,
thienoimidazolyl, thiophenyl, and xanthenyl.
2014/055254
II. FORMULATIONS
Biocompatible, low-viscosity protein solutions, such as those of
mAbs, can be used to deliver therapeutically effective amounts of proteins in
volumes useful for subcutaneous (SC) and intramuscular (1M) ions,
typically less than or about 2 mL for SC and less than or about 5 mL for 1M,
more preferably less than or about 1 mL for SC and less than or about 3 mL
for IM. The ns can generally have any molecular weight, although in
some ments high~molecular~weight proteins are preferred. In other
embodiments the proteins are low-molecular-weight proteins.
Formulations may have protein concentrations between about 10
mg/mL and about 5,000 mg/mL. The formulations, including mAb
ations, may have a protein concentration greater than 100 mg/mL,
preferably greater than 150 mg/mL, more preferably r than about 175
mg/ml, even more preferably greater than about 200 mg/mL, even more
preferably greater than about 225 mg/mL, even more preferably greater than
about 250 mg/mL, and most preferably greater than or about 300 mg/mL. In
the absence of a viscosity-lowering agent, the viscosity of a n
formulation increases exponentially as the concentration is increased. Such
protein formulations, in the absence of a viscosity-lowering agent, may have
viseosities greater than 100 GP, greater than 150 cP, greater than 200 cP,
greater than 300 cP, greater than 500 cP, or even greater than 1,000 cP, when
ed at 25° C. Such formulations are often unsuitable for SC or IM
injection. The use of one or more viscosity-lowering agents permits the
preparation of formulations having a viscosity less than or about 100 cP,
preferably less than or about 75 CF, more ably less than or about 50 CF,
even more preferably less than or about 30 GP, even more preferably less
than or about 20 cP, or most preferably less than or about 10 CF, when
measured at 25° C.
Although the viscosity—lowering agents may be used to lower the
viscosity of concentrated n formulations, they may be used in less»
concentrated formulations as well. In some embodiments, formulations may
have protein concentrations between about 10 mg/mL and about 100 mg/mL.
The formulations may have a protein concentration greater than about 20
mg/mL, greater than about 40 mg/mL, or greater than about 80 mg/mL.
For n ns, formulations not having a viscosity-lowering
agent may have ities greater than about 20 cP, r than about 50
CF, or greater than about 80 CF. The use of one or more viscosity-lowering
agents permits the preparation of formulations having a viscosity less than or
about 80 CF, preferably less than or about 50 CF, even more preferably less
than about 20 CR or most preferably less than or about 10 CF, when
measured at 25° C.
In some embodiments, the aqueous protein formulations have a
viscosity that is at least about 30% less than the analogous formulation
Without the viscosity_lowering agent(s), when measured under the same
conditions. In other embodiments, the formulations have a viscosity that is
40% less, 50% less, 60% less, 70% less, 80% less, 90% less, or even more
than 90% less than the ous formulation t the viscosity-lowering
agent(s). In a preferred embodiment, the formulation contains a
therapeutically effective amount of the one or more high-molecular-weight
proteins, such as mAbs, in a volume of less than about 2 mL, preferably less
than about 1 mL, or more preferably less than about 0.75 mL.
The reduced-viscosity formulations have improved inj ectability and
require less injection force compared to the analogous formulation without
the viscosity—lowering agent (e.g., in phosphate buffer) under otherwise the
same conditions. In some embodiments, the force of injection is decreased
by more than about 20%, more than about 30%, more than about 40%, more
than about 50%, or more than about 2 fold, as ed to standard
formulations without the ity-lowering agent(s) under otherwise the
same injection conditions. In some embodiments, the formulations s
“Newtonian flow characteristics,” defined as having viscosity which is
substantially independent of shear rate. The protein formulations can be
readily injected through needles of about 18-32 gauge. red needle
gauges for the delivery of the low-viscosity formulations include 27, 29, and
31 gauge, optionally thin walled.
The formulations may n one or more additional excipients,
such as buffers, surfactants, sugars and sugar alcohols, other polyols,
preservatives, antioxidants, and chelating agents. The formulations have a
pH and osmolarity suitable for administration without causing significant
adverse side effects. In some embodiments, the concentrated, low-viscosity
formulations have a pH between 5 and 8, between 5 .5 and 7.6, n 6.0
and 7.6, between 6.8 and 7.6, or between 5.5 and 6.5.
The low-viscosity n formulations can allow for greater
flexibility in formulation development. The low-viscosity formulations can
exhibit changes in viscosity that are less dependent upon the protein
concentration as compared to the otherwise same formulation t the
viscosity-lowering agent. The low-viscosity protein formulations can allow
for increased trations and decreased dosage frequencies ofthe protein.
In some embodiments the low-viscosity protein formulations contain 2 or
more, 3 or more, or 4 or more different proteins. For example, combinations
of 2 or more mAbs can be provided in a single low-viscosity protein
formulation.
Because protein (such as mAb) formulations may be administered to
patients at higher protein concentrations than otherwise. similar protein
formulations not containing a viscosity~lowering agent, the dosing frequency
of the protein can be reduced. For instance, ns previously requiring
once daily administration may be administered once every two days, every
three days, or even less frequently when the proteins are formulated with
ity-lowering agents. Proteins which currently require multiple
administrations on the same day (either at the same time or at ent times
ofthe day) may be administered in fewer injections per day. In some
instances, the fiequency may be reduced to a single injection once a day. By
increasing the dosage administered per injection multiple-fold the dosing
ncy can be decreased, for example from once every 2 weeks to once
every 6 weeks.
In some embodiments, the liquid formulations have a logical
osmolarity, for example, between about 280 mOsm/L to about 310 mOsm/L.
In some embodiments, the liquid formulations have an osmolarity greater
than about 250 , greater than about 300 mOsm/L, greater than about
350 mOsm/L, greater than about 400 mOsm/L, or greater than about 500
mOsm/L. In some embodiments, the formulations have an osmolarity of
about 200 mOsm/L to about 2,000 mOsm/L or about 300 mOsm/L to about
1,000 . In some embodiments, the liquid formulations are essentially
isotonic to human blood. The liquid formulations can in some cases be
hypertonic.
The additives, including the viscosity-lowering agents, can be
included in any amount to achieve the d viscosity levels of the liquid
formulation, as long as the amounts are not toxic or otherwise l, and
do not substantially interfere with the chemical and/or physical stability of
the formulation. The viscosity-lowering agent(s) in some embodiments can
be independently present in a concentration less than about 1.0 M, preferably
less than about 0.50 M, less than or equal to about 0.30 M or less ‘than or
equal to 0.15 M. Especially preferred concentrations include about 0.15 M
and about 0.30 M. For some embodiments having two or more viscosity~
lowering agents, the agents are preferably, but not necessarily, present at the
same concentration.
The viscosity-lowering agents permit faster reconstitution of a
lyophilized dosage unit. The dosage unit is a lyophilized cake of protein,
ity—lowering agent and other excipients, to which water, saline or
another pharmaceutically acceptable fluid is added. In the absence of
viscosity—lowering agents, periods of 10 minutes or more are often ed
in order to completely ve the lyophilized cake at high protein
concentration. When the lyophilized cake contains one or more viscosity-
lowering agents, the period required to completely ve the cake is often
reduced by a factor oftwo, five or even ten. In certain ments, less
than one minute is required to completely dissolve a lyophilized cake
containing greater than or about 150, 200 or even 300 mg/mL of protein.
The low-viscosity protein formulations allow for greater flexibility in
ation development. The low—viscosity formulations exhibit a viscosity
that changes less with increasing protein trations as compared to the
otherwise same formulation t the viscosity-lowering agent(s). The
low—viscosity protein ations exhibit a decreased viscosity gradient as
compared to the otherwise same formulation without the viscosity—lowering
agent
The viscosity gradient of the protein formulation may be 2-fold
less,3-fold less, or even more than 3-fold less than the viscosity gradient of
the otherwise same protein formulation without the viscosity-lowering
agent(s). The viscosity gradient of the protein formulation may be less than
2.0 cP mL/mg, less than 1.5 cP mL/mg, less than 1.0 cP mL/mg, less than 0.8
0P mL/rng, less than 0.6 cP mL/mg, or less than 0.2 cP mL/mg for a n
ation having a protein concentration between 10 mg/mL and 2,000
mg/mL. By reducing the viscosity gradient of the formulation, the protein
concentration can be increased to a greater degree before an exponential l
increase in viscosity is observed.
A. Proteins
Any protein can be formulated, including recombinant, ed, or synthetic
proteins, glycoproteins, or lipoproteins. These may be antibodies (including
antibody fragments and recombinant antibodies), enzymes, growth factors or
hormones, immunomodifiers, antiinfectives, antiproliferatives, es, or
other therapeutic, prophylactic, or diagnostic ns. In certain
embodiments, the protein has a lar weight greater than about 150
kDa, greater than 160 kDa, greater than 170 kDa, greater than 180 kDa,
greater than 190 kDa or even greater than 200 kDa.
In certain embodiments, the protein can be a PEGylated protein. The
term “PEGylated n,” as used herein, refers to a protein having one or
more poly(ethylene glycol) or other stealth polymer groups ntly
attached thereto, optionally through a chemical linker that may be ent
from the one or more polymer groups. PEGylated proteins are characterized
by their typically reduced renal filtration, decreased uptake by the
reticuloendothelial system, and diminished enzymatic degradation leading to,
for example, prolonged half-lives and enhanced ilability. Stealth
polymers include poly(ethylene glycol); poly(propylene glycol); poly(amino
acid) polymers such as poly(glutamic acid), poly(hydroxyethyl-L-
gine), and poly(hydroxethyl-L-glutamine); poly(glycerol); poly(2—
oxazoline) polymers such as poly(2—methyloxazoline) and poly(2-ethyl
ine); poly(acrylamide); poly(vinylpyrrolidone); -(2~
hydroxypropyl)methacrylarnide); and copolymers and mixtures thereof. In
preferred embodiments the h r in a PEGylated protein is
poly(ethylene glycol) or a copolymer thereof. PEGylated proteins can be
randomly PEGylated, 1'. e. having one or more stealth polymers covalently
attached at non-specific site(s) on the protein, or can be PEGylated in a site-
specific manner by ntly ing the stealth polymer to specific site(s)
on the protein. Site-specific PEGylation can be accomplished, for example,
using ted stealth polymers having one or more reactive onal
groups. Examples are described, for instance, in Hoffman et all, Progress in
Polymer Science, 32:922-932, 2007.
In the preferred embodiment, the protein is high-molecular-weight
and an antibody, most preferably a mAb, and has a high viscosity in aqueous
ed solution When concentrated sufficiently to inject a therapeutically
effective amount in a volume not ing 1.0 to 2.0 mL for SC and 3.0 to
.0 mL for 1M administration. High—molecular—weight proteins can include
those described in Scolnik, mAbS 1:179-184, 2009; Beck, mAbs 110, .
2011; Baumann, Curr. Drug Math. 7:15-21, 2006; or Federici, Biologicals
41 :13 1-447, 2013. The proteins for use in the formulations described herein
are preferably essentially pure and essentially homogeneous (i.e.,
substantially free from contaminating proteins and/or irreversible aggregates
thereof).
Preferred mAbs herein include natalizumab RI®), cetuximab
(ERBITUX®), bevacizurnab (AVASTIN®), trastuzumab P'1‘1N®),
infliximab (REMICADE®), rituximab (RITUXAN®), panitumumab
(VECTIBIX®), ofatumumab (ARZERRA®), and biosimilars thereof.
Exemplary high-molecular-weight proteins can include tocilizumab
(ACTEMRA®), alemtuzurnab (marketed under several trade names),
brodalumab (developed by Amgen, Inc (“Amgen”)), denosumab (PROLIA®
and XGEVA®), and biosimilars thereof.
Exemplary molecular targets for antibodies described herein include
CD ns, such as CD3, CD4, CD8, CD19, CD20 and CD34; members of
the HER receptor family such as the EGF or, HERZ, HER3 or HER4
receptor; cell adhesion molecules, such as LFA—l, M01, p150,95, VLA-4,
lCAM-l, VCAM, and (iv/[33 integrin, including either or or 0 subunits thereof
(e.g., anti-CD1 1a, D18, or anti—CD1 lb antibodies); growth factors,
such as VEGF; lgE; blood group antigens; flk2/flt3 receptor; y (OB)
receptor; protein C; PCSKQ; etc.
Antibody eutics Currently on the Market
Many n therapeutics currently on the market, ally
antibodies as defined herein, are administered via IV ons due to high
dosing requirements. Formulations can e one ofthe antibody
therapeutics currently on the market or a biosimilar f. Some protein
therapeutics currently on the market are not high—molecular—weight, but are
still administered via IV infusion because high doses are needed for
therapeutic y. In some embodiments, liquid formulations are provided
of these low—molecular-weight proteins as defined herein with concentrations
to deliver therapeutically effective amounts for SC or IM injections.
dy therapeutics currently on the market include belimumab
(BENLYSTA®), golimumab NIAR1A®), abciXimab (REOPRO®),
the combination of tositumomab and iodine-131 tositurnomab, marketed as
BEHAR‘E, alemtuzumab (CAMPATH® ,palivizumab (SYNAGIS®),
basiliximab (SIMULECT®), ado-trastuzumab emtansine (KADCYLA®),
pertuzumab (PERJETA®), capromab pendetide (PROSTASCJNT KIT® ,
caclizumab (ZENAPAX®), ibritumomab tiuxetan (ZEVALW®), eeulizumab
(SOLIRIS®), ipiiimumab (YERVOY®), muromonab—CD3 (ORTHOCLONE
, raxibacumab, nimotuzumab (THERACIM®), brentuximab vedotin
(ADCETRIS®), adalimumab (HUMIRA®), mab (SIMPONI®),
palivizumab (SYNAGIS®), ornalizumab (XOLAIR®), and ustekinumab
(STELARA®).
Natalizumab, a humanized mAb against the cell adhesion molecule
a4-integrin, is used in the treatment of multiple sclerosis and Crohn's disease.
Previously marketed under the trade name ANTEGREN®, natalizumab is
currently eo—marketed as TYSABRI® by Biogen Idec (“Biogen”) and Elan
Corp. (“Elan”) TYSABRI® is produced in murine myeloma cells. Each 15
mL dose contains 300 mg natalizumab; 123 mg sodium chloride, USP; 17.0
mg sodium phosphate, monobasic, monohydrate, USP; 7.24 mg sodium
phosphate, dibasic, heptahydrate, USP; 3.0 mg polysorbate 80, USP/NF, in
water for IV injection, USP at pH 6.1. zumab is lly stered
by monthly intravenous (IV) infusions and has been proven effective in
treating the symptoms of both multiple sis and Crohn's disease, as well
as for preventing relapse, vision loss, cognitive decline, and significantly
improving patient’s quality of life.
As used , the term “nataiizumab” es the InAb against the
cell adhesion molecule a4-integrin known under the International
Nonproprietary Name “NATALIZUMAB” or an antigen binding portion
thereof. Natalizumab includes antibodies described in US. Patent No.
,840,299, us. Patent No. 6,033,665, U.S. Patent No. 6,602,503, us.
Patent No. 5,168,062, US Patent No. 5,385,839, and US. Patent No.
,730,978. Natalizumab includes the active agent in products marketed under
the trade name TYSABR1® by Biogen Idec and Elan ation or a
biosimilar product thereof.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
used for the treatment of metastatic colorectal cancer and head and neck
cancer. mab is a chimeric (mouse/human) mAb typically given by IV
infusion. Cetuximab is marketed for IV use only under the trade name
ERBITUX® by Bristol—Myers Squibb Company (North America; ol-
Myers Squibb”), Eli Lilly and Company (North America; “Eli Lilly”), and
Merck KGaA. ERBITUX® is produced in mammalian (murine myeloma)
cell culture. Each single-use, 50me Vial ofERBITUX® contains 100 mg of
cetuximab at a concentration of 2 mg/mL and is ated in a preservative—
free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium
phosphate dibasic ydrate, 0.42 mg/mL sodium phosphate monobasic
monohydrate, and water for IV Injection, USP.
Cetuximab is indicated for the treatment of patients with epidermai
growth factor receptor —expressing, KRAS wild-type atic
colorectal cancer (mCRC), in combination With chemotherapy, and as a
single agent in patients who have failed oxaliplatin— and ecan—based
therapy or who are intolerant to irinotecan. Cetuximab is indicated for the
treatment of patients with squamous cell carcinoma of the head and neck in
combination with platinum-based herapy for the first-line treatment
of recurrent and/or metastatic disease and in ation with radiation
therapy for locally advanced disease. Approximately 75% of patients with
metastatic colorectal cancer have an EGFR—expressing tumor and are,
therefore, considered eligible for treatment with cetuximab or panitumumab,
according to FDA guidelines.
As used herein, the term “cetuximab” includes the mAb known under
the International Nonproprietary Name “CETUXIMAB” or an antigen
binding portion thereof. Cetuximab includes antibodies described in US.
Patent No. 6,217,866. Cetuximab includes the active agent in products
marketed under the trade name ERBITUX® and biosimilar ts f.
Biosimilars of ERBITUX® can include those currently being ped by
Amgen, AlphaMab Co., Ltd. aMab”), and Actavis plc (“Actavis”).
Bevacizumab, a humanized mAb that ts vascular endothelial
growth factor A (VEGF-A), acts as an ngiogenic agent. It is marketed
under the trade name AVASTIN® by Genentech, Inc. (“Genentech”) and F.
Hoffinann-La Roche, LTD (“Roche”). It is licensed to treat various cancers,
including colorectal, lung, breast de the U.S.A.), glioblastoma (USA.
only), kidney and ovarian. AVASTIN® was approved by the FDA in 2004
for use in metastatic colorectal cancer when used with standard
chemotherapy treatment (as first-line treatment) and With S-fluorouracil-
based therapy for second-«line atic colorectal cancer. In 2006, the FDA
approved N® for use in first-line advanced non-squamous non-small
cell lung cancer in combination with carboplatin/paclitaxei chemotherapy.
AVASTIN® is given as an IV infusion every three weeks at the dose of either
mg/kg or 7.5 mg/kg. The higher dose is usually given with carboplatin—
based chemotherapy, whereas the lower dose is given with cisplatin-based
chemotherapy. In 2009, the FDA approved AVASTIN® for use in metastatic
renal cell carcinoma (a form of kidney ). The FDA also granted
rated approval of AVASTIN® for the treatment ofrecurrent
glioblastoma multiforme in 2009. Treatment for initial growth is still in
phase III clinical trial.
The National Comprehensive Cancer Network (“NCCN”)
recommends bevacizurnab as standard first-line treatment in ation
with any platinum-based chemotherapy, followed by maintenance
bevacizumab until disease progression. The NCCN updated its Clinical
Practice ines for Oncology (NCCN Guidelines) for Breast Cancer in
2010 to affirm the recommendation regarding the use of bevacizuinab
(AVASTIN®, Genentech/Roche) in the treatment of metastatic breast cancer.
As used herein, the term izumab” es the mAb that
inhibits vascular endothelial growth factor A (VEGF-A) known under the
International prietary Name/Common Name “BEVACIZUMAB” or
an antigen binding portion thereof. Bevacizumab is described in U.S. Patent
No. 297. zumab includes the active agent in products marketed
under the trade name AVASTIN® and nilar products thereof.
Biosimilars of AVASTIN® can include those currently being developed by
Amgen, Actavis, AlphaMab, and Pfizer, Inc (“Pfizer”). Biosimilars of
AVASTIN® can include the biosimilar known as BCD-021 produced by
Biocad and currently in clinical trials in the U.S.
Trastuzumab is a mAb that eres with the HER2/neu receptor.
Trastuzumab is marketed under the trade name HERCEPTIN® by
Genentech, Inc. HERCEPTIN® is produced by a mammalian cell (Chinese
r Ovary (CHO)) line. HERCEPTIN® is a sterile, white to pale-
yellow, preservative-free lyophilized powder for IV administration. Each
HERCEPTIN® vial contains 440 mg trastuzumab, 9.9 mg L—histidine HCl,
6.4 mg L—histidine, 400 mg a,a—trehalose dihydrate, and 1.8 mg polysorbate
, USP. Reconstitution with 20 mL water yields a multi-dose solution
containing 21 mg/mL zumab. HERCEPTIN® is currently administered
via IV infusion as often as weekly and at a dosage ranging from about 2
mg/kg to about 8 mg/kg.
Trastuzumab is mainly used to treat certain breast cancers. The HER2
gene is amplified in 20-30% of stage breast cancers, which makes it
overexpress epidermal growth factor '(EGF) receptors in the cell membrane.
Trastuzumab is generally administered as a maintenance therapy for patients
with HERZ-positive breast cancer, typically for one year post~chemotherapy.
Trastuzumab is currently administered via IV infusion as often as weekly and
at a dosage g from about 2 mg/kg to about 8 mg/kg.
As used herein, the term “trastuzumab” includes the mAb that
interferes with the HERZ/neu receptor known under the International
Nonproprietary Name/Common Name “TRASTUZUMAB” or an antigen
binding portion thereof. Trastuzumab is described in U.S. Patent No.
,821,3 37. zumab includes the active agent in products ed
under the trade name HERCEPTIN® and biosimilars thereof. The term
“trastuzumab” es the active agent in biosimilar HERCEPTIN‘1D
products marketed under the trade names HERTRAZ® by Mylan, Inc.
(“Mylan”) and CANMAB® by Biocon, Ltd. (“Biocon”). Trastuzurnab can
include the active agent in biosimilar HERCEPTIN® products being
developed by Amgen and by PlantForm Corporation, Canada.
Infliximab is a mAb against tumor necrosis factor alpha L) used
to treat autoimmune diseases. It is marketed under the trade name
REMICADE® by Janssen Global Services, LLC (“Janssen”) in the U.S.,
Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Merck & Co
(“Merck”); elsewhere. Infliximab is a chimeric mouse/human monoclonal
antibody with a high molecular weight of approximately 144 kDa. In some
embodiments, the formulations contain a biosimilar ofREMICADE®, such
as REMSIMATM or INFLECTRATM. Both REMSIMATM, developed by
Celltrion, Inc. (“Celltrion”), and INFLECTRATM, developed by Hospira Inc,
UK, have been recommended for regulatory approval in Europe. Celltrion
has submitted a filing for REMSIMATM to the FDA. Infliximab is tly
administered Via IV on at doses g from about 3 mg/kg to about
mg/kg.
lnfliximab contains approximately 30% murine variable region amino
acid sequence, Which confers antigen-binding specificity to human TNFOL
The remaining 70% correspond to a human IgG1 heavy chain constant
region and a human kappa light chain constant region. rnab has high
for human TNFu, which is a cytokine with multiple biologic actions
. affinity
including ion of inflammatory ses and modulation of the
immune system.
Infliximab is a recombinant antibody generally produced and secreted
from mouse a cells (SP2/O cells). The antibody is currently
manufactured by continuous perfusion cell culture. The infliximab
monoclonal antibody is expressed using ic antibody genes consisting
ofthe variable region sequences cloned from the murine anti-TNFa
oma A2, and human antibody constant region sequences supplied by
the plasmid sion vectors. Generation ofthe murine anti-TNF or
hybridoma is performed by immunization of BALB/c mice with purified ,
recombinant human TNFOL. The heavy and light chain vector ucts are
linearized and transfected into the Sp2/0 cells by electroporation. Standard
purification steps can include chromatographic purification, viral
inactivation, nanofiltration, and ultrafiltration/diafiltration.
As used herein, the term “infliximab” es the chimeric
mouse/human monoclonal dy known under the International
Nonproprietary Name “INFLIXIMAB” or an antigen binding portion
thereof. Infliximab neutralizes the biological ty of TNFa by binding
with high y to the soluble and transmembrane forms ofTNFu and
inhibits binding of TNFG with its receptors. Inflixirnab is described in US.
Patent No. 5,698,195. The term “Infliximab” includes the active agent in
products marketed or proposed to be marketed under the trade names
REMICADE® by multiple entities; REMSIMATM by Celltrion and
INFLECTRATM by Hospira, Inc (“Hospira”). Infliximab is ed as a
sterile lyophilized cake for reconstitution and dilution. Each vial of
infliximab contains 100 mg infliximab and excipients such as monobasic
sodium phosphate monohydrate, c sodium phosphate dihydrate,
I _
sucrose, and polysorbate 80.
Denosumab A® and XGEVA®) is a human mAb - and the
first RANKL inhibitor - approved for use in nopausal women with
risk of osteoporosis and patients with bone metastases from solid .
Denosumab is in Phase II trials for the treatment of rheumatoid arthritis.
Panitumumab is a fully human mAb approved by the FDA for
ent of EGFR-expressing metastatic cancer with disease progression.
Panitumumab is marketed under the trade name VECTIBIX® by Amgen.
VECTIBIX® is packaged as a 20 mg/ml panitumumab concentrate in 5 ml,
ml, and 15 ml vials for IV infusion. When prepared according to the
packaging instructions, the final panitumumab concentration does not exceed
mg/ml. VECTIBIX® is stered at a dosage of 6 mg/kg every 14
days as an intravenous infilsion. As used herein, the term “panitumumab”
includes the anti—human epidermal growth factor receptor known by the
International Nonproprietary Name “PANITUMUMAB.” The term
“panitumuma ” includes the active agent in ts marketed under the
trade name VECTIBIX® by Amgen and biosimilars thereof. The term
umumab” includes onal antibodies described in US. Patent No.
6,235,883. The term “panitumuma ” includes the active agent in biosimilar
IX® products, including biosimilar IX® being developed by
BioXpress, SA (“BioXpress”).
mab (BENLYSTA®) is a human mAb with a molecular weight
of about 151.8 kDa that inhibits B—cell activating factor (BAFF). Belimumab
is approved in the United States, Canada, and Europe for treatment of
systemic lupus erythematosus. Belimumab is currently administered to lupus
patients by IV infusion at a 10 mg/kg dosage. A high-molecular-weight, low-
ity protein formulation can e Belimurnab, preferably in a
concentration of about 400 mg/mL to about 1,000 mg/mL. The preferred
ranges are calculated based upon body weight of 40-100 kg (approximately
80-220 lbs) in a 1 mL volume.
Abciximab O®) is manufactured by Janssen Biologics BV
and distributed by Eli Lilly & Company (“Eli Lilly”). Abciximab is a Fab
fragment ofthe chimeric human-murine monoclonal antibody 7E3.
Abciximab binds to the rotein (GP) IIb/IIIa receptor of human
platelets and inhibits platelet aggregation by ting the binding of
fibrinogen, von Willebrand factor, and other adhesive molecules. It also
binds to vitronectin (avB3) receptor found on platelets and vessel wall
endothelial and smooth muscle cells. Abciximab is a platelet aggregation
inhibitor mainly used during and after coronary artery procedures.
Abciximab is administered via IV infusion, first in a bolus of 0.25 mg/kg and
followed by uous IV infusion of 0.125 meg/kg/minute for 12 hours.
Tositumomab (BEXXAR®) is a drug for the treatment of follicular
lymphoma. It is an IgG2a anti-CD20 mAb derived from immortalized mouse
cells. Tositumomab is administered in sequential infusions: cold mAb
followed by iodine (1311) tositumomab, the same antibody covalently bound
to the radionuclide iodine-131. Clinical trials have established the efficacy of
the tositumomab/iodine tositumomab regimen in patients with relapsed
refractory follicular lymphoma. BEXXAR® is currently administered at a
dose of 450 mg via IV infusion.
Alemtuzumab (marketed as CAMPATH®, MABCAMPATH®, or
H-IH® and currently under further development as
LEMTRADA®) is a mAb used in the ent of chronic lymphocytic
leukemia (CLL), cutaneous T—cell lymphoma (CTCL), and T—cell ma.
It is also used under clinical trial protocols for treatment of some
autoimmune es, such as multiple sclerosis. zumab has a weight
of approximately 145.5 kDa. It is administered in daily IV infusions of 30
mg for patients with B—cell chronic lymphocytic leukemia.
Palivizumab (SYNAGIS®) is a humanized mAb ed t an
e in the A antigenic site of the F protein of respiratory syncytial virus.
in two Phase III clinical trials in the pediatric popuiation, palivizumab
reduced the risk of hospitalization due to respiratory syncytial virus infection
by 55% and 45%. Palivizumab is closed once a month via IM injection of 15
mg/kg.
Ofatumumab is a human anti-CD20 mAb which appears to inhibit
early~stage B lymphocyte activation. Ofaturnumab is marketed under the
trade name ARZERRA® by GlaxoSmithKline, plc (“GlaxoSmithKline”).
ARZERRA® is distributed in single-use vials containing 100 mg/5 mL and
1,000 mg/SO mL ofatumumab for IV infusion. Ofatumumab is FDA-
approved for treating chronic lymphocytic leukemia and has also shown
potential in treating Follicular non-Hodgkin’s lymphoma, Diffuse large B
cell lymphoma, rheumatoid tis, and relapsing remitting multiple
sclerosis. Ofatumumab has a molecular weight of about 149 kDa. It is
currently administered by IV infusion at an initial dose of 300 mg, followed
by weekly infusions of 2,000 mg. AS used herein, the term “ofatumurnab”
includes the anti-CD20 mAb known by the International Nonproprietary
Name “OFATUMUMAB.” The term “ofatumumab” includes the active
agent in ts marketed under the trade name ARZERRA® and
biosimilars thereof. The term “ofatumumab” includes the active agent in
biosimilar ARZERRA® products being developed by BioExpress. High-
molecularuweight, low-viscosity liquid protein formulations can e
ofatumumab, preferably in a concentration of about 300 mg/mL to about
2,000 mg/mL.
Trastuzumab ine (in the U.S., ado-trastuzumab emtansine,
marketed as A®) is an antibody-drug ate consisting of the
mAb trastuzumab linked to the cytotoxic agent mertansine (DM1®).
Trastuzumab, described above, stops growth of cancer cells by binding to the
HERZ/neu receptor, Whereas rnertansine enters cells and ys them by
binding to tubulin. In the United , trastuzumab emtansine was
approved specifically for treatment of recurring HERZ-positive metastatic
breast cancer. Multiple Phase III trials of trastuzumab emtansine are planned
or ongoing in 2014. zumab emtansine is currently administered by IV
infusion of 3.6 rug/kg. High—molecular—weight, low-viscosity liquid
formulations can include trastuzumab emtansine, ably in a
concentration of about 144 mg/mL to about 360 mg/mL.
Pertuzumab (PERJETA®) is a mAb that inhibits HER2 dimerization.
Pertuzumab received FDA approval for the treatment of HEM-positive
metastatic breast cancer in 2012. The currently recommended dosage of
umab is 420 mg to 840 mg by IV infusion. High-molecular-weight,
low-viscosity liquid formulations can include pertuzumab, preferably in a
concentration of about 420 mg/rnL to about 840 mg/mL.
Daclizumab is a humanized anti-CD25 mAb and is used to t
rejection in organ transplantation, especially in kidney transplants. The drug
is also under investigation for the ent of multiple sclerosis.
Daclizumab has a molecular weight of about 143 kDa. Daclizumab was
marketed in the US. by Hoffmann—La Roche, Ltd. (“Roche”) as
ZENAPAX® and administered by IV infusion of 1 rug/kg. Daclizumab High-
Yield Process (DAC HYP; BIIBOl9; Biogen Idec (“‘Biogen”) and Abeie,
Inc. e”)) is in phase III clinical trials as a 150 mg, once-monthly
aneous injection to treat relapsing, remitting multiple-sclerosis. High-
molecular-weight, low-viscosity liquid formulations. can include daclizumab,
preferably in a concentration of about 40 mg/mL to about 300 mg/mL.
Eculizumab (SOLIRIS®) is a humanized mAb ed for the
treatment of rare blood diseases, such as paroxysmal nocturnal
hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab, with
a molecular weight of about 148 kDa, is being developed by n
Pharmaceuticals, Inc (“Alexion”). It is administered by IV infusion in the
amount of about 600 mg to about 1,200 mg. High-molecular-weight, low-
viscosity liquid formulations can e eculizumab, preferably in a
concentration of about 500 mg/mL to about 1,200 mg/mL.
Tocilizumab (ACTEMRA®) is a humanized mAb against the
interleukin-6 receptor. It is an immunosuppressive drug, mainly for the
treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic
arthritis, a severe form ofRA in children. Tocilizumab is commonly
stered by IVinfusion in doses of about 6 mg/kg to about 8 mg/kg.
Highnmolecular-weight, low-viscosity liquid formulations can include
tocilizumab, preferably in a concentration of about 240 mg/mL to about 800
mg/mL.
Rituximab (RITUXAN®) is a chimeric anti-CD20 mAb used to treat a
y of diseases characterized by excessive numbers ofB cells, overactive
B cells, or dysfunctional B cells. Rituxirnab is used to treat cancers of the
White blood system, such as leukemias and lymphomas, including Hodgkin's
ma and its lymphocyte-predominant subtype. It has been shown to be
an effective toid arthritis treatment. Rituximab is Widely used off-
label to treat difficult cases of multiple sclerosis, systemic lupus
erythematosus, and autoimmune anemias.
Rituximab is jointly marketed in the US. under the trade name
RITUXAN® by Biogen and Genentech and outside the US. under the trade
name RA® by Roche. RITUXAN® is distributed in single-use vials
containing 100 rug/10 mL and 500 mg/50 mL. RITUXAN® is typically
administered by IV infusion of about 375 mg/mz. The term “rituximab,” as
used herein, includes the anti—CD20 InAb known under the International
Nonproprietary Name/Common Name IMAB.” Rituximab includes
mAbs described in US. Patent No. 5,73 6,137. Rituximab includes the active
agent in products marketed under the trade name N® and
MABTHERA® and biosimilars thereof.
High-molecular-weight, low—viscosity liquid ations can include
rituximab, ably in a concentration of about 475 mg/mL to about 875
rn mL (approximated using a body e area range of 1.3 to 2.3 square
meters, derived from the Mosteller formula for persons ranging from 5 ft, 40
kg to 6 ft, 100 kg). Concentrations are calculated for a 1 mL formulation.
Ipilimumab is a human mAb developed by Bristol—Myers Squibb
y (“Bristol-Myers Squibb”). Marketed as YERVOY®, it is used for
the treatment of ma and is also undergoing clinical trials for the
treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer
(SCLC), and metastatic hormone—refractory prostate cancer. Ipilimurnab is
currently administered by IV infusion of 3 mg/kg. High—molecular—weight,
scosity liquid formulations can include ipilimumab, preferably in a
concentration of about 120 mg/mL to about 300 mg/mL.
Raxibacumab (ABthrax®) is a human mAb intended for the
prophylaxis and treatment of inhaled x. It is currently stered by
IV infusion. The suggested dosage in adults and children over 50 kg is 40
mg/kg. High-molecularvweight, low-viscosity liquid formulations can
include cumab, ably in a concentration of about 1,000 mg/mL to
about 4,000 Ing/mL.
Nimotuzumab ‘(THERACIM®, BIOMAB EGFR®, THERALOC®,
CIMAher®) is a humanized mAb with a molecular weight of about 151 kDa
used to treat squamous cell carcinomas of the head and neck, recurrent or
refractory high~grade malignant glioma, anaplastic astrocytomas,
glioblastomas, and e intrinsic pontine glioma. zumab is
typically administered by IV infusion of about 200 mg weekly. High~
lar-weight, low-viscosity liquid formulations can include
nimotuzumab, preferably in a concentration of about 200 mg/mL.
Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate
directed to the protein CD30, expressed in classical Hodgkin’s lymphoma
and systemic anaplastic large cell lymphoma. It is administered by IV
on of about 1.8 mg/kg. High-moleculanweight, low-viscosity liquid
formulations can include brentuximab n, preferably in a concentration
of about 80 mg/mL to about 200 mg/mL.
Itolizumab (ALZUMAB®) is a humanized IgGl mAb developed by
Biocon. Itolizumab completed successful Phase III studies in patients with
moderate to severe psoriasis. Itolizumab has received marketing approval in
India; an application for FDA approval has not been submitted.
Obinutuzumab (GAZYVA®), originally developed by Roche and
being further developed under a collaboration agreement with Biogen is a
humanized anti-CD20 mAb approved for treatment of chronic lymphocytic
leukemia. It is also being investigated in Phase III clinical trials for patients
with s lymphomas. Dosages of about 1,000 mg are being administered
via IV infilsion.
Certolizumab pegol (CIMZIA®) is a recombinant, humanized
antibody Fab' fragment, with specificity for human tumor necrosis factor
alpha (TNFa), conjugated to an approximately 40kDa polyethylene glycol
(PEGZMAL40K). The molecular weight of certolizumab pegol is
approximately 91 kDa.
Other antibody therapeutics that can be formulated with viscosity-
lowering agents e CT—P6 from Celltrion, Inc. (Celltrion).
Antibody Therapeutics in Late-Stage Trials and Development
The progression of antibody therapeutics to late-stage clinical
development and regulatory review are proceeding at a rapid pace. In 2014,
there are more than 300 mAbs in clinical trials and 30 commercially-
sponsored antibody therapeutics undergoing evaluation in late-stage studies.
First marketing applications for two mAbs (vedolizumab and ramucinnnab)
were recently submitted to the FDA. Arngen is currently sponsoring
multiple ongoing Phase III trials on the use of brodalumab in patients with
plaque psoriasis, with additional trials planned or recruiting patients.
ch, Inc. has sponsored two Phase I clinical trials of MABpl (Xilonix)
for patients with ed cancer or type—2 diabetes. Additional trials of
MABpl are recruiting ts. le trials are sponsored by
MedImmune, LLC (“Medlmrnune”) and underway or recruiting patients for
the treatment of leukemia with moxetumomab pasudotox. Long-term safety
and efficacy studies are underway for the use oftildrakizumab for the
treatment of chronic plaque psoriasis. Multiple phase II trials have recently
completed for the use of rilotumumab for the treatment of various cancers.
At least 28 mAbs are high-molecular-weight proteins currently in or
having recently completed Phase III studies for the treatment of
inflammatory or immunological disorders, cancers, high cholesterol,
orosis, Alzheimer’s disease, and infectious diseases. The mAbs in or
having recently completed Phase III trials e AMG 145, elotuzumab,
zumab, farletuzumab (MORAb-OOB), erumab (RG1450),
gevokizumab, inotuzumab ozogamicin, umab, ixekizumab,
izuma’o, mepolizumab, omab natox, necitumuma‘o,
mab, ocrelizumab, onartuzumab, racotumornab, ramucirurnab,
umab, romosozumab, sariiumab, numab, mab,
solanezumab, tabalumab, and vedoiizumab. A mAb mixture (actoxumab and
bezlotoxumab) is also being evaluated in Phase III trials. See, e.g., Reichert,
MES 5:1-4, 2013.
Vedolizurnab is a mAb being developed by Millennium
Pharmaceuticals, Inc (“Miiiennium”; a subsidiary of Takeda Pharmaceuticals
Company, Ltd. (“Takeda”)). Vedolizumab was found safe and highly
effective for inducing and ining clinical remission in patients with
moderate to severe tive colitis. Phase III clinical trials showed it to
meet the objectives of inducing a clinical response and maintaining
remission in Crohn's and ulcerative colitis patients. Studies evaluating long-
term ciinicai es show close to 60% of patients achieving clinical
remission. A common dose ofvedolizumab are 6 mg/kg by IV on.
Ramucirumab is a human mAb being developed for the treatment of
umors. Phase III clinical trials are g for the treatment of breast
cancer, metastatic gastric adenocarcinoma, non-small cell lung cancer, and
other types of cancer. rumab, in some Phase III trials, is administered
at about 8 mg/kg via IV infusion.
Rilotumumab is a human mAb that inhibits the action of hepatocyte
growth factor/scatter factor. Developed by Amgen, it is in Phase III trials as a
treatment for solid tumors. An open Phase III study of rilotumumab
treatment in patients with advanced or metastatic esophageal cancer will
administer mumab at about 15 mg/kg Via IV infusion.
Evolocumab (AMG 145), also developed by Amgen, is a mAb that
binds to PCSK9. Evolocumab is indicated for hypercholesteroiemia and
hyperlipidemia.
Alirocumab (REGN727) is a human mAb from Regeneron
Pharmaceuticals, Inc. (“Regeneron”) and Sanofi—Aventis U.S. LLC
(“Sanofi”), indicated for hypercholesteroiemia and acute coronary syndrome.
Naptumomab estafenatox, AER-217620 from Active Biotech AB
(“Active Biotech”) is a mAb ted for renal cell carcinoma.
Racotumomab from CIMAB, SA (“CIMAB”); Laboratorio Elea
S.A.C.I.F.y A. is a mAb indicated for non-smali cell lung cancer.
Other antibodies which may be formulated with viscosity-lowering
agents include bocociznmab (PF-04950615) and tanezumab; ganitumab,
blinatumomab, trebananib from Amgen; x immune globulin from
Cangene Corporation; teplizurnab from MacroGenics, Inc.; MK-3222, MK-
6072 from Merck & Co (“Merck”); girentuximab from Wilex AG; RIGScan
from Navidea nnaceuticals (“Navidea”); PF-05280014 from Pfizer;
SA237 from Chugai Pharmaceutical Co. Ltd. ("Chugai"); guselkumab from
Janssen/ Johnson and Johnson Services, Inc. (“J&J”); Antithrombin Gamma
(KW-3357) from Kyowa; and CT-PlO from Ceiltrion.
Antibodies ianarlySrage al Trials
Many mAbs have recently entered, or are entering, clinical trials.
They can include proteins currently stered Via IV infilsion, preferably
those having a molecular weight greater than about 120 kDa, typically fiom
about 140 kDa to about 180 kDa. They can also include such high-
molecular—weight proteins such as Albumin-conjugated drugs or peptides
that are also entering clinical trials or have been approved by the FDA.
Many mAbs from Amgen are currently in clinical trials. These can be high-
molecular—weight proteins, for example, AMG 557, which is a human
monoclonal antibody ped jointly by Arngen and AstraZeneca and
currently in Phase I trials for treatment of lupus. Likewise, AMG 729 is a
humanized mAb developed by Amgen and currently in Phase I trials for the
treatment of lupus and rheumatoid tis. In addition, AMG 110 is a mAb
for epithelial cell adhesion le; AMG 157, jointly developed by
Amgen and AstraZeneca, is a human mAb currently in Phase I for the
treatment of asthma; AMG 167 is a humanized mAb that has been evaluated
in multiple Phase I trials for the treatment of osteopenia; AMG 334, having
ted Phase I dosing studies and currently in in Phase II studies for the
treatment of migraines and hot , is a human mAb that inhibits
Calcitonin Gene-Related Peptide; AMG 780 is a human anti-angiopoietin
mAb that inhibits the interaction between the endothelial cell-selective TieZ
or and its ligands Angl and AngZ, and recently completed Phase I
trials as a cancer treatment; AMG 811 is a human monoclonal antibody that
ts interferon gamma being investigated as a treatment for systemic
lupus erythematosus; AMG 820 is a human mAb that inhibits c~fms and
decreases tumor associated macrophage (TAM) function and is being
investigated as a cancer treatment; AMG 181, jointly developed by Amgen
and AstraZeneca, is a human mAb that inhibits the action of alpha4fbeta7
and is in Phase II trials as a treatment for tive colitis and Crohn's
disease.
Many mAbs are currently in clinical trials for the treatment of
autoimmune disorders. These mAbs can be included in low-Viscosity, high-
molecular-weight liquid formulations. RG7624 is a fully human mAb
ed to specifically and selectively bind to the human interleukin-17
family of nes. A Phase I clinical trial evaluating RG7624 for
autoimmune disease is ongoing. BIIB033 is an INGO-l mAb by
Biogen currently in Phase II trials for treatingmultiple sclerosis.
High-molecular—weight proteins also can include AGS-009, a mAb
targeting pha developed by Argos Therapeutics, Inc. that recently
completed phase I trials for the treatment of lupus. Patients are administered
up to 30 mg/kg ofAGS—009 via IV infilsion. BT-06l , developed by Abeie,
is in PhaSe II trials for patients with rheumatoid arthritis. Certolizumab pegol
(CIMZIA®) is a mAb in Phase II trials for ankylosing spondylitis and
juvenile toid arthritis. Clazakizumab, an anti-1L6 mAb, is in Phase II
trials by Bristol—Myers Squibb.
(INTO-I36 (sirukumab) and CNTO~1959 are mABs having ly
completed Phase II and Phase III trials by Janssen. Daclizumab (previously
ed as X® by Roche) is currently in or has recently completed
multiple Phase III trials by Abeie for the treatment of multiple sclerosis.
Epratuzumab is a zed mAb in Phase III trials for the ent of
lupus. Canakinurnab (ILARIS®) is a human mAb targeted at interleukin-1
beta. It was approved for the treatment of cryopyrin—associated periodic
syndromes. Canakinurnab is in Phase I trials as a possible treatment for
chronic obstructive puimonary disease, gout and coronary artery disease.
Mavriiimumab is a human mAb designed for the treatment of rheumatoid
arthritis. Discovered as CAM—3001 by Cambridge Antibody Technology,
mavrilimumab is being developed by Medlmmune.
MEDI—546 are 70 are mAbs currently in Phase I and Phase II
trials by AstraZeneca for the ent of lupus. MEDI—546 is administered
in the Phase II study by regular IV infusions of 300~l,000 mg. MEDI—SS 1,
another mAb being developed by AstraZeneca for numerous indications, is
also currently administered by IV infusion. NN8209, a mAb blocking the
C5aR receptor being developed by Novo Nordisk A/S( “Novo Nordisk”), has
completed a Phase II dosing study for treatment of rheumatoid arthritis.
NN8210 is another antiCSaR mAb being developed by Novo k and
currently is in Phase I trials. IPH2201 (NN8765) is a humanized mAb
targeting NKGZA being developed by Novo Nordisk to treat patients with
inflammatory conditions and autoimmune diseases. NN8765 ly
completed Phase I trials.
Olokizumab is a humanized mAb that potently targets the cytokine
IL-6. IL—6 is involved in several autoimmune and atory pathways.
Olokizumab has completed Phase II trials for the treatment of rheumatoid
arthritis. Otelixizumab, also known as TRX4, is a mAb, which is being
developed for the treatment oftype 1 diabetes, rheumatoid arthritis, and other
autoimmune diseases. Ozoralizumab is a humanized mAb that has completed
Phase II trials.
Pfizer currently has Phase Itrials for the mAbs PD-3 60324 and PF—
04236921 for the treatment of lupus. A rituximab biosimilar, 805 86,
has been developed by Pfizer and is in Phase e II trials for rheumatoid
arthritis.
Rontalizumab is a humanized InAb being developed by Genentech. It
recently completed Phase II trials for the treatment of lupus. 244
(anti-CXCRS) is a mAb by Sanofi in Phase I trials. Sifalimumab (anti—IFNn
alpha mAb) is a mAb in Phase II trials for the treatment of lupus.
A high-moiecular—weight low-viscosity liquid formulation can
include one of the mAbs in early stage clinical development for treating
various blood disorders. For example, Belirnumab (BENLYSTA®) has
recently ted Phase I trials for patients with itis. Other mAbs in
early-stage trials for blood disorders include 075 from nger
Ingelheim GmbH inger Ingelheim”, ferroportin mAb and hepcidin
WO 38818
mAb from Eli Lily, and SelGl from Selexys Pharmaceuticals, Corp.
xys”).
One or more mAbs in early-stage development for treating various
cancers and related ions can be included in a scosity, high-
molecular-weight liquid formulation. United Therapeutics, Corporation has
two mAbs in Phase I , 8H9 mAb and ch14.18 mAb. The mAbs ABT-
806, enavatuzurnab, and volociXimab from Abeie are in early-stage
development. Actinium Pharmaceuticals, Inc has conducted early-stage trials
for the mAbs ActimabuA (M195 mAb), anti-CD45 mAb, and Iomab—B.
Seattle Genetics, Inc. (“Seattle cs”) has several InAbs in early—stage
trials for cancer and related conditions, including anti-CD22 ADC (RG7593;
pinatuzumab vedotin), anti-CD79b ADC (RG7596), anti-STEAPI ADC
(RG7450), ASG—SME and ASG-ZZME from Agensys, Inc. (“Agensys”) the
antibody-drug conjugate RG7458, and vorsetuzumab mafodotin. The early-
stage cancer therapeutics from Genentech can be included in low-viscosity
formulations, including ALT-83 6, the dy-drug conjugates RG7600 and
DEDN6526A, anti-CD22 ADC (RG7593), anti-EGFL7 InAb (RG7414),
anti-HER3/EGFR DAF mAb (RG7597), anti—PD~L1 mAb (RG7446),
DFRF4539A, an MINT1526A. l-Myers Squibb is developing early-
stage mAbs for cancer therapeutics, including those identified as anti-
CXCR4, anti-PD-Ll, IL-21 (EMS—982470), lirilumab, and urelumab (anti-
CD137). Other mAbs in early-stage trials as cancer therapeutics include
(hu14.18-IL2) from Apeiron Biologics AG, AV-203 from AVEO
ceuticals, Inc. (“AVEO”), AVX701 and AVX901 from AlphaVaX,
BAX-69 from Baxter International, Inc. (“Baxter”), BAY 79-4620 and BAY
-10112 from Bayer HealthCare AG, BHQ880 from Novartis AG, 212-Pb-
TCMCtrastuzumab from AREVA Med, AbGn-7 from AbGenomics
International Inc, and ABIO-OSOI (TALL-104) from Abiogen Phanna S.p.A.
Other antibody therapeutics that can be formulated with viscosity-
lowering agents include b, GA101, daratumumab, imab, ALX-
0061, ALX—0962, ALX-0761, bimagumab (BYM338), CT-Oll
(pidilizurnab), ,actoxumab/bezlotoxumab (MK-3515A), MIC-3475
(pembrolizumab), dalotuzumab (MK-0646), mab (IMC-18F1,
LY3012212), AMG 139 (MED12070), SAR339658, dupilumab (REGN668),
SAR156597, SAR256212, 356, SAR3419, SAR153192 (REGN421,
enoticumab), SAR307746 (nesvacumab), SAR650984, SAR566658,
SAR391786, SAR228810, SAR252067, SGN—CDIQA, SGN-CD33A, SGN—
LIVIA, ASG 15MB, Anti-LINGO, BIIB037, ALXN1007, teprotumumab,
concizumab, anrukinzumab (IMA—63 8), ponezumab (PF-04360365), PF—
03446962, PF-06252616, etrolizumab (RG7413), quilizumab, ranibizumab,
lampalizumab, onclacumab, gentenerumab, umab (RG7412), IMC—
RONS (narnatumab), tremelimumab, vantictumab, eemcizumab,
ozanezumab, mumab, tralokinumab, XmAbS871, XmAb7195,
cixutumumab (LY3 012217), LY2541546 (blosozumab), olaratmnab
(LY3012207), MEDI4893, MEDIS73, MEDIO639, MEDI3617, MEDI473 6,
MEDI6469, 80, MED15872, PF-05236812 03), PF-
05082566, BI 1034020, RG7116, RG7356, RG7155, RG7212, RG7599,
RG7636, , RG7652 (MPSK3169A), RG7686, HuMaxTFADC,
MOR103, BT061, MORZOS, OMP59R5 (anti-notch 2/3), VAY736,
MOR202, BAY94-9343, LJM716, OMP52M51, GSK933776, GSK249320,
GSK1070806, NN8828, CEP-37250/KHK2804 M8F, AGS-16C3F,
LY3016859, 655, LY28753 58, and LY2812176.
Other early stage InAbs that can be formulated with Viscosity-
lowering agents include benralizumab, 968, anifrolumab,
MEDI7183, sifalimumab, MEDI—575, tralokinumab from AstraZeneca and
Medlmmune; BAN2401 from Biogen Idec/Eisai Co. LTD ("Eisai")/
BioArctic cience AB; CDP7657 an anti~CD40L monovalent
pegylated Fab antibody fragment, STX-IOO an anti-avB6 mAb, BIIBOS 9,
Anti-TWEAK (BHB023), and BIIB022 from Biogen; umab from
Janssen and Amgen; BI—204/RG741 8 from BioInvent
International/Genentech; BT-062 (indatuximab ravtansine) from Biotest
ceuticals Corporation; XInAb from Boehringer eim/Xencor;
anti-11310 from Bristol—Myers Squibb; J 591 LII-177 from BZL Biologics
LLC; CDX-Oll (glembatumumab vedotin), CDX~0401 from Celldex
Therapeutics; foravirumab from Cmceli; tigatuzumab from Daiichi Sankyo
Company Limited; 004, MORAb-009 (amatuximab) from Eisai;
LY23 82770 from Eli Lilly; DIl7E6 from EMD Serono Inc; zanolimumab
from Emergent BioSolutions, 1110.; FG—3019 from FibroGen, 1nc.;
catumaxomab from Fresenius SE & Co. KGaA; pateclizumab, rontalizumab
from Genentech; fresolimumab from Genzyme & Sanofi; GS-6624
(simtuzumab) from Gilead; 28; bapineuzumab (AAB-OOI),
ab, 36 from n; K3003 from KaloBios Pharmaceuticals,
Inc.; ASKP1240 from Kyowa; RN—307 from Labrys Biologics 1n0.;
ecromeximab from Life Science Pharmaceuticals; LY249565S, LY292805 7,
LY3015014, LY2951742 from Eli Lilly; MBL-HCVl from 'MassBiologics;
AME-133V fiom MENTRIK Biotech, LLC; abituzumab from Merck KGaA;
MM~121 from Merrimack Pharmaceuticals, 1110.; MCSl 10; QAX576,
QBX258, QGE031 from Novartis AG; HCD122 from Novartis AG and
XOMA Corporation (“XOMA”); NN8555 from Novo Nordisk; bavituximab,
cotara from Peregrine Pharmaceuticals, 1110.; PSMA~ADC from Progenics
Pharmaceuticals, 1110.; omab from Quest Pharmatech, 1110.; fasinumab
(REGN475), REGN1033, 893, REGN846 from Regeneron;
RG7160, CIM331, RG7745 from Roche; ibalizumab (TMB-355) from
TaiMed Biologics 1110.; TCN-032 from Theraclone Sciences; TRClOS from
TRACON Pharmaceuticals, Inc.; UB—421 from United Biomedical Inc;
from ia Bio, 1110.; ART-110 from Abeie; Caplaciiumab,
Ozoralizumab from Ablynx; PRO 140 from CytoDyn, Inc.; GS-CDAI,
MDX-1388 from Medarex, 1110.; AMG 827, AMG 888 from Amgen;
ublituximab from TG Therapeutics 1110.; TOLlOl from Tolera Therapeutics,
Inc.; —DM1 (lorvotuzuma‘o mertansine) from ImmunoGen 1nc.;
epratuzumab Y-90/veltuzumab combination (1MMU-102)from
Immunomedics, 1110.; anti-fibrin mAb/ 3B6/22 T0-99m from Agenix,
Limited; ALD403 from Alder Biopharmaceuticals, 1110.; RN6G/ PF-
23 from Pfizer; CG201 from CG Therapeutics, Inc. ; KBOOl-A from
KaloBios Pharmaceuticals/Sanofi; KRN-23 fiom Kyowa.; Y—90 hPAM 4
from Immunomedics,lnc.; Tarextumab from Morphosys AG & OncoMed
Pharmacetuicals, 1110.; LFG316 from Morphosys AG & Novartis AG;
CNTO3157, CNT06785 from Morphosys AG & Jannsen; RG6013 from
Roche & Chugai; MM—l 1 1 from Merrimack Pharmaceuticals, Inc.
(“Merrimack”); GSK2862277 from GlaxoSmithKline; AMG 282, AMG 172,
AMG 595, AMG 745, AMG 761 from Amgen; BVX—20 from Biocon; CT-
P19, CT-P24, CT-PZS, CT-P26, , CT—P4 from Celltrion;
GSK284933, GSK2398852, GSK2618960, GSK1223249, GSK933776A
from GlaxoSmithKline; anetumab ravtansine from sys AG & Bayer
AG; BI-836845 from Morphosys AG & Boehringer Ingelheim; NOV-7,
NOV— 8 from Morphosys AG & Novartis AG; MM—302, MM—3 10, MM—141,
MM-131, MM~151 from Merrimack, RG7882 from Roche & e
Genetics; RG7841 from Roche/ Genentech; PF-06410293, PF—0643 8179,
PF-0643953 5, PF-04605412, PF-05280586 from Pfizer; RG7716, RG793 6,
gentenerumab, RG7444 from Roche; 47, 65, MED11814,
MEDI4920, MED18897, MEDI-4212, MEDI-5117, MEDI—7814 from
Astrazeneca; ulocuplurnab, PCSK9 adnectin froin Bristol-Myers Squibb;
FPAOOQ, FPA145 from FivePrime Therapeutics, Inc.; GS—5745 from Gilead;
BIW—8962, 3, KHK6640 from Kyowa Hakko Kirin; MM-141 from
Merck KGaA; REGN1154, REGN1193, REGN1400, REGN 1 500,
REGN1908-1909, REGN2009, REGN2176-3, REGN728 from Regeneron;
SAR307746 from Sanofi; SGN—CD70A from Seattle Genetics; ALX—0141,
ALX—Ol 71 from Ablynx; milatuzumab-DOX, milatuzhmab, TF2, from
Immunornedics, Inc.; MLN0264 from Millennium; ABT—981from Abeie;
AbGn-l68H from AbGenomics International Inc.; ficlatuzumab from
AVEO; BI—505 from Biolnvent ational; CDX-l 127, CDX-301 from
Celldex Therapeutics; CLT-008 from Cellerant Therapeutics Inc.; VGX~100
from Circadian; U3-1565 from Daiichi Sankyo Company d; DKN—Ol
from Dekkun Corp.; flanvotumab (TYRPI protein), IL—l I?» antibody, IMC-
CS4 from Eli Lilly; VEGFR3 mAb, IMC-TRl (LY3022859) from Eli Lilly
and ImClone, LLC; Anthim from Elusys Therapeutics Inc.; HuL2G7 from
Galaxy Biotech LLC; IMGB853, IMGN529 from ImmunoGen Inc.; CNTO-
, ONTO—5825 from n; KD-247 from Kaketsuken; K3004 from
KaloBios Pharmaceuticals; MGA27I, MGAH22 from MacroGenics, Inc.;
XmAbSS74 from MorphoSys AG/Xencor; ensituximab (NPC—l C) from
ix Oncology, Inc.; LFA102 from is AG and XOMA; ATI355
from Novartis AG; SAN-300 from Santarus Inc.; SelGl from Selexys;
/rGel from Targa Therapeutics, Corp. ; VX15 from Teva
2014/055254
Pharmaceuticals, Industries Ltd. (“Teva”) and Vaccinex Inc.; TCN—202 from
Theraclone es; XmAb2513, XmAb5872 from Xencor; XOMA 3AB
from XOMA and National Institute for Allergy and Infectious Diseases;
neuroblastoma antibody vaccine from MabVax Therapeutics; Cytolin from
CytoDyn, Inc; Thravixa from Emergent utions Inc; and FE 301 from
Cytovance Biologics; rabies mAb from Janssen and Sanofi; flu mAb from
Janssen and partly funded by National Institutes of Health; MB-003 and
ZMapp from Mapp Biopharmaceutical, Inc; and ZMAb from s Inc.
Other Protein Therapeutics
The n can be an , a fusion protein, a stealth or ted
protein, vaccine or otherwise a biologically active protein (or protein
e). The term “enzyme,” as used herein, refers to the protein or
functional fragment thereof that catalyzes a mical transformation of a
target molecule to a desired product.
s as drugs have at least two ant features, namely i)
often bind and act on their targets with high affinity and specificity, and ii)
are catalytic and convert multiple target molecules to the desired products.
In certain embodiments, the protein can be PEGylated, as defined herein.
The term “fusion protein,” as used herein, refers to a protein that is
created from two different genes encoding for two separate proteins. Fusion
proteins are generally produced through recombinant DNA techniques
known to those skilled in the art. Two proteins (or protein fragments) are
fused together covalently and exhibit properties from both parent proteins.
There are a number of fusion proteins that are on the market.
ENBREL® (Etanercept), is a fusion protein marketed by Amgen that
competitively inhibits TNF.
ELOCTATE®, Antihemophilic Factor (Recombinant), Fc Fusion
Protein, is a recombinant DNA derived, mophilic factor indicated in
adults and children with Hemophilia A (congenital Factor VIII deficiency)
for control and tion of bleeding episodes, perioperative management,
routine prophylaxis to prevent or reduce the frequency of bleeding es.
EYLEA® (aflibercept) is a recombinant fusion protein consisting of
portions of human VEGF receptors 1 and 2 extracellular domains fused to
the Fc portion of human IgG1 formulated as an iso-osmotic solution for
intravitreal administration. EYLEA (aflibercept) is a inant fusion
protein consisting of portions of human VEGF receptors 1 and 2 extracellular
domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic
solution for intravitreal administration. Aflibercept is a dimeric glycoprotein
with a protein molecular weight of 97 ltons (kDa) and contains
glycosylation, constituting an additional 15% of the total molecular mass,
resulting in a total molecular weight of 115 kDa. Aflibercept is produced in
recombinant Chinese hamster ovary (CHO) cells, marketed by ron.
ALPROLIXTM, Coagulation Factor IX (Recombinant), Fe Fusion
Protein, is a inant DNA derived, ation Factor IX concentrate is
indicated in adults and children With hemophilia B for control and prevention
ofbleeding episodes, perioperative management, routine prophylaxis to
prevent or reduce the frequency of bleeding episodes.
Pegloticase (KRYSTEXXA®) is a drug for the treatment of severe,
treatment-refractory, c gout, developed by Savient Pharmaceuticals,
Inc. and is the first drug approved for this indication. Pegloticase is a
pegylated recombinant porcine-like uricase with a molecular weight of about
497 kDa. Pegloticase is currently administered by IV ons of about 8
mg/kg. High—molecular-weight, low-viscosity liquid formulations can
include pegloticase, preferably in a concentration of about 300 Ing/mL to
about 800 mg/mL.
Alteplase (ACTIVASE®) is a tissue plasminogen tor produced
by recombinant DNA technology. It is a purified glycoprotein comprising
527 amino acids and sized using the complementary DNA (cDNA) for
natural human tissue-type plasminogen activator obtained from a human
melanoma cell line. ase is administered via IV infusion of about 100
mg immediately following ms of a stroke. In some embodiments,
low—viscosity formulations are provided containing ase, preferably in a
concentration of about 100 mg/mL.
Glucarpidase AZE®) is a FDA—approved drug for the
treatment of elevated levels of methotrexate (defined as at least 1
ol/L) during treatment of cancer patients who have impaired kidney
function. Glucarpidase is administered via IV in a single dose of about 50
IU/kg. In some embodiments, low-viscosity formulations are provided
containing glucarpidase.
Alglucosidase alfa (LUMIZYME®) is an enzyme replacement therapy
orphan drug for treatment ofPompe disease gen storage disease type
II), a rare lysosomal storage disorder. It has a molecular weight of about 106
kDa and is tly administered by IV infusions of about 20 mg/kg. In
some embodiments, a low-viscosity pharmaceutical formulation of
alglucosidase alfa is provided, preferably with a concentration of about 100
mg/mL to about 2,000 mg/mL.
Pegdamase bovine (ADAGEN®) is a modified enzyme used for
enzyme replacement therapy for the treatment of severe ed
immunodeficiency disease (SCID) associated with a deficiency of adenosine
deaminase. Pegdamase bovine is a conjugate of numerous strands of
monomethoxypolyethylene glycol (PEG), molecular weight 5,000 Da,
covalently attached to adenosine deaminase enzyme that has been derived
fi‘om bovine ine.
u-Galactosidase is a lysosomal enzyme that catalyses the hydrolysis
ofthe glycolipid, globotriaosylceramide (GL6), to galactose and ceramide
dihexoside. Fabry disease is a rare inheritable lysosomal storage disease
characterized by subnormal enzymatic activity of u—Galactosidase and
resultant accumulation of GL—3. Agalsidase alfa GAL®) is a human
a-galactosidase A enzyme produced by a human cell line. dase beta
(FABRAZYME®) is a inant human a—gaiactosidase expressed in a
CHO'cell line. Replagal is stered at a dose of 0.2 mg/kg every other
week by intravenous infusion for the treatment of Fabry disease and, off
label, for the treatment of Gaucher disease. FABRAZYME® is administered
at a dose of 1.0 mg/kg body weight every other week by IV infusion. Other
lysosomal enzymes can also be used. For example, the protein can be a
lysosomal enzyme as bed in US 2012/0148556.
RasburicaSe (ELITEK®) is a recombinant urate-oxidase indicated for
initial management of plasma uric acid levels in pediatric and adult patients
with leukemia, lymphoma, and solid tumor malignancies who are receiving
anti-cancer therapy ed to result in tumor lysis and subsequent
elevation of plasma uric acid. ® is administered by daily IV infusion
at a dosage of 0.2 mg/kg.
Imiglucerase (CEREZYME®) is a recombinant analogue ofhuman B-
glucocerebrosidase. Initial dosages range from 2.5 U/kg body weight 3 times
a week to 60 U/kg once every 2 weeks. ME® is administered by IV
infusion.
Abraxane, paclitaxel—conjugated albumin, is approved for metastatic
breast cancer, all cell lung cancer, and late stage pancreatic cancer.
Taiiglucerase alfa (ELEYSO®) is a hydrolytic lysosomal
glucocerebroside-specific enzyme indicated for long-term enzyme
replacement therapy for Type 1 Gaucher disease. The reconnnended dose is
60 U/kg of body weight administered once every 2 weeks Via intravenous
infusion.
Laronidase (ALDURAZYME®) is a polymorphic t of the
human enzyme o-L—iduronidase that is produced via CHO cell line. The
recommended dosage regimen ofALDURAZYME® is 0.58 mg/kg
administered once weekly as an intravenous infusion.
Elosufase alfa (VIMIZIM®) is a human N-acetylgalactcsamine-QS-
ase produced by CI-IO cell line by BioMarin Pharmaceuticals Inc
(“BioMarin”). It was ed by the FDA on February 14, 2014 for the
treatment of Mucopolysaccharidosis Type NA. It is administered weekly via
intravenous infusion at a dosage of 2 mg/kg.
Other biologics which may be formulated with viscosity-lowering
agents include asparaginase erwinia chrysanthemi (ERWINAZE®),
incobotulinumtoxin A (XEOMIN®), EPOGEN® (epoetin Alta), PROCRIT®
(epoetin Alfa), ARANESP® (darbepoetin alfa), ORENCLA® cept),
BATASERON® (interferon beta-1b), NAGLAZYME® (galsulfase);
ELAPRASE® ulfase); MYOZYME® (LUMIZYME®, algucosidase
alfa); VPRIV® lucerase), abobotulinumtoxin A (DYSPORT®); BAX-
326, Octocog alfa from Baxter; Syncria from mithKline; liprotamase
from Eli Lilly; Xiaflex (collagenase clostridium histolyticum) from Auxilium
and BioSpecifics Technologies Corp. ; anakinra from Swedish Orphan
Biovitrum AB; eptin from l-Myers Squibb; Avonex, Plegridy
(BIIBOl 7) from Biogen; NN1841, NN7008 from Novo Nordisk; KRN321
poetin alfa), AMG531 (romiplostim), KRNlZS (pegfilgrastim), KW-
0761 ulizumab) from Kyowa; IB 1001 from Inspiration
Biopharmaceuticals; Iprivask from Canyon Pharmaceuticals Group.
Protein Therapeutics in Development
Versartis, Inc.’s VRS—3 17 is a recombinant human growth hormone
(hGH) fusion protein utilizing the XTEN ife extension technology. It
aims to reduce the frequency ofhGH injections necessary for patients with
hGH deficiency. VRS-317 has completed a Phase II study, comparing its
efficacy to daily injections of non-derivatized hGH, with positive results.
Phase III s are planned.
lysin is a proteolytic enzyme secreted by the Gram-negative
marine rganism, Vibrio proreolytz'cus. This endoprotease has specific
affinity for the hydrophobic s of proteins and is capable of cleaving
proteins adjacent to hydrophobic amino acids. Vibriolysin is currently being
igated by Biomarin for the cleaning and/or treatment of burns.
lysin formulations are described in patent W0 02/092014.
PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or
“‘PAL”) is an investigational enzyme substitution therapy for the treatment of
phenylketonuria (PKU), an ted metabolic disease caused by a
ncy ofthe enzyme phenylalanine hydroxylase (PAH). PEG—PAL is
being ped as a potential treatment for patients whose blood
phenylalanine (Phe) levels are not adequately controlled by KUVAN®. PEG-
PAL is now in Phase 2 clinical development to treat patients who do not
adequately respond to KUVAN®.
Other n therapeutics which may be formulated with viscosity-
lowering agents include Alprolix/ rFlXFc, Eloctate/ rFVIIIFc, BMN—l90;
BMN-250; Lamazyme; Galazyme; ZA-Ol 1 ; Sebelipase alfa; SEC-103; and
HGT—1 l 10. Additionally, fusionuproteins containing the XTEN half-life
extension technology including, but not limited to: VRS-317 GH~XTEN;
Factor VIIa, Factor VIII, Factor IX; PF05280602, VRS-859; Exenatide-
XTEN; AMX—256; GLP2~2GlXTEN; and AMX-l 79 Folate-XTEN—DMl can
be formulated with visco sity-lowering agents.
Other late—stage protein therapeutics which can be ated with
viscosity-lowering agents include CM-AT from CureMark LLC; NN7999,
NN7088, Liraglutide (NN8022), NN9211, Semaglutide (NN9535) from
Novo Nordisk; AMG 386, Fiigrastim from Amgen; 4, Factor VIII
from CSL Behring; LA-EP2006 (pegfilgrastim biosimilar) from is
AG; Multikine (leukocyte interleukin) from CEL-SCI Corporation;
LY260554], Teriparatide (recombinant PTH 1—34) from Eli Lilly; NU—lOO
from Nuron Biotech, Inc.; Calaspargase Pegol from Sigma-Tau
Pharmaceuticals, Inc.; ADI-PEG-20 from Polaris Pharmaceuticals, Inc.;
BMN—l 10, BMN—702 from BioMarin; NGR—TNF from Molmed S.p.A.;
recombinant human C1 se inhibitor from Pharming Group/Santarus
Inc. ; Somatropin biosimilar from LG Life Sciences LTD; a from NPS
Pharmaceuticals, Inc.; ART123 from Asahi Kasei Corporation; BAX-11 1
from Baxter; OBI-1 from Inspiration Biopharrnaceuticals; Wilate from
arma AG; Talactoferrin alfa from Agennix AG; eplase from
Lundbeck; Cinryze from Shire; RG7421 and Roche and Exelixis, Inc.;
aurin (PKC412) from Novartis AG; Damoctocog alfa pegol, BAY 86-
6150, BAY 94-9027 from Bayer AG; Peginterferon lambda-1a, Nulojix
(Belatacept) from Bristol-Myers Squibb; Pergoveris, Corifollitrcpin alfa
(MK-8962) from Merck KGaA; recombinant coagulation Factor IX Fc
fusion protein c; BIIB029) and recombinant coagulation Factor VIII
Fc fusion protein (rFVIIIFc; BIIB031) from Biogen; and Myalept from
AstraZenec'a.
Other early stage protein biologics which can be ated with
viscosity-lowering agents include Alferon LDO from Hemispherx
BioPharma, Inc.; SL-40l from Stemline Therapeutics, Inc.; PRX-lOZ from
Protalix Biotherapeutics, Inc.; KTP-OOI from Kaketsuken/Teijin Pharma
Limited; Vericiguat from Bayer AG; BMN—l 11 from in; ACC—OOl
(PFw05236806) from Janssen;LY2510924, LY2944876 from Eli Lilly;
NN9924 from Novo Nordisk; INGAP peptide from Exsulin; ART-122 from
Abbvie; AZD9412 from AstraZeneca; STIN (BGOOOIO) from
Biogen; Luspatercept (ACE-536), Sotatercept (ACE-011) from Celgene
ation; PRAME immunotherapeutic from GlaXOSmithKline; Plovamer
acetate (PI-2301) from Merck KGaA; PREMIPLEX (607) from Shire;
BMN~701 from BioMarin; Ontak from Eisai; rHuPHZO/insulin from
Halozyme, Inc.; PB-1023 from PhaseBio Pharmaceuticals, Inc.; ALV-003
from Alvine Pharmaceuticals Inc. and ; NN8717 from Novo Nordisk;
PRT-201 from Proteon Therapeutics Inc.; PEGPH20 from Halozyme, Inc.;
A1nevive® ept from Astellas Pharma Inc.; F-627 from Regeneron;
AGN—214868 (semebotase) from Allergan, Inc.; BAX-817 from Baxter;
PRT4445 from Portola Pharmaceuticals, Inc.; VENlOO from Ventria
Bioscience; Onconase/ ranpirnase from Tamir Biotechnology Inc.; interferon
alpha«2b infusion from Medtronic,1nc; pase alfa from Synageva
BioPharma; IRX-2 from IRX eutics, Inc; GSK2586881 from
GlaxoSmithKline; 3 from Seikagaku Corporation; ALXN1101,
asfotase alfa from Alexion; SHP611, SHP609 ase, idursulfase) from
- Shire; PF-04856884, 80602 from Pfizer; ACE—031, Daiantercept
from Acceleron Pharma; ALT-801 from Altor BioScience Corp; BA—210
from BioAxone Biosciences, Inc.; WTI immunotherapeutic from
GlaxoSmithKiine; GZ402666 from Sanofi; MSBOOIO445, Atacicept from
Merck KGaA; Leukine (sargramostim) from Bayer AG; KUR—le from
Baxter; fibroblast growth factor-1 from CardioVascular BioTherapeutics
Inc.; SPI—2012 from Hanrni Pharmaceuticals Co., LTD ruIn
Pharmaceuticals; FGF-18 (sprifermin) fiom Merck KGaA; MK—i 293 from
Merck; interferon-alpha—Zb from HanAll Biopharma; CYT107 fiom Cytheris
SA; RTOOI from Revance Therapeutics; Inc.; MEDI6012 from AztraZeneca;
E2609 from Biogen; BMN—190, BMN-270 from BioMarin; ACE-661 from
Acceleron Pharrna; AMG 876 from Amgen; GSK3 052230 from
GlaxoSmithKline; RG7813 from Roche; SAR342434, Lantus from Sanofi;
A201 from Aliozyne Inc. ; ARX424 from Ambrx, Inc.; FP-1040, FP-1039
from FivePrime eutics, Inc.; ATX-MS-1467 from Merck KGaA;
XTEN fusion proteins from Amunix Operating Inc.; entolimod (CBLBSOZ)
from Cleveland BioLabs, Inc.; HGT2310 from Shire; HM10760A from
Hannu' Pharmaceuticals Co., LTD; ALXNl 102/ ALXN1103 from n;
CSL-689, CSL-627 from CSL Behring; glial growth factor 2 from Acorda
Therapeutics, Inc. ; NXOOI from Nephrx Corporation; NN8640, NN1436,
NN1953, NN9926, NN9927, NN9928 from Novo Nordisk; NHS-IL 12 from
EMD Serono; 3K3A-APC from 22 Biotech LLC; PB-1046 from PhaseBio
Pharmaceuticals, Inc. ; RU-IOI from R—Tech Ueno, Ltd.; insulin
WO 38818
lispro/BC106 from Adocia; l from Iconic Therapeutics,_lnc.; PRT-IOS
from Protalix BioTherapeutics, Inc; PF-04856883, CVX-096 from Pfizer;
ACP-501 from AlphaCore Pharma LLC; BAX-855 fiom Baxter; CDX-1135
from Celldex Therapeutics; PRM-151 from Promedior, Inc.; T801 from
Thrombolytic Science International; TT-173 from Thrombotargets Corp;
QBI—139 from Quintessence Biosciences, Inc.; Vatelizumab, GBRSOO,
GBR600, GBR830, and GBR900 from rk Phannaceuticals; and
91 from Cytimmune Sciences, Inc.
Other Biologic Agents
Other biologic drugs that can be formulated with Viscosity-lowering
agents include PF-05285401, 31023, RN317 (PF-05335810), PF-
06263507, PF-05230907, Dekavil, PF-06342674, PF06252616, RG7598,
RG7842, RG7624d, OMP54F28, GSK1995057, 9470, IMC—3G3,
IMC-18F1, IMO-3 5C, IMC~20D7S, 80605, PF—0_6647263, PF-
06650808, PF»05335810 (RN317) PD-0360324, PF—00547659 from Pfizer;
MK—8237 from Merck; B1033 from Biogen; GZ402665, SAR43 8584/
REGN2222 fiom Sanofi; IMC-lSFl; and Icrucumab, IMC—3G3 from
ImClone LLC; Ryzodeg, Tresiba, Xultophy from Novo Nordisk; Touj60
(U300), LiXiLan, Lyxumia (lixisenatide) from Sanofi; MAGE-A3
immmotherapeutic from GlaxoSmithKline; Tecemotide from Merck KGaA;
Sereleaxin (RLX030) from Novartis AG; Erythropoietin; rastim;
LY2963016, Dulaglutide (LY2182965) from Eli Lilly; and Insulin Glargine
from Boehringer Ingelheim.
B. Viscosity-lowering Agents
The ity of liquid protein formulations, including low-
lar-weight and/or high-molecular-weight proteins, is reduced by the
addition of one or more ity-lowering agents. The pharmaceutical
formulations may be converted from non-Newtonian to ian fluids by
the addition“ of an effective amount of one or more Viscosity-lowering agents.
When employed in a ation intended for administration to a
human or other mammal, the Viscosity-lowering agents, like the formulation
itself, must be pharmaceutically able. The viscosity~lowering agents
are typically organic compounds containing at least one non-carbon, non-
hydrogen atom. Preferably, the Viscosityulowering agents contain hydrogen,
carbon, oxygen and at least one other type of atom. In certain embodiments,
the Viscosity-lowering agents are characterized by at least one of the
following:
1) organic nds having at least four carbon and four hydrogen
atoms, and at least one sulfur, oxygen, nitrogen, or phosphorus atom;
2) a molecular weight between about 85 and 1,000 Da;
3) the presence of at least one charged, or other hydrophilic, moiety;
4) the presence of at least one, preferably two, and more preferably
three, freely rotating bonds;
) the presence of at least one substituted ring; -
6) a molecular polar Surface area of at least 24 43, ably at least 50
A2, and more preferably at least 80 A2;
7) a molar volume of at least 75 cm3, preferably at least 85 cm3, more
preferably at least 100gcm3, and most preferably at least 120 cms;
a polarizability of at least 10 cm3, preferably at least 15 cm3, more
ably at least 20 01113, and most preferably at least 25 cm3; and
9) the presence of at least one, preferably two, and more preferably three
' hydrogen bond donors and/or
acceptors.
In certain embodiments, the viscosity-lowering agent is characterized by
at least two, three, four, five, Six, seven, eight or all nine of the above listed
attributes. In certain embodiments, the viscosity-lowering agent is r
characterized in that it does not contain an aldehyde or carbon—carbon triple
bond functional group.
In other embodiments, the viscosity-lowering agent is a combination
oftwo or more compounds, each of which is characterized by at least two,
three, four, five, six, seven, eight or all nine of the above listed attributes.
In some embodiments, the viscosity-lowering agents are listed as
GRAS by the US. Food and Drug Administration (“the FDA”), as of
September 11, 2014. "GRAS" is an acronym for the phrase generally
Recognized As fiafe. Under sections 201(s) and 409 of the Federal Food,
Drug, and Cosmetic Act (the Act), any substance that is intentionally added
to food is‘a food additive and is subject to premarket review and approval by
FDA unless the substance is generally recbgnized, among ed experts,
as having been adequately shown to be safe under the conditions of its
intended use, or unless the use of the substance is otherwise excluded from -
the definition of a food additive. Another source of compounds is the
Inactive ient Guide of the FDA (HG), and equivalents listed by the
International Pharmaceutical Excipients Council (IPEC) and the European
Medicines Agency (EMA), as of September 11, 2014. The substances used
in formulations must be safe for injection. Preferably, the GRAS—listed
viscosity~lowering agent is characterized by at least two, three, four, five,
six, seven, eight or all nine of the above listed utes.
In other embodiments, the viscosity-lowering agent is an FDA- or
EMA-approved drug product as of September 11, 2014. Like compounds
drawn from the GRAS and HG lists, the toxicity and safety profiles of FDA-
and EMA-approved drug ts are well established. In addition to
lowering the viscosity of the protein solution, the use of an FDA- or EMA-
approved drug product provides the opportunity for combination therapies.
Preferably a FDA— or EMA-approved drug product Viscosity-lowering agent
is characterized by at least two, three, four, five, six, seven, eight or all nine
of the above listed utes.
In some embodiments, the viscosityJowering agent includes at least
one compound ofFormula (I):
(R3); A
, (R3);
(3 3).: (Ra): Formula (1),
or a pharmaceutically acceptable salt f;
wherein ii represents either a single or double bond, A is a ed from O,
s, 802, NR3, C(R3)2 or:
(at): _ (R32;
”is. M
wherein R3 is independently selected from hydrogen, R2, -OH, NH;, -
F, -Cl, -Br, -1, -N02, —CN, —C(=O)R4a, -C(=NR4a)R4, -C(=O)OH, OR4,
)R4, -OC(=O)OR4, _s03H, -SOgN(R43 2, soar, -SOgNR4aC(=O)R4,
-PO3H2, ~R4aC(=NR4a)N(R4a 2, -NHC(=NR4a)NH-CN, -NR4“C(=O)R4, -
NR4aSO2R4, ~NR43C(=NR43)NR4aC(=NR4a)N(R4a 2, (=O)N(R4a)2, -
C(=0)NH2, -C(=O)N(R4a)2, -OR4, -s12.4a, and -N(R4a 2;
wherein R2 is independently selected from Cuzalkyl, C3-1gcycloalkyl,
C5_;2aryl, C1-1zheteroary1 and C2_12heterocyclyl;
wherein each szalkyl may be substituted one or more times with
C3420ycloalkyl, C5.12aryl, C1-12heter0aryl, C2-12heterocyclyi, -OH, NH;,
(:0), (=NR4a), -F, _c31, ~Br, —1,-No2, -CN, -C(=O)R4a, -C(=NR4E)R4, —
C(=O)0H, -C(=O)OR4, -OC(=O)R4, -OC(:0)0R4, -SO3H, -so2N(R“a 2, —
so2R4, -SOgNR4aC(=O)R4, -P02H2, -R43C(=NR4a)N(R4a 2, —
NHC(=NR4a)NH-CN, —NR4aC(:0)R4, «114330216, -
, NR4aC(=NR4a)NR4aC(=NR4a)N(R4a)2, -NR4aC(=O)N(R4" 2, —C(:0)NH2,
C(=O)N(R4a)2, -OR4, s11“, or -N(R4a)2;
wherein each C3.12cycloalky1 may be substituted one or more times
with C1_12a1ky1, Ca-lzflI‘YL C1-12heteroary1, C2_;2heterocyclyl, -OH, NH;, —F, -
(:1, Br, -1, -No2, -CN, -C(=0)R4“, -C(=NR4a)R4, -C(=O)OH, -C(=O)OR4, -
OC(=O)R4, »OC(:O)OR4, -so2H, -so2N(R“a 2, —so2R4, 2so2NR4aC(=0)R4,
—P02H2, -R4“C(=NR43)N(R4a 2, —NHC(=NR4a)NH-CN, -NR4aC(=O)R4, —
NR4aso2R“, -NR4“C(=NR4a)NR4aC(=NR4a)N(R4a 2, (:O)N(R4a)2, -
C(=0)NH2, -C(=O)N(R4a)2, -0R4, s11“, or —N(R4a 2;
wherein each ry1 may be substituted one or more times with C1-
Igalkyl, C3.1gcycloa1kyl, C1_1;2heteroaryl, erocyclyl, -OH, NHg, -F, -Cl,
-Br, -1, ~N02, -CN, -C(=O)R4a, -C(=NR43)R4, -C(=O)OH, —C(=0)0R4, -
OC(=O)R4, -OC(=O)OR4, -802H, —s02N(R4a 2, , -so2NR4aC(=0)R4,
-P03H2, -R4aC(=NR4a)N(R4a 2, NR4a)NH-CN, —NR4aC(=O)R4, -
NR4aSOgR4, -NR4aC(:NR4")NR4aC(=NR4a)N(R4a)2, -NR4aC(=O)N(R4a 2, —
C(=0)NH2, -C(=O)N(R4a)2, -0R4, -SR4a, or —N(R4a)2;
wherein each C1.1zheteroaryl may be substituted one or more times
with C1.12a1kyl, cloalkyl, €5-12aryl, C2_1gheterocyc1yl, -OH, NHz, -F, -
Cl, —Br, -1, -N02, ~CN, -C(=O)R4a, -C(=NR4a)R4, -C(=O)OH, -C(=0)0R4, —
OC(=0)R4, )OR4, —so2H, R4a 2, -so2R“, -SOzNR4aC(=O)R4,
-P03H2, -R4aC(=NR4“)N(R4a)2, ~NHC(=NR4a)NH-CN, -NR4aC(=O)R4, -
2R4, (=NR4a)NR4aC(=NR4a)N(R4a 2, -NR43C(=O)N(R4a)2, -
C(=O)NH2, —C(:0)N(R4“)2, -0R4, -SR4a, or -N(R4a)2;
wherein each C2.12heterocyclyl may be substituted one or more times
with C}-;2aikyl, ycloalkyl, C5-1garyl, C1.12heteroaryl, -OH, NHz, ~F, —Cl,
-Br, -I, -N02, -CN, -C(=O)R4a, -C(=NR4a)R4, —C(=O)OH, -C(=O)OR4, -
OC(=O)R4, —OC(=0)0R4, -s03H, -SO;N(R4a)2, , -SO;NR4aC(=O)R4,
—P03H2, -R4aC(=NR4a)N(R4a 2, NR4a)NH-CN, -NR4aC(=O)R4, —
NR4as02R4, -NR‘iaC(=NR4a)NR4aC(=NR4a)N(R4a 2, —NR4aC(=O)N(R4a 2, -
C(=O)NH2, -C(=0)N(R4a 2, ~0R4, -SR4a, or -N(R4a 2;
wherein R4 is independently selected from C1-12a1kyl, C3_1gcycloalkyl,
C6_1zaryl, C1_12heteroaryl and C2-lgheterocyclyl, each Of which may be
substituted one or more times by -OH, -NH2, -F, -Cl, -Br, -1, -N02, -CN, —
C(=0)OH, -SO3H, -PO3H2, or -C('—“O)NH2;
wherein K“ may be R4 or hydrogen;
wherein any two or more of R2, R3 , R4 and R43 groups may er
form a ring;
wherein when two R3 groups are bonded to the same carbon atom, the
two R3 groups may together form an (=0), (=NR4a or (:C(R4a)2);
wherein z is in each case independently selected from 1 or 2,
provided that when the (15(3)z tuent is connected to an sp2 hybridized
carbon, 2 is 1, and when the (R3)z substituent is connected to an sp3
hybridized carbon, 2 is 2.
When the substituent -NR43C(=NR4a)NR4aC(=NR43)N(R4a)2 is
t, it is preferred that R421 is selected so as to give -
NHC(=NH)NHC(=NH)NH2.
In n embodiments, the compound of Formula (1) ns at
least one substituent selected from -C(=O)OH, -SO3H, -SOgNHC(=O)R4,
and —PO3H2. In some embodiments, the compound of Formula (1) contains
at least one —SO3H group.
In certain embodiments, one or more of the R3 substituents may be:
O {Rag H x
,gJLNncasbzt-ew N CR3” “N2}‘
‘5 a," fir‘ was
H R o
R33.
7:510/(Gama); R3“
/ 4:: (033”2 x—-N’
N\ ‘57» Y FR“
R32:
01' 0
wherein R3a and R3b are independently ed from hydrogen, C1-1231ky1,
C3.120ycloalkyl, ryl, C1_1zheteroaryl and C2-12heterocyclyl, C(=O)R4a, —
H, -C(=O)OR4, -SO3H, —5102N(R4a 2, ~SOZR4, -SOgNHC(=O)R-4,
C(=O)NH2, -C(=O)N(R4a)2, -0R4, -SR“, and -N(R43 2, and when any two R3b
are bonded to the same carbon atom, the two R3ID groups may together form
an (=0), (:NR“), or a)2);
wherein each C1_12alkyl, C3.1gcycloalkyl, C5_uary1, C1_12heteroaryl and
C2.1gheterocyclyl may be substituted one or more times with -OH, NHz, -F, -
(:1, -Br, -1, -NO;, -CN, -C(=O)R4a, -C(=NR4a)R4, -C(=O)OH, —C(=0)0R4, -
OC(=0)R4, -OC(=O)OR4, -503H, ~S02N(R4” 2, -soZR4, -SO;NR4‘1C(:O)R4,
-P03H2, -R4aC(=NR4a)N(R4a 2, -NHC(=NR4a)NH-CN, ~NR4aC(=0)R4, -
NR43802R4, -NR4ac(:NR“)NR4*‘C(:NR43)N(R43)2, (=O)N(R4a)2, —
C(=O)NH2, -C(:O)N(R4a)2, -0R4, -SR4a, or -N(R43 2;
wherein R4 and R4a are as defined above;
wherein x is ed from 1, 2, 3, 4, 5, 7, 8, 9 or 10; and
wherein any two or more of R3 , R3a, R4 and RA"1 groups may together
form a ring.
In certain embodiments, the compound of Fom1ula(l) may be
represented by either the compound of Formula (la) or (lb):
Formula (la) Formula (1b)
wherein R3 has the meanings given above.
In certain embodiments, the compound of Formula (la) may be
represented by the compounds of Formulas (la-i—iv):
R3 Ea
R3 /(CR352)KW\
:12 R38
R3 Formula (la-i)
Formula (1 a-ii),
Formula (la-iii),
Formula (la—iv)
n R3 is independently selected from hydrogen, NHz, CH3, C1,
OR“ and NHR“;
wherein x is 1 or 2;
wherein R33 and R3‘) are independently Selected from hydrogen and
C142 alkyl;
n said lkyl may be substituted one or more times by C3-
lgcycloalkyl, C5-12aryl, Cuzheteroaryl, €2.12heterocyclyl, ~OH, NHz, ~F, -Cl,
—Br, -1, -N02, -CN, -C(=O)R4a, -C(=NR4"‘)R“, OH, —C(=0)0R4, _
OC(=0)R“, -0C(=0)0R4, sogH, ~SOZN(R4a 2, 60212“, -802NR4aC(=0)R4u
-P03H2, - 4aC(=NR4a)N(R4a)2, -NHC(=NR4B)NH-CN, -NR4aC(=O)R4, —
NR4aS02K: — R4aC(=NR4&)NR4“C(:NR43)N(R43 2, -NR4‘*C(:O)N(R43)2, -
C(=O)NH2, —C(=O)N(R4a 2, -0114, $1142 or -N(R43 2;
R4 and 11’” are as defined above; and
wherein any two or more R33, R3b, R4 R451 may together form a ring.
The compound of Formula (1) may be represented by the compound
of Formula (1 a-V, Vi or Vii):
R3 R3 R3!
R3 R3 R3
R3 R3 R3 ' R3
R3 (1 a—v), R3 R3 (la-vi),
R3 R3 (vii)
wherein R3f is selected from -C(=O)OH, —so3H, -SOgNHC(=O)R4, and —
P03H2, and R3 is as defined above. In certain preferred embodiments, R3 is
independently selected from en, OH, NHZ, C1_5alkyl and COOH.
In other embodiments, the compound of Formula (1) may be
represented by any of the compounds of ae (10), (1d), (1e) or (if):
Formula (1d)
3 a
R R3 R38
a (le) Formula (It),
wherein R3 has the meanings given above.
In other embodiments, the compound of Formula (1) may be
represented by a compound of Formula (lg):
R3:! 3'
R33 R3138 6 Formula (1 g),
wherein R3c is independently selected from hydrogen and R2, wherein
R2 has the meanings given above;
wherein R3d is independently ed from hydrogen, OH, NH;,
NH(C1-5alky1), N(C1_6alky1)2; NHC(=O)(Cl_5alkyl), COOH and CHZOH;
or any two R“ and R3d groups connected to the same carbon may
together form an oxo (=0), imino (=NR43), or an olefin (=C(R4a)2), wherein
R4a has the meanings given above;
WO 38818
wherein R3'3 is selected from hydrogen, —OH or 0R4; and
wherein R4 has the meanings given above.
In n embodiments, the viscosity-lowering agent includes a
compound of a (1 g-i):
R301! 0 R313
£10 0H
0“ Formula (1 g-i),
n R3e is selected from OH and -OC1.12alkyl, which is further
substituted with at least one OH and at least one COOH: and
wherein R3d is selected from COOH and CHZOH.
In some embodiments, the viscosity—lowering agent includes a
compound of Formula (2):
ea):
(R3): Formula (2),
or a phannaceutically acceptable salt thereof;
wherein i represents a single or double bond;
X is ndently selected from chalcogen, N(R3)z and C(R3)z;
X1 is absent, or is chalcogen, N(R3)Z, C(R3)Z or:
(R3):
“a.“M1,;
wherein R3 has the meanings given for the compound of Formula (1);
provided that when the (R3)Z tuent is connected to an sp2 hybridized
nitrogen, z is 0 or 1, when the (R3)z substituent is connected to an sp2
hybridized carbon or an sp3 hybridized nitrogen, z is 1, and when the (R3)Z
substituent is ted to an sp3 hybridized carbon, 2 is 2;
wherein at least one ofX or X1 is chalcogen or N(R3)z.
In certain embodiments, the compound may be an aromatic ring.
Exemplary aromatic rings include the compounds of Formulas (2a-e):
R3 1}? R3
“a. X 93%)4
R3 ”2%
R3 Formula (2a), R3 Formula (2b),
0 w'
R3 - X2
R3 R3 Formula (2c), R3 Formula (2d),
XQ/ X
k 1 9-4?
R3 X2 X2
Formula (26),
n R3 and X have the meanings above, and X2 is ed from N(R3)z
and C(R3)z.
In certain embodiments, the viscosity-lowering agent is a compound
of Formula :
3" N (Formula 2a—i),
wherein R4 is as defined above and is ably hydrogen or CH3;
wherein R6 is C1.12heteroaryl, which may be substituted one or more
times by C1-5alkyl;
wherein said C1.6alkyl may be substituted one or more times by OH,
-NH2, «F, -c1, -Br, —1, ~N02, —CN, —C(=0)R4, —C(=NR4a)R4, -C(=O)OH, —
C(=O)OR4, -s03H, —s02NR4-, -S02R4, $0,117,, —NHC(=O)R4, —
NHC(=O)N(R4)2, -C(:0)NH2, -C(=O)N(R4)2, -OR4b, -SR4b, -N(R4b)2,
wherein R4 has the meanings given above; or
. (iii-{O SR7
a/ij/AMR‘
wherein R4 is as defined above, and R7 is selected from SR4 and —C(=0)R4.
The double bond in the group above may be in either the E or Z geometry.
2014/055254
In preferred embodiments, R6 is a heterocycle having the structure:
rug/AXi
R53 R63
n X4 is a chalcogen and R6&1 is hydrogen or C1-5alkyl, wherein the C1.
fialkyl may be substituted one or more times by ~0H, —NH2, -F, -Cl, -Br, -I, -
N02, -CN, —C(=0)OH. In an even more preferred ment, R6 is a
heterocycle having the structure:
{Rug/\sC425
Rue R63
wherein R6a is selected from unsubstituted C1_6alkyl and C1.5alkyl substituted
one or more times with IQH.
The viscosity—lowering agent may be an imidazole of a (Zb-i)
R3 R“ Formula (2134),
wherein R3 is as defined above. In certain embodiments, R3 is independently
selected from hydrogen, N02, and R4. In certain preferred embodiments, the
compound of Formula (2b-i) has the structure:
N(Luna
wherein R3 is independently ed from CH; alkyl, which may be
unsubstituted or substituted one or more times with a group selected from
0H, NH;, SR4, F,C1, Br and I; and
R3g is either hydrogen or N02.
In other embodiments, the viscosity—lowering agent has the structure
of Formula (2a-ii) or Formula (EC-i):
2014/055254
R3 Formula (2a-ii), R3 R3 Formula (204),
wherein R3 is independently selected from OH, Cl, Br, F, I, N(R4a)2,
C(IO)OH, H2.
In further embodiments, at least one R3 substituent is NHR4, n
R4 is a C1_5alky1, optionally substituted by one or more groups selected from
Cl, Br, F, I, OH, C(=O)OH, NHz, NH(C1_5alkyl) and N(C1.5alkyl)2.
In other embodiments, the Viscosity-lowering agent is a pyridinium
salt of Formula (2a—iii):
R3 / P/Rfi
R3 R3
wherein R3 and R4 are as defined above.
In other embodiments, the heteroeyclie ring is not a aryl ring.
Exemplary non—aromatic rings include the compounds of Formulas (2f—k):
- R3 )4 R3
R3 R3 R3 R3 R3 R3
R3 Ra Ra R3 R3 R3
x3 R3
3R3 XXX
R3 Formula (2f) R333 R Formula (2g), P.3 Ra
Formula (2h)
Formula (Zj),
Formula (2k)
wherein R5 and X have the meanings above, and X3 is gen or N(R3)z.
In certain embodiments, the compound of a (2f) is a beta-
lactam of Formula (Zf-i),
R3 R3
R3itR3
0 R3 Formula (2fni).
The beta lactam of Formula (2f—i) includes penicillin-type
compounds, as well cephalosporin-type and cephamycin—type compounds of
the Formula (2f-ii) and (2f—iii):
will?“a a
9.ng R3
0::37 3
X R;
- R3}? 0 R3
as Formula (2f-ii) - R3 Formula (2m).
wherein X and R3 are as defined above. In preferred embodiments, X is
sulfur.
In n embodiments, the compound of Formula (2i) is a
compound ofFormula :
or;Formula (2i-i)
wherein X and R3 are as defined above. In certain embodiments, X is in both
cases NR4, whereinR4 has the meanings given above, and R3 is in both cases
hydrogen.
In other embodiments, the compound of Formula (2) is represented
by a compound of Formula (2i-ii):
F?3 x
R3 R3
R" x
R3 Formula (21-111),
wherein X, X1 and R3 are as defined above.
The nd ula (Zj) may be represented by the compound
ofFormula (2j ~i):
WO 38818
IRE.
R3(Formu1a (Zj-i),
wherein X3 and R3 are as defined above, and R8 is selected from the
NHC(=0)R2 and OC(=O)R2. In preferred embodiments, X3 is N+(CH3)2, R3
are both hydrogen, or R3 together form an epoxide or double bond.
The compound ula (2k) may be represented by the compound
of Formula (2k-i):
a3 Formula ,
wherein X3 and R8 are as defined above.
In other embodiments, the viscosity-lowering agent includes a
compound of the structure of Formula (3):
stif"R€
R5 Formula (3),
or a pharmaceutically acceptable salt thereof;
wherein R5 is in each case independently selected from hydrogen, and R2,
R5, is either R5 or absent;
providing that at least one R5 substituent is not hydrogen, n R2
has the same meanings given for the compound or Formula (1).
In certain embodiments, the viscosity-lowering agent is a mixture of
two or more compounds selected from nds of Formula (1), Formula
(2) and Formula (3).
In preferred embodiments, the viscosity—lowering agent is
camphorsulfonic acid (CSA), or a pharmaceutically acceptable salts thereof,
such as an alkaline or alkaline earth metal salt. The camphorsulfonic acid or
salt thereof is combined with one or more compounds of Formula (1), (2) or
(3) to give es such as CSA-piperazine, GSA-TRIS, CSA—4-amino
pyridine, CSA—l-(c-tclyl)biguanide, ocaine, CSA-Na—
2014/055254
aminocyclohexane carboxylic acid, CSA-Na—creatinine and GSA-Na-
omidazole. Other red viscosity-lowering agents include thiamine,
procaine, biotin, nine, metoclopramide, amine, cimetidine,
chloroquine phosphate, mepivacaine, granisetron, sucralose, HEPES-tris,
nicotinamide, ionic acid-TRIS, glucuronic acid-TRIS, sulfacetamide,
CSA-4~aminopyridine, CSA—piperazine and cefazolin. Any two or more of
the viscosity-lowering agents listed above may further be ed in the
same formulation.
In other embodiments, the viscosity-lowering agent is an
organosulfonic acid. Exemplary organosulfonic acids include, but are not
limited to, camphorsulfonic acid, naphthalene—Z-sulfonic acid,
benzenesulfonic acid, toluenesulfonic acid, cyclohexylsuflonic acid,
xylenesulfonic acids (including p-Xylene-Z-sulfonic acid, m-xylene-Z-
sulfonic acid, m-Xylenesulfonic acid and o-Xylene-3 —sulfonic acid),
esulfonic acid, 1,2 ethane disulfonic acid, 4-(2-hydroxyethyl)—l-
piperazine ethane sulfonic acid, 2-hydroxyethanesulfonic acid, 3—
hydroxypropane-l-sulfonic acid, cymenesulfonic acid, 4-hydroxybutane
sulfonic acid and pharmaceutically acceptable salts thereof. The
sulfonic acid may be in the form of an ne or alkaline earth metal
salt, such as lithium, sodium, potassium, magnesium, and calcium salt. The
organosulfonic acid (or salt thereof) may be combined With one or more
compounds ula (2) or Formula (3).
In certain embodiments, the yiscosity—lowering agent contains at least
one carboxylic acid. The carboxylic acid may be in the form of an alkaline or
alkaline earth metal salt, such, as lithium, , potassium, magnesium,
and calcium salt. Exemplary carboxylic acid compounds include lactobionic
acid, glucuronic acid, l-aminocyclohexane carboxylic acid, biotin, brocrinat,
cyclopentane propionic acid, ynaphthoic acid, phenyipropionic acid,
gentisic acid, salicylic acid, camphoric acid, mandelic acid, sulfosalicyclic
acid, hydroxybenzoyl benzoic acid, phenyl acetic acid, acetyl salicylic acid,
cinnamic acid, t-butyl acetic acid, ic acid, trimethylacetic acid,
anthrallic acid and pharmaceutically acceptable salts thereof. The carboxylic
acid (or salt thereof) may be combined with one or more compounds of
Formula (2) or Formula (3).
The following compounds may also be used as Viscosity-lowering
: colistin, articaine, tetracaine, etacaine, metoclopramide,
procaine, lidccaine, cyclomethylcaine, piperocaine, chloroprocaine,
etidocaine, aine, phenylephrine, bupivacaine, mepivacaine,
cinchocaine, mixtures thereof and and pharmaceutically acceptable salts
thereof.
Other agents which may be employed as viscosity-lowering agents
include lmaminocyclohexane carboxylic acid, 1-(o-tolyl)biguanide,
benzethonium chloride, benzoic acid, brocrinat, calcium carrageenan,
calcium cyclamate, calcobutrol, caloxetic acid, camphorsulfonic acid,
creatinine, dalfampridine, dehydroacetic acid, diazolidinyl urea,
dichlorobenzyl alcohol, dimethyl isosorbide, epitetracycline, ethyl maltol,
ethyl vanillin, ornidazole, gentisic acid ethanolamide, HEPES (4~(2-
hydroxyethyl)-l-piperazine ethane sulfonic acid), gentisic acid, glucuronic
acid, iodoxamic acid, menthol, galactose, medronic acid, m—cresol,
glutathione, lactobionic acid, maltitol, octisalate, oxyquinoline, pentetic acid,
piperazine, yl guaethol, propyl gallate, propylene carbonate,
propylparaben, protamine e, QUATERNHIM-15, QUATERNIUM-SZ,
satialgine H, sodium 1,2—ethanedisulfonate, sodium cocoyl sarcosinate,
sodium lauroyl sarcosinate, sodium polymetaphosphate, sodium
pyrophosphate, pyroglutamic acid, sodium aphosphate, sodium
tripolyphosphate, sorbitan, tartaric acid, lactic acid, mine, sucralcse, 1—
(4—pyridyl)pyridinium de, aminobenzoic acid, sulfacetamide sodium,
naphthalenenZ—sulfonic acid, tert-butylhydroquinone, thimerosal, trolamine,
tromantadine, in, versetamide, nioxime, amide,
methylisothiazolinone, mannose D, maltose, lidofenin, lactose, lactitol,
isomalt esulfonic acid, xylenesulfonic
, imidurea, gluconolactone,
acid, sulfobutylether B—cyclodextrin and pharmaceutically acceptable salts
In certain embodiments, the Viscosity-lowering agent includes an
organic base. Exemplary organic bases include N-methylglucamine,
line, piperidine, and primary, secondary, tertiary, and quaternary
amines, substituted amines, and cyclic amines. For example, they can be
isopropylamine, trimethylamine, lamine, triethylamine,
tripropylarnine, ethanolamine, 2-diethylaminoethanoi, trimethamine,
dicyclohexylamine, lysine, ne, histidine, caffeine, procaine, lidocaine,
hydrabamine, cholines, betaines, choline, e, nediamine,
theobrornine, purines, piperazine, N—ethylpiperidine, N-
rnethylpiperidinepolyamine. Particularly preferred organic bases are
arginine, histidine, lysine, ethanolamine, thiamine, 2-amin0—2-
hydroxymethyl-propane~ l l (TRIS), 4~aminopyridine,
aminocyclohexane carboxylic acid, lybiguanide, ornidazole, urea,
njctoinamide, benzethonium chloride, S-amino—l-pentanol, 2—(2-
arninoethoxy)ethanol, trans—cyclohexaneul,4udiamine, cyclohexane—
1R, 2R-diamine, ethylenediamine, propane-1,3-diarnine, butane-1,4-diamine,
pentane—1,5~diamine, -1,6—diamine, octane—1,8—diamine, 5-amino
pentanol, 2-(2-aminoethoxy)ethanarnine, 2-(2-(2-aminoeth0xy)-
)ethanamine, 3-(4-(3-aminopropoxy)-butoxy)propan—1-arnine, 3-(2-(2—
(3 propoxy)-ethoxy)-ethoxy)propan—l-amine, N—(2-(2—
thylamino)ethy1)ethane-1 ,2-diamine, N—(2-aminoethy1)ethane-1 ,2—
e, N— l -(2-(2-(2-aminoethylamino)ethylamino)-ethyl)ethane- 1,2—
e, N,N-dimethylhexane-1,6-diamine, N,N,N,N—tetramethylbutane-l ,4-
diarnine, phenyltrimethylammonium salts, isopropylarnine, diethylamine,
ethanolamine, trimethamine, choline, 1-(3-aminopropy1)—2-methyl-lH-
imidazole, piperazine, 1—(2-aminoethyl)piperazine, 1-[3-
(dimethylamino)propy1]piperazine, l-(2-aminoethyl)piperidine, 2-(2—
aminoethyl-l-methylpyrrolidine, mixtures thereof, and ceutically
acceptable salts thereof.
Exemplary beta-lactams include benzylpenicillin (penicillin G),
phenoxymethylpenicillin (penicillin V), cloxacillin, dicloxacillin,
flucloxacillin, methicillin, nafcillin, oxacillin, temocillin, amoxicillin,
ampicillin, mecillinarn, carbenicillin, ticarcillin, llin, mezlocillin,
piperacillin, cefoxitin, cefazolin, cephalexin, cephalosporin C, cephalothin,
cefaclor, cefamandole, cefuroxime, cefotetan, cefixime, cefotaxime,
cefpodoxime, ceftazidime, ceftriaxone, cefepime, cefpirome, ceftobiprole,
biapenem, doripenem, ertapenem‘faropenem, imipenem, meropenem,
panipenem, razupenem, tebipenem, thienamycin, aztreonam, tigemonam,
nocardicin a, inine, clavulanic acid, clavulanic acid, tazobactam, sulbactam
and pharmaceutically acceptable salts thereof.
Other viscosity-lowering agents include tropane N-heterocycles, such as
atropine, amine, scopolamine, and salts thereof, as well as tiotropium and
ipratropium salts, thiamine, iamine, prosultiamine, fursultiamine,
benfotiamine, iamine, quaternium 15; 1-(3-aminopropyl)methyl-1H-
imidazole dihydrochloride; creatinine; biotin, cimetidine, piperocaine,
cyclomethylcaine, granisetron, moxifloxacin, quine, mepivacaine,
levetiracetam, bupivacaine, caine, clindamycin and pharmaceutically
able salts thereof. Thiamine is an especially preferred viscosity-lowering
agent.
In certain formulations, the following compounds are not preferred:
creatinine, cadaverine, lidocaine, ne and lysine, and are excluded from the
scope of the foregoing formulas and definitions of useful viscosity-lowering
agents.
C. Excipients
A wide variety of pharmaceutical excipients useful for liquid protein
formulations are known to those skilled in the art. They include one or more
additives, such as liquid solvents or vents; sugars or sugar alcohols such as
mannitol, trehalose, e, sorbitol, fructose, maltose, lactose, or dextrans;
surfactants such as TWEEN® 20, 60, or 80 (polysorbate 20, 60, or 80); buffering
agents; preservatives such as benzalkonium chloride, benzethonium chloride,
tertiary ammonium salts, and chlorhexidinediacetate; carriers such as
poly(ethylene glycol) (PEG); antioxidants such as ascorbic acid, sodium
metabisulfite, and nine; chelating agents such as EDTA or citric acid; or
biodegradable polymers such as water soluble polyesters; cryoprotectants;
lyoprotectants; bulking agents; and stabilizing agents.
Other pharmaceutically acceptable carriers, excipients, or stabilizers, such
as those described in Remington: “The Science and Practice of cy”, 20th
edition, Alfonso R. Gennaro, Ed., cott Williams & Wilkins (2000) may also
be included in a protein formulation described herein, provided that they do not
adversely affect the desired characteristics of the formulation.
The viscosity-lowering agents described herein can be combined with
one or more other types of Viscosity-lowering agents, for example,
organophosphates described in co—filed PCT application entitled “LIQUID
PROTEIN FORMULATIONS NING ORGANOPHOSPI-IATES”
by Arsia Therapeutics; water soluble dyes described in d PCT
application entitled “LIQUID N FORNIULATIONS CONTAINING
WATER SOLUBLE ORGANIC DYES” by Arsia Therapeutics; ionic liquids
described in co-filed PCT application entitled “LIQUID PROTEIN
FORMULATIONS CONTAINING IONIC LIQUIDS” by Arsia
eutics.
III. Methods of Making
The protein, such as a mAb, to be ated may be produced by
any known technique, such as by culturing cells transformed or transfected
with a vector containing one or more nucleic acid sequences encoding the
protein, as is well known in the art, or through synthetic techniques (such as
recombinant techniques and peptide synthesis or a combination of these
ques), or may be isolated from an endogenous source of the n.
Purification of the protein to be formulated may be conducted by any
suitable technique known in the art, such as, for example, ethanol or
um sulfate precipitation, reverse phase HPLC, chromatography on
silica or -exchange resin (e.g., ellulose), dialysis,
chromatofocusing, gel filtration using protein A OSE® columns
(cg, SEPHADEX® (1-75) to remove contaminants, metal chelating
columns to bind epitope-tagged forms, and ultrafiltration/diafiltration (non-
lirniting examples include centrifilgal filtration and tangential flow filtration
(TFFD.
inclusion of Viscosity-lowering agents at viscosity—reducing
concentrations such as 0.010 M to 1.0 M, preferably 0.050 M to 0.50 M,
most preferably 0.10 M to 0.30 M, allows a solution ofthe pharmaceutically
active mAb to be purified and/or concentrated at higher mAb concentrations
using common methods known to those skilled in the art, including but not
limited to tangential flow filtration, centrifugal tration, and dialysis.
In some embodiments, iyophilized formulations of the proteins are
provided and/or are used in the preparation and manufacture of the low-
ity, trated protein formulations. In some embodiments, the pre—
lyophilized protein in a powder form is reconstituted by dissolution in an
formulation is filled into a
aqueous solution. In this embodiment, the liquid
c dosage unit container such as a vial or pre—filled mixing e,
lyophilized, optionally with lyoprotectants, vatives, antioxidants, and
other typical pharmaceutically acceptable excipients, then stored under
sterile storage ions until shortly before use, at which time it is
reconstituted with a defined volume of diluent, to bring the liquid to the
desired concentration and viscosity.
The formulations described herein may be stored by any suitable
method known to one d in the art. Non-limiting examples of methods
for preparing the protein formulations for storage include freezing,
lyophilizing, and spray drying the liquid protein formulation. In some cases,
the lyophilized formulation is frozen for storage at subzero temperatures,
such as at about °C or in liquid nitrogen. In some cases, a lyophilized or
aqueous formulation is stored at 2-8°C.
miting examples of diluents useful for reconstituting a
lyophilized formulation prior to injection include sterile water, bacteriostatic
water for injection (BWFI), a pH buffered solution (e.g., phosphate—buffered
saline), sterile saline solution, Ringer's solution, dextrose solution, or
aqueous solutions of salts and/or buffers. In some cases, the formulation is
spray—dried and then stored.
IV. Administration to an Individual in Need Thereof
The protein formulations, including, but not d to, reconstituted
formulations, are administered to a person in need thereofby intramuscular,
intraperitoneal (i.e., into a body cavity), erobrospinal, or subcutaneous
injection using an 18-32 gauge needle (optionally a thin-walled needle), in a
volume of less than about 5 mL, less that about 3 mL, preferably less than
about 2 mL, more preferably less than about 1 mL.
The appropriate dosage (“therapeutically ive amount”) of the
protein, such as a mAb, will depend on the condition to be treated, the
severity and course of the disease or ion, Whether the protein is
administered for preventive or therapeutic purposes, previous therapy, the
patient's clinical history and response to the protein, the type of protein used,
and the discretion of the ing physician. The protein is suitably
stered at one time in single or multiple injections, or over a series of
treatments, as the sole treatment, or in conjunction with other drugs or
therapies.
Dosage formulations are designed so that the injections cause no
significant signs of irritation at the site of injection, for example, wherein the
primary irritation index is less than 3 when evaluated using a Draize scoring
system. In an alternative embodiment, the ions cause macroscopically
similar levels of irritation when compared to injections of equivalent
volumes of saline solution. In another embodiment, the bioavailability of the
protein is higher when compared to the otherwise same formulation without
the viscosity-lowering agent(s) administered in the same way. In r
embodiment, the formulation is at least approximately as effective
pharmaceutically as about the same dose ofthe protein administered by
enous on.
In a preferred ment, the formulation is injected to yield
increased levels of the eutic protein. For example, the AUC value may
be at least 10%, preferably at least 20%, larger than the same value computed
for the otherwise same formulation without the viscosity-lowering agent(s)
administered in the same way.
The viscosity-lowering agent may also affect bioavailability. For
example, the t bioavailability of the protein may be at least 1.1 times,
preferably at least 1.2 times the percent bioavailability of the otherwise same
formulation without the ity-lowering agent(s) administered in the same
way.
The Viscosity-lowering agent may also affect the pharmacokinetics.
For example, the CM after SC or IM ion may be at least 10%,
preferably at least 20%, less than the CM of an approximately equivalent
phannaceutically effective intravenously administered dose.
In some embodiments, the proteins are administered at a higher
dosage and a lower frequency than the otherwise same formulations without
the viscosity-lowering agent(s).
WO 38818
The lower viscosity ations require less injection force. For
example, the ion force may be at least 10%, preferably at least 20%,
less than the ion force for the otherwise same formulation without the
viscosity-lowering agent(s) administered in the same way. In one
embodiment, the injection is administered with a 27 gauge needle and the
injection force is less than 30 N. The formulations can be administered in
most cases using a very small gauge needle, for example, between 27 and 31
gauge, typically 27, 29 or 31 gauge.
The ity-lowering agent may be used to prepare a dosage unit
formulation suitable for reconstitution to make a liquid pharmaceutical
formulation for aneous or intramuscular injection. The dosage unit
may contain a dry powder of one or more ns; one or more viscosity—
lowering agents; and other excipients. The ns are present in the dosage
unit such that after titution in a pharmaceutically acceptable solvent,
the resulting formulation has a protein concentration from about 100 mg to
about 2,000 mg per 1 mL (mg/mL). Such reconstituted formulations may
have an absolute viscosity of from about 1 cP to about 50 cP at 25°C.
The low viscosity formulation can be provided as a solution or in a
dosage unit form where the protein is lyophilized in one vial, with or without
the Viscosity-lowering agent and the other ents, and the solvent, with or
without the viscosity-lowering agent and other excipients, is provided in a
second vial. In this embodiment, the solvent is added to the protein shortly
before or at the time of injection to ensure uniform mixing and dissolution.
The viscosity-lowering agent(s) are present in the formulations at
concentrations that cause no significant signs of toxicity andlor no
irreversible signs of toxicity when administered via subcutaneous,
intramuscular, or other types of injection. As used , “significant signs
of toxicity” include intoxication, lethargy, behavioral modifications such as
those that occur with damage to the central nervous system, infertility, signs
of serious cardiotoxicity such as cardiac arrhythmia, cardiomyopathy,
myocardial infarctions, and cardiac or congestive heart failure, kidney
failure, liver failure, difficulty breathing, and death.
In preferred embodiments the formulations cause no significant
irritation when administered not more than twice daily, once daily, twice
weekly, once weekly or once monthly. The protein ations can be
administered causing no significant signs of tion at the site of injection,
as measured by a primary irritation index of less than 3, less than 2, or less
than 1 when evaluated using a Draize scoring system. As used herein,
“significant signs of irritation” include erythema, redness, and!or swelling at
the site of injection having a diameter of greater than 10 cm, greater than 5
cm, or greater than 2.5 cm, necrosis at the site of injection, exfoliative
dermatitis at the site of injection, and severe pain that prevents daily ty
and/or es l attention or hospitalization. In some embodiments,
injections of the protein formulations cause copically similar levels of
irritation when ed to injections of equivalent volumes of saline
solution.
The protein formulations can exhibit increased bioavailability
compared to the ise same protein formulation without the viscosity-
lowering agent(s) when administered via subcutaneous or intramuscular
injection. “Bioavailability” refers to the extent and rate at which the
bioactive species such as a mAb, s circulation or the site of action. The
overall bioavailability can be increased for SC or IM injections as compared
to the otherwise same formulations without the viscosity-lowering agent(s).
“Percent ilability” refers to the fraction of the stered dose of the
bioactive species which enters circulation, as determined with respect to an
intravenously administered dose. One way ofmeasuring the bioavailability
is by comparing the “area under the curve” (AUC) in a plot of the plasma
concentration as a function of time. The AUC can be ated, for example,
using the linear trapezoidal rule. “AUCOD”, as used herein, refers to the area
under the plasma concentration curve from time zero to a time where the
plasma concentration returns to baseline levels. “AUCM”, as used herein,
refers to the area under the plasma tration curVe from time zero to a
time, t, later, for example to the time of reaching baseline. The time will
typically be measured in days, although hours can also be used as will be
apparent by context. For example, the AUC can be increased by more than
%, 20%, 30%, 40%, or 50% as compared to the otherwise same
formulation without the viscosity-lowering agent(s) and administered in the
same way.
As used herein, “tum” refers to the time after administration at Which
the plasma concentration reaches a maximum.
As used herein, “ max” refers to the maximum plasma concentration
after dose administration, and before administration of a subsequent dose.
As used herein, "Cm-n" or "Cmugh" refers to the minimum plasma
tration after dose administration, and before administration of a
subsequent dose.
The Cmax after SC or IM injection may be less, for example, at least
%, more preferably at least 20%, less than the Cmax of an intravenously
administered dose. This reduction in Cm may also result in decreased
toxicity.
The pharmacokinetic and pharmacodynamic parameters may be
imated across species using approaches that are known to the skilled
artisan. The pharmacokinetics and pharmacodynamics of antibody
therapeutics can differ markedly based upon the specific antibody. An
approved murine mAb was shown to have a half-life in humans of~ 1 day,
while a human mAb Will typically have a half-life of ~ 25 days (Waldmann
et at, Int. Immunol, 2001, 13 : 1551—1559). The pharmacokinetics and
eodynarnics of antibody therapeutics can differ markedly based upon
the route of administration. The time to reach maximal plasma concentration
after IM or SC injection of lgG typically ranges from 2 to 8 days, although
shorter or longer times may be encountered (Wang et at, Clin. Pharm. Ther.,
2008, 84(5):548-558). The pharmacokinetics and pharmacodynamics of
antibody eutics can differ markedly based upon the formulation.
The low-viscosity protein formulations can allow for greater
flexibility in dosing and decreased dosing ncies compared to those
protein formulations without the Viscosity—lowering agent(s). For example,
by increasing the dosage stered per injection le-fold, the dosing
frequency can in some embodiments be decreased from once every 2 weeks
to once every 6 weeks. The protein formulations, ing, but not
limited to, reconstituted formulations, can be administered using a heated
and/0r self-mixing syringe or j ector. The protein formulations can also
be ated in a separate warming unit prior to filling the syringe.
i. Heated es
The heated syringe can be a standard syringe that is pre-heated using
a syringe warmer. The syringe warmer will generally have one or more
gs each capable of receiving a syringe ning the protein
formulation and a means for heating and maintaining the syringe at a specific
(typically above the ambient) temperature prior to use. This will be ed
to herein as a pre-heated syringe. Suitable heated syringe warmers e
those available from Vista Dental Products and Inter-Med. The warmers are
e of accommodating various sized syringes and heating, typically to
within 1°C, to any temperature up to about 130°C. In some embodiments the
syringe is pre-heated in a heating bath such as a water bather maintained at
the desired temperature.
The heated syringe can be a self-heating syringe, i.e. capable of
g and maintaining the liquid formulation inside the syringe at a specific
ature. The self-heating syringe can also be a standard medical syringe
having attached thereto a heating device. Suitable heating devices capable of
being ed to a syringe include e heaters or syringe heater tape
available from Watlow Electric Manufacturing Co. of St. Louis, MO, and
syringe heater blocks, stage heaters, and in—line perfusion heaters available
from Warner Instruments of Hamden, CT, such as the SW—61 model syringe
warmer. The heater may be controlled through a central controller, e.g. the
TC-324B or TC-344B model heater controllers available from Warner
Instruments.
The heated syringe maintains the liquid protein formulation at a
specified temperature or to within 1°C, within 2°C, or within 5°C of a
specified temperature. The heated syringe can maintain the protein
ation at any temperature from room temperature up to about 80°C, up
to about 60°C, up to about 50°C, or up to about 45°C as long as the protein
formulation is sufficiently stable at that temperature. The heated syringe can
maintain the protein formulation at a temperature n 20°C and 60°C,
between 21°C and 45°C, between 22°C and 40°C, between 25° C and 40° C,
or between 25°C and 37°C. By maintaining the protein formulations at an
elevated temperature during injection, the viscosity of the liquid ation
is decreased, the lity of the protein in the formulation is increased, or
WO 38818
both.
_ 1
ii. Self—Mixing es 1
The syringe can be ixing or can have a mixer attached. The
mixer can be a static mixer or a dynamic mixer. Examples of static mixers
include those disclosed in US. Patent Nos. 5,819,988, 6,065,645, 6,394,314,
6,564,972, and 622. Examples of some dynamic mixers can include
those disclosed in U.S. Patent Nos. 6,443,6l2 and 6,457,609, as well as U.S.
Patent Application Publication No. US 2002/0190082.The syringe can
include multiple barrels for mixing the components of the liquid protein
formulation. US. Patent No. 5,819,998 describes syringes with two barrels
and a mixing tip for mixing two-component viscous substances.
iii. Autoiniectors and Pre-ijiled Syringes of n Formulations
The liquid protein formulation can be administered using a pre-filled
syringe autoinj ector or a needleless injection device. Autoinj ectors e a
handheld, often pen—like, cartridge holder for holding replaceable pre—filled
cartridges and a spring based or analogous mechanism for subcutaneous or
intramuscular injections of liquid drug dosages from a pre-filled cartridge.
Autoinj ectors are typically ed for self-administration or administration
by untrained personnel. Autoinj ectors are available to dispense either single
dosages or multiple dosages from a pre-filled cartridge. Autoinj ectors enable
different user settings including inter alia ion depth, injection speed,
and the like. Other injection systems can include those described in U. S.
Patent No. 8,500,681.
The lyophilized protein formulation can be provided in pre-filled or
unit-dose syringes. US. Patent Nos. 3,682,174; 4,171,698; and 5,569,193
describe sterile es containing ambers that can be pre-filled With
a dry formulation and a liquid that can be mixed immediately prior to
injection. U.S. Patent No. 5,779,668 describes a syringe system for
lyophilization, reconstitution, and stration of a pharmaceutical
composition. In some embodiments the protein formulation is provided in
lyophilized form in a pre-filled or unit-dose syringe, tituted in the
syringe prior to administration, and administered as a single subcutaneous 0r
intramuscular injection. Autoinj ectors for delivery of unit-dose lized
drugs are described in W0 10,832. Auto injectors such as the Safe
WO 38818
Click LyoTM (marketed by Future Injection Technologies, Ltd, Oxford,
UK.) can be used to administer a unit-dose protein formulation where the
formulation is stored in lyophilized form and reconstituted just prior to
administration. In some embodiments the protein formulation is provided in
unit-dose cartridges for lyophilized drugs (sometimes referred to as Vetter
cartridges). Examples of suitable cartridges can include those described in
U.S. Patent Nos. 5,334,162 and 5,454,786.
V. Methods of cation and Concentration
The viscosity-lowering agents can also be used to assist in protein
purification and concentration. The viscosity-lowering agent(s) and
excipients are added to the protein in an effective amount reduce the
viscosity of the protein solution. For example, the Viscosity-lowering agent
is added to a concentration of between about 0.01 M and about 1.0 M,
preferably between about 0.01 M and about 0.50 M, and most preferably
between about 0.01 M and about 0.25 M.
The viscosity-lowering agent solution containing protein is then
purified or concentrated using a method selected from the group consisting
of ultrafiltration/diafiltration, tial flow filtration, centrifugal
concentration, and dialysis.
Examples
The foregoing will be r understood by the following non-
lim‘iting examples.
All Viscosities of well-mixed aqueous mAb solutions were measured
using either a mVROC uidic viscometer (RheoSense) or a DV2T
cone and plate viscometer (Brookfield; “C & P”) after a 5 minute
equilibration at 25°C (unless otherwise ted). The mVROC viscometer
was equipped with an “A” or “B” chip, each manufactured with a 50 micron
channel. Typically, 0.10 mL ofprotein solution was back-loaded into a
gastight ab instrument syringe (Hamilton; 100 uL), affixed to the chip,
and measured at multiple flow rates, approximately 20%, 40%, and 60% of
the maximum re for each chip. For example a sample of
approximately 50 GP would be measured at around 10, 20, and 30 nL/min
ximately 180, 350, and 530 5'1, respectively, on an “A” chip) until
viscosity stabilized, typically after at least 30 seconds. An average absolute
viscosity and standard deviation was then calculated from at least these three
measurements. The C & P viscometer was equipped with a CPE40 or
CPESZ spindle (cone angle of 08° and 3.0°, respectively) and 0.50 mL
samples were measured at multiple shear rates between 2 and 400 5'1.
Specifically, samples were measured for 30 seconds each at 22.58, 24.38,
26.25, 28.13, 30, 31.88, 45, 67.5, 90, 112.5,135, 157.5, 180, 202.5, 247, 270,
292.5, 315, 337.5, 360, 382, 400 3'], starting at a shear rate that gave at least
% torque, and continuing until instrument torque reached 100%. An
extrapolated zero-shear ity was then determined from a plot of
c viscosity versus shear rate for the samples measured on a DV2T
cone and plate viscometer. The extrapolated zero—shear viscosities reported
are the average and standard deviation of at least three measurements.
Example 1: Effect of a viscosity-lowering agent, camphorsulfonic acid
lysine (CSAL), on the viscosity of solutions of ilar ERBITUX®
Materials and Methods
A commercially—obtained biosimilar ERBITUX® (100-400 mg)
containing pharmaceutical ents (Polysorbate 80, phosphate buffer, and
NaCl) was purified. First, Polysorbate 80 was removed using
DETERGENT-OUT® TWEEN® Medi Columns (G—Biosciences). Next, the
resulting solutions were extensively buffer-exchanged into 20 mM sodium
phosphate buffer (PB; pH 7.0) or 20 mM CSAL (pH 7.0) and trated to
a final volume of less than 10 mL on Jumbosep centrifiigal concentrators
(Pall Corp). The ted n solution was freeze-dried. The dried
protein cakes, containing protein and buffer salts or agent, were reconstituted
to a final volume of 0.15 - 1.3 mL. These samples were reconstituted using
additional PB (pH 7.0) or CSAL (pH 7.0) sufficient to bring the final
tration ofPB or CSAL to 0.25 M. The final concentration ofmAb in
solution was determined by light absorbance at 280 nm. Reported n
concentrations represent the range of all protein samples included in each
Table or Figure. Specifically, ed values are the median plus or minus
e range. Extrapolated zero-shear using an experimentally determined
extinction coefficient of 1.4 L/g'cm and viscosities reported were ed
on a DV2T cone and plate viscometer.
2014/055254
Results
The data in Figure 1 demonstrate the viscosityulowering effect of
CSAL on aqueous solutions ofbiosimilar ERBITUX®. The Viscosity of a
solution of biosimilar ERBITUX® in phosphate buffer (PB) increases
exponentially with increasing mAb concentration. The ity of a
solution of biosimilar ERBITUX® in the presence of CSAL is seen to
increase exponentially with increasing mAb concentration, but to a lesser
extent than the ation in PB i.e. the ity gradient is reduced. The
data in Figure 1 show that the higher the concentration of mAb, the greater '
the viscosity-lowering . The magnitude of viscosity-lowering s
afforded by the replacement ofPB with CSAL varied from 1.1-fold at 100 i
mg/mL to 10.3-fold at 227 i 5 mg/mL mAb.
Example 2: Viscosity-lowering effect of a Viscosity-lowering agent,
camphorsulfonic acid lysine (CSAL), as a function of concentration of
biosimilar AVASTIN®
Materials and Methods
A biosimilar AVASTIN® ed commercially and containing
pharmaceutical excipients (Polysorbate 20, phosphate buffer, citrate buffer,
mannitol, and NaCl) was purified, buffer exchanged, concentrated, dried,
reconstituted, and analyzed as described in Example 1 above (using the
extinction coefficient of 1.7 Mg cm at 280 nm). The protein was formulated
to contain either 0.25 M phosphate buffer or 0.25 M CSAL.
Results
Figure 2 depicts the ity of aqueous mAb solutions as a function
ofmAb concentration in aqueous buffered solution and with CSAL. The
viscosity of biosimilar N® in aqueous phosphate buffer and in the
presence of CSAL increases exponentially with increasing concentration;
however, as in the case of ilar X®, this increase is much less
marked for the CSAL—containing formulation, i.e. the viscosity gradient is
reduced. In general, the higher the mAb concentration, the greater the
viscosity-lowering effect ed. The magnitude of viscosity-lowering
effects afforded by the replacement of PB with CSAL varied from 2.1-fold at
80 mg/mL to 3.7-fold at 230 i 5 mg/mL mAb.
Example 3: Viscosity-lowering effect as a function of CSAL
concentration for aqueous solutions of biosimilar ERBITUX®
Materials and s
Samples were purified, buffer exchanged, concentrated, dried,
reconstituted, and analyzed similarly to Example 1 above. The final
concentration of CSAL upon reconstitution in an aqueous CSAL solution
ranged from 0.25 M to 0.50 M.
Results
Table 1 shows the Viscosity of solutions of biosimilar ERBITUX®
formulated in 0.25 M phosphate buffer (no CSAL as a l) and with
g concentrations of CSAL. The viscosity-lowering effect of CSAL is
seen to rise from 8.4- to 12.1-fold with increasing viscosity-lowering agent
concentration. The data in Table 1 ShOW that the higher the concentration of
CSAL, the greater the Viscosity-lowering effect, at least Within the agent
concentration range tested.
Table I. Viscosities of aqueous solutions of biosimilar ERBITUX® (155
i 5 mglmL, pH 7.9) in the presence of different concentrations of CSAL
at 25°C.
Fold Viscosity ion
red to no CSAL
[CSAL], M Viscosity, cP present)
0 154 d: 0 l
0.25 18.3 i 0.0 8.4
0.38 14.9 $0.1 10.3
0.50 12.7 i 0.1 12.1
Example 4: Viscosities of solutions of biosimilar ERBITUX® as a
on of temperature in the presence of various viscosity—lowering
agents
Materials and Methods
Aqueous solutions ofbiosimilar ERBITUX® containing various
viscosity-lowering agents were prepared as described in Example 1.
Specifically, 20 mM solutions ofthe ity-lowering agents of interest
were used for buffer ge, and the lyophilized cakes were reconstituted
to 0.25 M of each viscosity-lowering agent. For the sample containing CSA—
APMI, biosimilar ERBITUX® was extensively buffer exchanged into 2 mM
PB (pH 7.0), and concentrated to a final volume of less than 10 mL on
Jumbosep centrifugal concentrators (Pall Corp). The sample was first
aliquoted. Then, an appropriate amount of CSAAPMI solution (pH 7.0) was
added to each aliquot such that upon reconstitution with water, the final
excipient concentration is 0.25 M. The protein solutions were then freeze-
dried. The dried protein cakes, containing protein and ity-lowering
agent (and a negligible amount of buffer salts) were reconstituted to a final
volume of approximately 0.10 mL and ity—lowering agent
concentration as previously described.
Results
Table 2 shows viscosity data for biosimilar ERBITUX® in the
ce of six ity-lowering agents — cainphorsulfonic acid iysine
(CSAL), camphorsulfonic acid arginine (CSAA), esulfonic acid lysine
(BSAL), benzenesulfonic acid arginine (BSAA), naphthalenesulfonic acid
arginine (NSAA), and camphorsulfonic acid 1-(3-aminopropyl)methyl—
1H—imidazole (CSAAPMI). The data in Table 2 Show a reduction in
viscosity of at least about 9—fold for all six ity-lowering agents
compared to a solution of biosimilar X® in phosphate buffer under
otherwise the same conditions. The most efficacious viscosity-lowering
agent — CSAAPMI — lowered viscosity by >40-fold.
onally, the data in Table 3 show that at multiple temperatures
ranging from 20°C to 30°C, a 225 mg/mL solution of biosimilar ERBITUX®
prepared with 0.25 M CSAA had the lowest Viscosity ofthe five viscosity-
lowering agents. Thus, the observed trends in Viscosities at 25°C seem to be
predictive of those at temperatures of at least 20°C and 30°C.
Table 2. Reduction in viscosity of aqueous solutions of ilar
ERBITUX® (226 i 6 mg/mL, pH 7.0) formulated with various 0.25 M
viscosity-lowering agents, as ed to that in 0.25 M sodium
phosphate buffer (PB) at 25°C.
Agent Viscosity, cP Fold reduction
PB 1130 d: 7 1
CSAL 109-3: 1 10.4
CSAA 58.0 d: 0.3 19.5
BSAL 126 :i: 1 9.0
BSAA 61.3 :1: 0.9 18.4
NSAA 69.4 i 0.6 16.3
CSAAPMI 25.7 i 1.5 44.0
Table 3. Viscosities of aqueous solutions of biosimilar ERBITUX® (225 i
mg/mL, pH 7.0) formulated with various 0.25 M viscosity-lowering
Viscosity, cP
Temp. . Agent
PB CSAL CSAA BSAL BSAA NSAA
1810i 796i . 85.2 :I:
°C 10 166 :I: 2 0.9 193 i 0 0.6 103 :I: 0
1130i 58.0i 61.3 i 69.4 i
°C 7 109 ii 0.3 126 $1 0.9 0.6
46.9 :t: 50.5 :I: 60.9 i
°C 723 :t 0 78.4 i 1.5 0.6 89.8 A: 0.8 1.9 4.3
Example 5: The effect of temperature on viscosity of aqueous solutions
of biosimilar AVASTIN® formulated with various viscosity-lowering
agents
Materials and Methods
Solutions of biosimilar AVAST1N® containing different viscosity-
lowering agents were prepared as described in Example 1 above. In
particular, 20 mM solutions of the viscosity-lowering agents of interest were
used for buffer ge, and the lyophilized cakes were reconstituted to
0.15 or 0.25 M viscositynlowering agent.
Results
As seen in Table 4, 0.25 M CSAL lowered the ity of a 230 i 5
mg/mL on of biosimilar N® at all three temperatures between
and 30°C. Furthermore, 0.15 M CSAL reduces viscosity to
approximately the same absolute value as 0.25 M CSAL at 20 and 25°C and
is equally effective at 30°C.
The data in Table 5 compare the effects of CSAL and BSAL at a
tration of 0.15 M. CSAL is a superior ity—lowering agent
compared to BSAL at all three temperatures.
Table 4. ities of aqueous solutions of biosimilar AVASTIN® (230 i
mg/mL, pH 7.0) formulated with 0.25 and 0.15 M CSAL at different
temperatures.
Viscosity, cP
Temperature 0.25 M PB 0.25 M CSAL 0.15 M CSAL
°C 563i2 152i0 157i0
°C 397i2 107i4 113i0
°C 311i4 95.5i5.4 91.7133
Table 5. Viscosities of aqueous solutions of biosimilar AVASTIN® (230 i
mg/mL, pH 7.0) formulated with 0.15 M CSAL and BSAL at ent
temperatures.
Viscosity, cP
Temperature 0.25 M PB 0.15 M CSAL 0.15 M BSAL
°C 56312 157i0 395i3
°C 397i2 113i0 227i5
°C 311d:4 91.7i3.3 175:1:7
Example 6: Removal of CSAL reverses viscosity-lowering effect in
mAb solutions
Materials and Methods
Three samples each ofbiosimilar ERBITUX® and biosimilar
AVASTIN® were prepared. First, Polysorbate was removed from the
commercially obtained mAb solutions. The resulting on With
remaining pharmaceutical excipients was either (i) concentrated on a
fugal device with a lOO-kDa molecular weight cutoff (MWCO) (Pall
Corp.) as a control sample (original excipients), (ii) buffer exchanged into
0.25 M CSAL as described in Example 1, or (iii) buffer exchanged into 0.25
M CSAL as described in e 1, reconstituted, and then r
exchanged into 0.25 M PB. In this third instance, exchange into 0.25 M
phosphate buffer proceeded first by overnight dialysis against 20 mM PB
(50-kDa MWCO, Spectrum Labs). The lly dialyzed samples were then
diluted to 60 mL in 0.25 M PB and subjected to centrifugal concentration
(30-kDa MWCO Jumbosep (Pall Corp), ed by a lOO-kDa MWCO
Macrosep device (Pall Corp.)). The viscosities of these three aqueous
solutions were determined as described in Example 1 above.
Results
The viscosities of aqueous solutions of both biosiinilar ERBITUX®
and biosimilar AVASTIN® decreased in the presence of CSAL — 2.7- and
1.5—fold, respectively — but then increased when CSAL was removed (see
Tables 6 and 7). Furthermore, upon removal of CSAL, mAb solution
viscosities returned to approximately the same level as the original solutions,
ting that CSAL does not damage the protein and showing that it is
ary for the observed Viscosity ion.
Table 6. Viscosities of aqueous solutions of biosimilar X® (80 i
mg/mL, pH 7.0) at 25°C.
Formulation Viscosity, cP
Original excipients 8.30 :l: 0.04
0.25 M CSAL 3.08 a 0.18
0.25 M CSAL exchanged into 0.25 M PB 9.43 d: 0.04
Table 7. Viscosities of aqueous ons of biosimilar AVASTIN® (101 i
mg/InL, pH 7.0) at 25°C.
Formulation Viscosity, cP
Original excipients 6.08 d: 0.19
0.25 M CSAL 4.03 :I: 0.24
0.25 M CSAL ged into 0.25 M PB 6.61 i 0.08
Example 7: rsulfonic acid-containing viscosity-lowering agents
provide large viscosity reductions in aqueous solutions ofAVASTIN®
and biosimilar AVASTIN®
Materials and Methods
AVASTIN® and a biosimilar AVASTIN® obtained commercially and
containing ceutical excipients (AVASTIN®: trehalose, sodium
phosphate buffer, and Polysorbate 20; biosimilar AVASTIN®2 Polysorbate
, phosphate buffer, citrate buffer, mannitol, and NaCl) were purified,
buffer exchanged, trated, freeze-dried, and reconstituted as bed
above. Samples in Table 8 were ed as described in Example 1 above
(using the protein extinction coefficient of 1.7 L/g-cm at 280 nm) and
measured on a C & P viscometer. Viscosity-reduced samples in Table 9 were
prepared as described in Example 4 above, but mAb was extensively buffer
exchanged into 2 mM PB. Subsequently, the appropriate amount of
viscosity-lowering agent was added to result in a final viscosity-lowering
agent concentration of 015—03 5 M upon reconstitution. Viscosities were
ed using a RheoSense mVROC uidic viscometer equipped
with an “A” or "B” chip. Results
The data in Tables 8 and 9 demonstrate the viscosity-lowering effect
of different viscosity-lowering agents 011 aqueous solutions of biosimilar
AVASTIN®. Viscosity reductions up to 25-fold (compared to mAb
solutions in PB) are ed for aqueous solutions of biosimilar
AVASTIN® in the presence of viscosity-lowering agents containing CSA.
Table 8. Viscosities of aqueous solutions of biosimiar AVASTIN® (200 :i:
mg/mL, pH 7.0) at 25°C with various viscosity-lowering agents.
Agent [Salt] (M of anion) Viscosity (cP)
PB 0.25 96.8 i 0.9
NaCl 0.25 121 i 8
Arginine-HCI 0.25 83.2 i 2.8
Argininc-HCI 0.3 71.8 d: 2.2
Lysine-HCI 0.25 137 d: 2
BSA sodium salt 0.25 133 d: 3
CSA sodium salt 0.25 55.7 i 0.2
BSAA 0.25 75.3 d: 0.4
Bcnzoic acid arginine 0.15 52.2 i 0.5
Benzoic acid nc 0.25 51.4 d: 0.5
CSAA 0.25 48.5 i 1.9
CSA betaine* 0.25 66.0 i 0.7
diCSA cadaverine 0.25 85.5 i- 5.2
diCSA cadavcrine 0.35 65.6 i 1.6
CSA canavanine 0.15 60.5 i 0.6
CSA nine 0.25 75.6 i 3.0
CSA camitine* 0.25 72.4 :J: 1.7
CSA dimethylpiperazinc 0.25 47.4 i 1.3
CSA dimethylpiperazine 0.35 51.7 i 0.9
CSAL 0.25 54.9 :I: 0.9
Chlorotheophyllinc arginine 0.25 104.5 i 6.5
Ethandisulfonate nine* 0.15 77.1 d: 0.3
Ethandisulfonate diarginine* 0.25 105 i 4
MSA arginine 0.25 93.1 d: 0.9
Toluenesulfonic acid arginine 0.25 159 i 5
Toluenesulfonic acid lysine 0.25 118 i l
* Contains equimolar NaCl; CSA = Camphorsulfonic acid, BSA =
Benzenesu1fonic acid, MSA = Methanesulfonic acid, PB = Phosphate buffer
Table 9. Viscosities of aqueous solutions of biosimilar AVASTIN® (pH
7.0) at 25°C with 0.15 M viscosity—lowering agents s ise
noted).
milar .
Agent AVASTIN] Viscosity (0P)
(mg/mL)
0.25 M PB 220 213 i 10
0.25 M PB 200 96.8 :1: 0.9
CSA—piperazine 212 64.5 :1: 13.1
Lactobionic acid-tris 219 109 d: 5
CSA-4—aminopyridine 229 86.4 i 1.1
Glucuronic acid-tris 221 151 i 5
The viscosity of a 200 i 9 mg/mL aqueous solution of biosimilar
AVASTIN® with CSAA was measured as a on of pH as depicted in
Figure 3. As pH increases, the magnitude of the Viscosity-lowering effect
resulting from the presence of CSAA in aqueous solutions of biosimilar
AVAST1N® also increases, reaching a minimum Viscosity and maximum
viscosity-lowering effect around pH 7. The Viscosity reduction by CSAA
was compared as a function ofpH for two different concentrations of
biosimilar AVASTIN®. Figure 4 demonstrates that 0.25 M CSAA s in a
greater reduction in viscosity with increasing (i) tration of the
biosimilar AVASTIN® and (ii) pH.
Table 10 es the viscosity reduction of biosimilar AVASTIN®
to that of branded AVASTIN® with and without CSAL. The branded
AVASTIN® solution has a muchhigher viscosity than a solution ofthe
biosimilar mAb in the absence ofthe agent. However, the presence of 0.25
M CSAL results in a 1.8- and 33-fold reduction in viscosity of the ilar
and branded AVASTIN® respectively; the viscosities of biosirnilar and
d AVASTIN® are seen to be similar in the presence of 0.25 M CSAL.
Table 10. ities of aqueous solutions ning 205 :I: 5 mg/mL of
biosimilar N® or branded AVASTIN® with or without 0.25 M .
CSAL measured at 25°C and pH 7.0.
Salt Biosimilar AVASTIN® Branded AVASTIN® (GP)
(9P)
Phosphate Buffer 96.8 d: 0.9 154 i 4
0.25 M CSAL 54.9 :I: 0.9 46.7 d: 0.9
CSAL = camphorsulfonic acid lysine
As demonstrated in Table 11, CSA l-(3-aminopropyl)-2—methyl-1H-
imidazole (CSAAPMI) with HCl provides superior viscosity reduction than
CSAL, reducingr the viscosity more than 5—fold as compared to the PB
control for a solution of 210 mg/mL biosimilar AVASTIN®.
Table 11. Viscosities of aqueous solutions of biosimilar AVASTIN® with
s viscosity~lowering agents at 25°C and pH 7.0.
Agent [Agent], M [23:13:] ’ Viscosity, cP
PB 0.25 220 213:1:10
CSAL 0.25 210 63.0 d: 1.8
I—ZHCI 0.25 210 40.9 d: 0.5
APMI = 1-(3—amjnopropyl)methyl-1H—imidazole
For a solution containing ~ 230 mg/mL biosimilar AVASTIN®,
Table 12 demonstrates Viscosity reduction of approximately 5—fold with
sulfosalicylic ontaining viscosity-lowering agents as well as for
CSAAPMI and CSA ne.
Table 12. Viscosities of aqueous solutions containing 228 :l: 5 mg/mL
biosimilar AVASTIN® with viscosity-lowering agents at 25°C and pH
7.0.
Agent
Viscosity
Agent Concentrati
(UP)
on [M]
PB 0.25 397 :l: 2
CSAA 0.25 116i2
CSAL 0.25 113 d: 0
Sulfosalicylic acid diarginine 0.15 81.6i1.7
Sulfosalicylic acid dilysine 0.25 73.45204
CSAAPMI—ZHC] 0.25 71.8i3.2
CSAthiamine- 2NaCl 0.15 83.721: 2.2
APMI = 1-(3—aminopropyl)methyl-1H—imidazole; CSA =
camphorsulfonic acid
Example 8. The effect of Viscosity—lowering agents on aqueous solutions
of ERBITUX® and biosimilar ERBITUX®
Materials and Methods
Aqueous solutions of biosimilar and branded ERBITUX® ning
various Viscosity-lowering agents were ed as described in Example 1.
Specifically, 20 mM solutions ofthe salts of interest were used for buffer
exchange, and the lyophilized cakes were reconstituted to contain 0.25 M of
each agent. ViSCosities were measured using either a RheoSense mVROC
microfluidic viscometer equipped with an “A” or "B” chip or a DVZT cone
and plate viscometer.
Results
Table 13 shows data for biosimilar ERBITUX® (222 i 5 mg/mL) in
the presence of five Viscosity-lowering agents: CSAA, CSAL, BSAA,
BSAL, and NSAA. Table 14 es the Viscosity reduction of biosimilar
ERBITUX® solutions using CSAA and CSAL to arginine or lysine alone.
Table 13. ities of aqueous solutions of biosimilar ERBITUX® (222
:l: 5 mglmL, pH 7.0) with 0.25 M Viscosity-lowering agents at 25°C.
Agent Viscosity (cP) Fold Reduction
ate Buffer 1130 i 7 1.0
CSA Arginine 52.5 d: 1.0 21.5
CSA Lysine 109 :1: 1 10.4
BSA Arginine 53.4:t: 5.5 21.2
BSA Lysine 126 i 1 9.0
NSA Arginine 69.4 :t 0.6 16.3
Table 14. ities of aqueous solutions of biosimilar ERBITUX® (222
:1: 5 mg/mL, pH 7.0) with 0.25 M viscosity—lowering agents at 25°C.
Agent Viscosity (cP) Fold Reduction
Phosphate Buffer 1130 i 7 1.0
CSAA 52.5 :1: 1.0 21.5
CSA Sodium 393 i 14 2.9
Arginine HCl 45.3 :1: 0.5 24.9
CSAL 109 i 1 10.4
Lysine HCI 128 i 2 8.8
The data in Table 13 Show a ion in ity of at least 90-fold
for all five Viscosity-lowering agents compared to an aqueous solution of
biosimilar ERBITUX® in phosphate buffer under otherwise the same
conditions. The most efficacious Viscosity—lowering agents, CSAA and
BSAA, lowered the solution Viscosity some 21-fold. The viscosities of
aqueous solutions of biosimilar ERBITUX® containing 0.25 M CSAA were
compared as a function ofpH at varying protein concentrations. Figure 5
demonstrates thata Viscosity minimum is observed around pH 7.0 for all
protein concentrations. The effect ofpH on viscosity is most nced for
higher protein trations (253 mg/mL in the example).
As seen in Table 15, the s solutions of biosimilar and branded
ERBITUX® have similar viscosities in the presence ofthe arginine salt
BSAA at 0.25 M .
Table 15. Viscosities of 224 :l: 4 mg/mL aqueous solutions of biosimilar
ERBITUX® or branded X® with or Without 0.25 M BSAA at
°C and pH 7.0.
Agent Biosimilar ERBITUX® Branded ERBITUX®
Viscosity (0P) Viscosity (0P)
Phosphate Buffer 1130 i: 7 556 i- 20
0.25 M BSAA 53.4 d: 5.5 44.1 i 0.5
The impact of the Viscosity-lowering agents on the formation of
irreversible protein aggregates was examined for biosimilar ERBITUX®.
Aqueous liquid formulations were prepared of (i) biosimilar ERBITUX® and
.(ii) ilar ERBITUX® containing 0.25 M CSAL. These ons were
stored for 90 days at 4°C and pH 5.4 and 7.0, tively. The stored
samples were examined using size exclusion tography (column:
Tosoh TSngl W Aggregate; mobile phase: 0.1 M potassium
phosphate/0.1 M sodium sulfate, pH 6.8 at 0.8 mL/min; injection: 20 pL of a
mg/mL mAb solution). The data in Table 16 reveal no significant
aggregate formation in either the cial drug product or high-
concentration viscosity~lowered formulation.
Table 16. Percentage of protein aggregate formation after 90 days of
storage at 4°C as measured by size exclusion chromatography for
aqueous solutions containing of biosimilar ERBITUX® with or without
0.25 M CSAL.
Sample % Monomer % Dimer % Aggregate
Biosimilar ERBITUX® 5 mg/mL 99.0 1.0 ' 0.0
Biosimilar ERBITUX® 210 mg/mL
98.4 0.9 0.7
with 0.25 M CSAL
e 9. The effect of viscosity—lowering agents on aqueous solutions
of DE®
Materials and Methods
Commercially-obtained REMICADE® containing pharmaceutical
excipients (sucrose, Polysorbate 80, sodium phosphate buffer) was prepared
as per instructions in the ibing information sheet. uently, the
aqueous drug product was d, buffer exchanged, concentrated, dried,
reconstituted, and analyzed as described in Example 1 above (using the
extinction coefficient of 1.4 L/g*cm at 280 nm). Viscosities were measured
using either a RheoSense mVROC microfluidic viscometer equipped with an
“A” or “B” chip.
Results
The data for aqueous REMICADE® solutions in Table 17
demonstrate that (i) visco sity—lowering agents containing a bulky cyclic
group e greater than 15-fold viscosity reductions, and (ii) CSAA,
CSAAPMI, and sulfosalicylic acid diarginine (SSA DiArg) e the
greatest ity reduction of about 29-fold. Solution viscosities in the
presence of ArgHCl alone are significantly higher than those with the bulky
cyclic groups.
Table 17. Viscosities of aqueous solutions of REMICADE® containing
0.25 M viscosity-lowering agents at 25°C and pH 7.0.
[REMICADE®]_Viscosity (cP)
(mg/mL)
ArgHCl CSAA CSA BSAA CSAL SSA
APMI DiArg
1557 486 i 53.7 :1: 56.3 4 92.3 i 95.3 i
222% 559$ 1.8
i 22 34 9.3 2.7 1.4 1.1
5132b 19.1 d: 31.721: 26.7:E 27.43:
166i4 110:1:1 27.1i0.3
0.2 0.3 1.2 0.2
PB = phosphate buffer; ArgHCl = argim'ne HCI; CSAA = camphorsulfonic acid
arginine; CSA APMI = camphorsulfonic acid l-(3 -aminopropyl)methyl—1H-
imidazole; BSAA = benzene sulfonic acid arginine; CSAL = orsulfonic acid
lysine; SSA DiArg Z sulfosalicylic acid di—arginine.
The dependence of the viscosity reduction on the agent concentration
was examined for aqueous solutions ofREMICADE® in the presence of
CSAA. The results presented in Table 18 demonstrate that viscosity
reduction increases with increasing agent concentration. The Viscosity
reduction, for example, is more than twice as large (the viscosity is less than
halt) with 0.35 M agent as compared to 0.20 M agent.
Table 18. Viscosity of an aqueous solution of REMICADE® (215 :l: 5
mglmL) in the presence of various trations of CSAA measured at
°C and pH 7.0.
, (M) Viscosity (0P)
0 1557 2k 22
0.20 81.3 :I: 1.0
0.25 53.7 a: 9.3
0.35 38.2 :t: 0.9
Biophysical properties of solutions CADE® formulated with
0.25 M CSAA were assessed over 90 days. Samples ofREMTCADE®
formulated with 0.25 M CSAA were prepared as described in Example 1
above. As seen in Table 19 and Figure 6, the monomer t of
trated ons of REMICADE® in 0.25 M CSAA as determined by
size exclusion chromatography (Tosoh TSngl UltraSW Aggregate column;
0.1 M potassium phosphate/0.1 M sodium sulfate buffer pH 6.8 at 0.8
mL/mjn; 20 uL injection of ~4.5 mg/mL solutions), is similar to the drug
product at all time points and no detectable ation is observed after
storage for 100 days at 4°C. The viscosity, as measured using a microfluidic
viscometer, was demonstrated to remain stable after storage for 30 days at
4°C (Table 20). Additionally, antigen binding of this processed
REMICADE® protein was ed with a REMICADE®-specific ELISA
assay and no decrease in binding was seen between days 0 and 100 (Table
). Similarly, the monomer content (Table 21) and antigen binding
(normalized to that of the drug t, Table 22) of concentrated solutions
ofREMICADE® in 0.25 M CSAA are comparable to the drug t after 1
week of storage at room temperature. Lastly, Table 23 demonstrates that
storage of a lyophilized cake containing CSAA at 4°C for 75 days has no
negative effects on the solution Viscosity or extent of protein aggregation
when the sample is tituted. The s in Tables 19-23 and Figure 6
demonstrate the biophysical stability ofREMICADE® formulated With
CSAA before and after storage for at least 100 days at 4°C.
Table 19. N0 increased ation red to drug product) is
observed in an aqueous solution of REMICADE® (227 mg/mL, pH 7)
after formulation with 0.25 M CSAA and storage at 4°C.
Day % monomer
Drug Product 99.9 i 0.03
0 99.7 i 0.07
99.7 i 0.04
100 . 99.9 i 0.1
Table 20. Reduced viscosity and antigen binding are retained over time
in an aqueous solution of REMICADE® (227 mg/mL, pH 7) after
formulation with 0.25 M CSAA and storage at 4°C.
Viscosity % binding
(0P) (ELISA)
0 65.2 a 0.7 105 i 14
62.2 :I: 1.4 98 :i: 12
100 nd. 101 i 5
Table 21. No increased aggregation (compared to drug product) is
observed in an aqueous solution of REMICADE® (219 mg/mL, pH 7)
after formulation with 0.25 M CSAA and storage at room temperature.
% monomer
Drug Product (Elia/1
D 99.7 i 0.1 99.9 :J: 0.1
4 99.9 d: 0.1 97.9 i O
7 100 i 0 100 i 0
Table 22. Antigen binding persists in an aqueous solution of
REMICADE® (219 mg/mL, pH 7) after formulation with 0.25 M CSAA
and storage at room temperature.
% binding (normalized to
drug t)
Drug Product }:
0 1002!: 12 88.6i5.2
7 100:1:28 “43:22.4
Table 23. RENEGADE® stored as a lyophilized powder retains low
viscosity and monomer content upon reconstitution after e at 4°C
for 75 days
Storage time (days) ity, cP % Monomer (SEC)
0 65.2i0.7 99..7:|:0.1
75 59.3i1.0 98.9:|:0.1
WO 38818
Example 10. The effect of Viscosity-lowering agents on aqueous solutions
of HERCEPTIN®
Materials and Methods
Commercially-obtained HERCEPTIN® containing pharmaceutical
excipients (histidine buffer, trehalose, Polysorbate 20) was prepared as per
instructions in the prescribing information sheet. Subsequently, the aqueous
drug product was purified, buffer exchanged, concentrated, dried,
reconstituted, and analyzed as described in Example 1 above (using the
extinction coefficient of 1.5 L/g*cm at 280 nm). Viscosities were measured
using a RheoSense mVROC microfluidic viscometer ed with an “A”
or “B” chip.
The data ted in Table 24 show that the Viscosity of an aqueous
solution of HERCEPTIN® containing viscosity-lowering agents - compared
to those containing PB - is lowest in the presence of CSAA. At higher
n trations (i.e. >250 Ing/mL) Arginine HCl alone reduces
Viscosity significantly and CSA further enhances the effect.
Table 24. Viscosities of aqueous solutions of HERCEPTIN® containing
0.25 M salts at 25°C and pH 7.0.
[HERCEPTIN®] Viscosity (0P)
(mg/mm
PB ArgHCl CSAA BSAA
270% 40014 7 96.7:t4.7 115m
254i3 172i5 116i24 78.04: 8.7 75.44: 5.0
216 :i: o n.d. 44.8 $1.1 55.7 :I: 2.3 n.d.
PB = phosphate buffer; ArgHCl = arginine HCl; n.d. = not determined
Example 11. The effect of viscosity-lowering agents on aqueous solutions
of TYSABRI®
Materials and Methods
Commercially-Obtained TYSABR1® containing pharmaceutical
excipients (sodium phosphate , sodium chloride, Polysorbate 80) was
purified, buffer exchanged, concentrated, dried, reconstituted, and analyzed
as described in e 1 above (using the extinction coefficient of 1.5
L/g*cm at 280 nm). Viscosities were measured using a RheoSense mVROC
microfluidio viscometer equipped with an “A” or “B” chip.
Results
The data presented in Table 25 show that the ity ion of an
aqueous solution of TYSABRI® containing viscosity~lowering agents is
approximately 25-fold (compared to solution containing PB) near 276
mg/mL protein.
Table 25. Viscosities of aqueous solutions of TYSABRI® containing 0.25
M viscosity-lowering agents at 25°C and pH 7.0.
[TYSABRI®] ity (cP)
(mg/mL)
PB ArgHCl CSAA BSAA
276 :t: s 255 d: 5 97.2 :t: 5.7 92.9 :1: 2.6 n.d.
237 a 4 182 :l: 5 52.3 a: 4.5 47.1 :I: 2.1 n.d.
230 :I: 2 n.d. 37.0 a 0.1 n.d. 34.9 :I: 1.3
PB = phosphate ; ArgHCI : arginine HCl; n.d. = not determined.
e 12. The effect of viscosity-lowering agents on aqueous solutions
of biosimilar RITUXAN®
Materials and Methods
cially-obtained biosimilar RITUXAN® containing
phantnaceutical excipients (citrate buffer, sodium chloride, and TWEEN® 80)
was purified, buffer exchanged, concentrated, dried, reconstituted, and
analyzed as described in Example 1 above (using the extinction coefficient of
1.7 L/g*cm at 280 nm). ities were measured using a RheoSense
mVROC microfluidie viscometer equipped with an “A” or “B” chip.
Rails
The data presented in Table 26 Show that the Viscosity reduction for
an s solution of biosimilar R1TUXAN® containing ity—lowering
agents is over 13-fold at approximately 213 mg/mL protein and over 5-fold
at approximately 202 mg/mL, compared to the mAb formulated in PB.
Table 26. Viscosities of aqueous solutions of biosimilar RITUXAN® with
viscosity-lowering agents at 25°C and pH 7.0.
Arg SSA SSA CSA CSA CSA
CSAA
HCl diArg diAPMI Na APMI DMP
0.45 0.25
0.25 M 0.25 M 0.25 M 0.25 M 0.25 M
M M
86.8i 533$ 45m:
211i2 103%
76.13: 78.421:
' '
. . 1.3 0.3
* [RITUXAN®] is 220 mg/mL
DMP = dimethylpiperazine
Example 13. The effect of viscosity-lowering agents on aqueous solutions
of IX®
Materials and Methods
Commercially-obtained VECTIBIX® containing pharmaceutical
excipients was purified, buffer exchanged, concentrated, dried, reconstituted,
and analyzed as described in Example 1 above (using the extinction
coefficient of 1.25 L/g*cm at 280 nrn). ities were measured using a
nse mVROC microfluidic viscometer equipped with an “A” or “B”
chip.
Rinks
The data presented in Table 27 show that the Viscosity reduction of an
aqueous solution of VECTIBIX® containing Viscosity-lowering agents is
approximately 2-fold at 291 mg/mL and 3-fold at 252 mg/mL, compared to
solutions with PB but no viscosity—lowering agents.
Table 27. Viscosities of aqueous solutions of VECTIBIX® with 0.25 M
viscositynlowering agents at 25°C and pH 7.0.
BIX®] ity (0P)
(mg/mm '
PB ArgHCl CSAA
291 :b 3 32s :I: 12 n.d. 162 3:1
264 n.d mi. 44.3 3: 2.3
252 a 3 80.3 :I: 3.3 36.2 a 1.0 27.4 3: 1.2
233i4 38.73: 1.8 24.73: 1.3 26.2i6.5
Example 14. The effect of viscosity-lowering agents on aqueous
solutions of ARZERRA®
als and Methods
Commercially-obtained ARZERRA® containing pharmaceutical
ents was purified, buffer exchanged, concentrated, dried, reconstituted,
and analyzed as described in Example 1 above (using the extinction
coefficient of 1.5 L/g*cm at 280 nm). Viscosities were measured using a
RheoSense mVROC microfluidic viscometer equipped with an “A” or “B”
chip.
Results '
The data presented in Table 28 show that the viscosity reduction of an
s solution ofARZERRA® containing viscosity-lowering agents is
approximately 3-fold at 274 mg/mL and 2-fold at 245 mg/mL, compared to
solutions with PB but no viscosity-lowering agents.
Table 28. Viscosities of aqueous ons of ARZERRA® with 0.25 M
viscosity—lowering agents at 25°C and pH 7.0.
[ARZERRA® ] Viscosity (0P)
(mg/mL) PB CSAA CSAAPMI
274 :i: 10 349 a 2 125 :l: 7 98.9 :I: 0.7
245 :l: 4 120 :i: 4 n.d. 53.6 :I: 0.6
Example 15. Comparison of Different Methods for Measuring Viscosity
Materials and Methods
Aqueous solutions containing 220 mg/mL DE® and 0.25 M
CSAA were prepared as bed above Example 1. The viscosities at 25°C
and pH 7.0 are reported in Table 29 as extrapolated zero-shear viscosities
from cone and plate viscometer measurements and as absolute ities
measured with a microfluidic viscometer. The cone and plate measurements
used a DV2T cone and plate viscometer (Brookfield) equipped with a CPE40
or CPESZ spindle measured at multiple shear rates between 2 and 400 5'1.
An extrapolated zero-shear viscosity was determined from a plot of absolute
viscosity Versus shear rate. The microfluidic viscometer measurements were
performed using a RheoSense mVROC microfluidic viscometer equipped
with an “A” or “B” chip at multiple flow rates (approximately 20%, 40%,
and 60% of the maximum pressure for each chip).
Results
The data in Table 29 demonstrates that the absolute Viscosities from
the microfluidic eter can be directly compared to the extrapolated
zero-shear ities determined from the cone and plate viscometer.
Table 29. Viscosities of s solutions of REMICADE® (220 mg/mL)
with 0.25 M CSAA at 25 °C and pH 7.0 measured on two different
viscometers.
Instrument Viscosity (0?)
Cone and plate
62.3 :1: 0'1
viscometer (C&P)
Microfluidic eter
53 7 i. 9 3.
on a chip (mVROC)
In order to compare a broader range of Viscosities and protein
concentrations, aqueous solutions of a model antibody, bovine gamma
globulin, were prepared with and Without 0.25 M CSAL. The viscosities
were measured as described above at protein concentrations ranging from
110 mg/mL to 310 mg/mL. The data presented in Table 30 demonstrates that
the absolute viscosities from the microfluidic viscometer can be directly
compared to the olated zero—shear viscosities for both low and high
viscosity n solutions.
Table 30. Viscosities of aqueous gamma globulin solutions with and
without 0.25 M CSAL at 25°C and pH 7.0 measured on two ent
eters.
Viscosity (cP)
[gamma
globulin] without CSAL With CSAL
(mg/mm
microfiuIdlc. . . C & P microfluldic. . .
C & P
110 3.81s: 0.19 2.66 :t 0.01 n.d. n.d.
170 12.0i0.6 11.0i0.1 10.3 :t 1.0 10.6i0.1
260 167 3:1 161 :1: 1 93.5 $1.2 85.3 i 0.3
310 399i1 377322 223i1 203i2
Example 16. Viscosity—lowering agents show no signs of toxicity when
injected subcutaneously
Materials and Methods
Thirty 11-week old euDaney rats were separated into 6
groups of 5 rats each (3 saline control groups and 3 CSAA groups). The rats - ~ -
were injected subcutaneously with 0.5 mL of either endotoxin—free
phosphate—buffered saline or endotoxin—free 0.25 M CSAA according to the
following schedule: One group from each condition was injected once on day
1 and then sacrificed 1 hour later; one group from each condition was
injected once on day 1 and once on day 2 and then sacrificed 24 hours after
the second injection; and one group from each ion was injected once
on day 1, once on day 2, and once on day 3, and then sacrificed 24 hours
after the third injection.
Clinical observations were recorded for any co-toxicological
signs pre-dose, immediately postudose, at l and 4 hours (3: 15 minutes) post-
dose, and daily thereafter. Irritation, if any, at injection sites was scored
using the Draize evaluation scores pre-dose, immediately post—dose, at 1
hour (3:15 minutes) post close, and prior to sacrifice.
Results
Overall, the observed consequences of the injections of saline and
CSAA were macroscopically r throughout the course of the study.
Both induced from no irritation to slight irritation with edema scores of 0-2
at various time points. Microscopic examination of injection sites suggests a
very minor, clinically insignificant, irritative effect with CSAA that was no
longer evident by day 4.
Example 17. Concentrated aqueous solutions of REMICADE®
formulated with viscosity-lowering agents t low syringe extrusion
forces and high monomer content when expelled through various gauge
needles.
Materials and Methods
Commercially-obtained REMICADE® containing pharmaceutical
excipients (sucrose, Polysorbate 80, sodium phosphate buffer) was prepared
per instructions in the prescribing information sheet. Subsequently, the
aqueous drug product was purified, buffer exchanged, concentrated, dried,
reconstituted, and ed as described in Example 1 above (using the
extinction cient of 1.4 L/g*cm at 280 nm). 20 mM solutions of either
phosphate buffer, CSAAPMI or CSAA were used for buffer exchange, and
the lized cakes were tituted to 0.25 M of each Viscosity-
lowering agent. Following reconstitution, the Viscosity of each solution was
measured using the microfluidic viscometer as described in previous
examples. The solutions were then back-loaded into 1 mL BD n
syringes with 27, 29, or 31 gauge fixed s. The force required to
extrude the concentrated REMICADE® solutions was then ed using
an Instron at a rate of displacement lent to a fluid flow rate of 3
mL/min. The expelled solution was collected from the syringe and analyzed
by size-exclusion chromatography.
RLHI’ES
All REMICADE® solutions containing viscosity-lowering agents
were able to be expelled h the syringes at vely low extrusion
forces (Table 31). The solution containing phosphate buffer could not be
expelled due to high viscosity. Both solutions containing ity—lowering
agents retained high monomer content post-extrusion regardless of needle
WO 38818
gauge, as indicated in Table 31.
Table 31. Syringeability of concentrated aqueous solutions of
REMICADE® extruded through various gauge needles.
[REMICADE ®I
Needle Syringe
Agent (mg/mL) % Monomer
gauge Force (N)
(viscosity in c?)
0.25 M 27
ate 220 (1,500)
could not be
Buffer -29 extruded
0.25 M
230(90.8:t8.4)
cs FMI
29 99.0 :I: 0.0
0.25 M 99.5 d: 0.1
224 (60.9 2121.1)
CSAA
29 99.4 i 0.2 24.9
Example 18: Viscosity-lowering agents reduce the viscosity of
concentrated aqueous solutions of biosimilar AVASTIN®
Materials and Methods
A commercially—obtained biosimilar AVASTIN® containing
ceutical excipients (Polysorbate 20, phosphate and citrate buffers,
mannitol, and NaCl) \vas purified. First, rbate 20 was removed using
DETERGENT-OUT® TWEEN Medi Columns (G-Biosciences). Next, the
resulting solutions were ively buffer—exchanged into 20 mM sodium
phosphate buffer (PB) for PB samples and 2 mM PB for viscosity-lowering
agent samples, and concentrated to a final volume of less than 10 mL on
2014/055254
Jumbosep centrifugal concentrators (Pall Corp). The viscosity-lowering
agent was then added to the 2 mM PB samples as described in Example 4
above. The Viscosity-lowering agent(s) were added in an amount sufficient to
give concentration upon reconstitution as specified below. In cases of
combinations of agents, the concentration of each component is 0.15 M. The
protein solutions were then freeze-dried. The dried protein cakes were
reconstituted in phosphate buffer (for PB samples) or water (for s
containing viscosity-«lowering agents) to a final volume of approximately
0.10 mL. The final tration ofmAb in solution was determined by
either a Coomassie protein quantification assay by comparing unknown
concentrations of s to a standard curve of biosimilar AVASTIN® or by
A280 using the extinction coefficient of 1.7 L/g*cm, when possible.
Viscosities reported were measured on a RheoSense mVROC microfluidic
eter. Results are reported in Table 32.
Many GRAS, 116, and API compounds are capable ofreducing the
viscosity of concentrated biosimilar AVASTIN® solutions relative to
phosphate-buffered samples. Of those nds included in Table 32, local
anesthetics such as procaine and lidocaine, as well as GRAS agents such as
biotin are among the most efficacious Viscosity reducing exeipients.
Table 32: Effect of Viscosity-Lowering Agents on ons of Biosimilar
AVASTIN®.
[Biosimilar
AVASHNfi,
mg/ml IIIIHHHHHIIIIII
0.25 M Phosphate Buffer
CSA-l t01ybiguanide :1:
CSA--Na-aminocyclonexane 01
carboxylic acid
Ethane disulfonate-diTris—
2Na 219 >150
CSA—piperazineT 212 t 0 64.5
Sulfacetamide-Na 214 1 13
Trimetaphosphate-3Na 21 1 121
Creatinine (0.6 M)
Creatinine (0.3 M)
—---
Glucuronic acid-Tris
Procaine HCl
Lidocaine HCl
N—(4-Pyridiy1)pyridinium Cl
Creatim'ne Thiamine HCl
Pyridoxine
Wm —-II
"III
Chloroquine Phosphate (0.10—
586II
718II
Scopolamine HBr III
_imetidineHCI 203
iptan Succinate (0.25
vir hydrate (0.02 M)-
Piperacillin sodium salt
Colistin sulfate salt
Ceftriaxone sodium salt
Cefazolin
Granisetron HCI
'i'Average of two biological replicates
CSA = camphorsulfonic acid.
Example 19. Viscosity Reduction is an Agent—Concentration-Dependent
Effect
Materials and Methods
Aqueous solutions of a commercially-obtained biosimilar
AVASTIN® were ed as described in Example 4. The dried protein
cakes were reconstituted in phosphate buffer or water to a final volume of
about 0.10 mL and a final 1-(3 —a.r_n_inopropy1)_—2_-methy_l-1H—imidaz_ole
dihydrochloride (APMI*2HCl) concentration of either 0.10 or 0.25 M. The
final concentration ofmAb in solution was determined by a Coomassie
protein quantification assay by comparing unknown trations of
samples to a standard curve of biosimilar AVASTIN®. Viscosities reported
were measured on a RheoSense mVROC microfluidic viscometer.
Results
As depicted in Figure 7, Viscosity-lowering effect was increased as
the concentration of HCI was increased.
Example 20. A single viscosity-lowering agent lowers the ity of
many therapeutically relevant monoclonal antibodies
Materials and Methods
Aqueous ons of a commercially-obtained biosimilar
AVASTIN® were prepared as described in Example 4. The dried protein
cakes were reconstituted in phosphate buffer or water to a final volume of
about 0.10 mL and a final thiamine HCl concentration of 0.10 or 0.25 M.
The final concentration ofmAb in solution was determined by a Coomassie
protein fication assay by comparing unknown concentrations of
samples to a standard curve of biosimilar AVASTIN®.
Commercially—obtained TYSABRI® containing pharmaceutical
excipients (sodium ate buffer, NaCl, Polysorbate 80) was purified,
buffer exchanged, concentrated, dried, reconstituted, and ed in the
same manner. Commercially-obtained HERCEPTTN® containing
ceutical excipients (sodium phosphate buffer, NaCl, Polysorbate 80)
was purified, buffer exchanged, concentrated, dried, reconstituted, and
analyzed in the same manner. Commercially obtained biosimilar ERBITUX®
containing pharmaceutical excipients (Polysorbate 80, phosphate buffer, and
NaCl) was purified, buffer exchanged, concentrated, dried, tituted and
analyzed in the same manner. Commercially—obtained REMICADE®
containing pharmaceutical ents (sucrose, Polysorbate 80, sodium
phosphate buffer) was prepared as per instructions in the prescribing
ation sheet. Subsequently, the aqueous drug product was purified,
buffer exchanged, concentrated, dried, reconstituted, and analyzed as
described in the same manner. Viscosities reported were measured on a
RheoSense mVROC microfluidic viscometer. _
Results
The data in Table 33 demonstrate that thiamine HCl can lower the
viscosity of concentrated aqueous solutions ofmany eutically relevant
mAbs. Thiamine HCl can produce a greater than 4—fold Viscosity reduction
for each mAb.
Table 33: Effect of Thiamine HCl on Solution Viscosity.
[Excipient] ,
Viscosity, cP
Biosimilar '
Thiamine
TYSABRI®
Thiamine
HERCEPTIN®
Thiamine
Biosimiiar 235 1370i 3
ERBITUX®
Thlamme. ,
0.15
HCl 245 29.5 :i: 0.9
PB 0.25
176 432 i 30
Thiamine
0.15
H01 178 40.7 :I: 0.3
Examples 21~24. Viscosity~lowering agents reduce the viscosity of
aqueous ons of many therapeutically relevant monoclonal
antibodies
Materials and Methods
Aqueous ons of commercially-obtained ilar RITUXAN®,
TYSABRI®, HERCEPTIN®, biosimilar ERBITUX®, and REMICADE®
were prepared as described in es 18 and 19. Tables 34-38
demonstrate that viscosity-lowering agents can be advantageously employed
for many different monoclonal antibodies.
Results
Table 34: Viscosities of Aqueous Solutions of Biosimilar RITUXAN® in
the Presence of 0.15 M Viscosi —Lowerin_ A_ents
[biosirnilar
RITUXAN®],
Viscosity, cP
mg/ml
0.25 M Phosphate Buffer 215
CSA— 1-o-tolybiguanide 190
HEPES- Tris 191
CSA—Na—Creatinine (0.3 M) 190
CSA-Na—aminocyciohexane
carboxylic acid 191 61.3.-d: 2.5
Ethane disulfonate- diTris-
2Na 191 80.3.-i 16.0
CSA—piperazine 191 57.5 :1:
Sulfacetamide-Na 181 64.1 A:
CSA-Tris 191 59.1 d:
Creatim'ne (0.6 M) 197 28.4 i
--EI
CSA—4-amino pyridine
“III
I—III
I—III
Glucummc ris
Lu U1
CSA-Na—Omidazole
Proceu'ne HCl
Metoclopramide HCl
Scopolamine HBI‘
--lm
———fll
Chloroquine Phosphate
(0 10 M)
Penicillin G sodium salt -11
Piperacillin sodium salt -:
Moxifloxacin HCl
Ceftriaxone sodium salt
2014/055254
mycin Phosphate —19
Colistin sulfate salt _22
TAverage of 1two biological
replicates
Table 35: Viscosities of Aqueous Solutions of TYSABRI® in the
Presence of 0.15 M Viscosity-Lowering Agents (Unless Otherwise
Indicated).
[TYSABRI®},
Vlscosfiy, 0P. .
Agent
mg/mL
3 10 71 5 i 106
PB 278 255 " :l: 5
23 7 182 :1: 6
Creatinine (0.30 M) 219 40.8 i 1.8
Procaine HCI 228 45.1 i 1.5
Biotin Na 233 75 .8 i 0.4
Thiamine HCl (0.10 M) 244 43 .4 i 0.7
Table 36: Viscosities of Aqueous Solutions ofHERCEPTIN® in the
Presence of 0.15 M ity—Lowering Agents (Unless Otherwise
Indicated).
[HERCEPTINCE],
Agent Viscosity, cP
mg/mL
272 400 i 4
253 172 :l: 5
239 122 i 17
218 71.6 H. 3.9
Creatinine (0.3 M) 222 45.7 0.3
Procaine HCl 222 41.8 0.6
CSA piperazine 236 50.3 0.6
GSA-Na Olrnidazole 232 60.1 0.6
Biotin-Na 230 69.9 2.3
Thiamine HCl (0.10 M) 245 41.5 444444 0.5
Table 37: Viscosities of Aqueous Solutions of ERBITUX® in the Presence
of 0.15 M Viscosity~Lowering Agents (Unless Otherwise Indicated).
[ERBITUX®],
Agent Viscosity, cP
mg/mL
235 1370
0* '
Creatinine (0.30 M) 240 131 :t 4
Procaine HCl 230 35.9 3: 0.3
ine HCl 223 33.8 d: 0.4
Niootinamide 232 292 :1: 10
RiboflavinPhosphate (0.1 0
M) 237 492 3: 9
djne HCl 183 19.7 :I: 0.2
Metocloprmhide HCl 172 23.0 :I: 0.2
Granisetron HCl 180 23.0 :1- 0.2
Scopolamjne HBr 173 23.4 :1: 0.6
caine HCl 182 27.8 3: 0.2
Clindamycin Phosphate 209 36.5 3; 0.0
179 37.4 :I: 0.9
Chloroquine Phosphate (0.10
M) 199 54.8?02
Phenylephrine HCl 183 54.1 :I: 2.9
Moxifloxacin HCl 186 66.7 :I: 1.0
Piperacillin sodium salt 182 75.3 at 1.6
Penicillin G sodium salt
Levetiracetam
Fosphenytoin disodium salt
Ceftriaxone sodium salt
Colistin sulfate salt 203 138 :l: 4
Cefoxitin sodium salt 194 166 :l: 8
Aztreonam (0.02 M) 179 256 :l: 4
Cidofovir hydrate (0.02 M) 189 284 :1: 5
Table 38: Viscosities of Aqueous Solutions of REMICADE® in the
Presence of 0.15 M Viscosity-Lowering Agents s Otherwise
Indicated).
[REMICADE®],
Agent Viscosity, CF
mg/mL
PB 176 432 30
Creatinine 144 37.1 0.5
Procaine HCl 174 23.4 0.2
Thiamine HCI 178 40.7 0.3
Example 25. Viscosity-lowering effect of TPP and TPPAPNII, as a
function of concentration of biosimilar AVASTIN®
Aqueous ons of a commercially-obtained biosimilar
N® were prepared as bed in Example 1 above. The protein
was formulated to contain either 0.25 M phosphate buffer, 0.10 M ne
pyrophosphate (TPP), or 0.10 M TPP- 1-(3-aminopropyl)methyi-1H-
imidazole (TPPAPMI).
Figure 8 depicts the viscosity of aqueous biosirnilar AVASTIN®
solutions as a function ofmAb concentration with either ate buffer,
TPP, or TPPAPMI. The viscosity of nilar AVASTIN® in phosphate
buffer increases exponentially within the tested protein concentration range.
In the presence of TPP-containing excipients, the se in viscosity is
attenuated i.e. the viscosity gradient is reduced.
Example 26: Viscosity-reducing effect of a viscosity—lowering agent,
thiamine HCl, as a function of tration of biosimilar SIMPONI
ARIA®
Materials and s
SIMPONI ARIA® ed commercially and containing
pharmaceutical excipients (Histidine, ol, Polysorbate 80) was purified,
buffer exchanged, concentrated, dried, reconstituted, and analyzed as
described in e 1 above (using the extinction coefficient of 1.4 L/g-crn
at 280 nm). The protein was formulated to contain either 0.15 M phosphate
buffer or 0.15 M thiamine HCl.
Results
Figure 9 depicts the viscosity of aqueous SIMPONI AR1A® solutions
as a function ofmAb concentration with either phosphate buffer or thiamine
HCl. The viscosity of I ARIA® in ate buffer increases
exponentially within the tested protein concentration range. In the presence
ofthiamine HCl, the increase in viscosity is attenuated i.e. the Viscosity
gradient is reduced.
Example 27. Viscosity-lowering effect of Thiamine I-ICl, as a function of
concentration ofENBREL®
Materials and Methods
® obtained commercially and containing pharmaceutical
excipients (Mannitol, Sucrose, Tromethamine) was purified, buffer
exchanged, concentrated, dried, reconstituted, and analyzed as described in
Example 1 above (using the extinction coefficient of 0.96 L/g-crn at 280
um). The protein was formulated to contain either 0.15 M phosphate buffer
or 0.15 M Thiamine HCl.
Realms
Table 39 depicts the Viscosity of aqueous ENBREL® solutions with
either phosphate buffer or thiamine HCl. The addition ofthiamine HCI
reduces the ity ofENBREL® up to about 2-fold.
Table 39: Viscosities of s Solutions of ENBREL® in the Presence
of 0.15 M PB or Thiamin HCl
[ENBREL] 0.15 M Th1am1n
0.15 M PB
,mg/mL HCl
271m 1120 1:26 626:}:32
250a3 439 in 305i7
212M 316 in l41:|:3
Example 28. Isotonic solutions of viscosity-lowering excipients reduce
the viscosity of concentrated solutions of REMICADE®
als and Methods
Commercially-obtained REMICADE® containing pharmaceutical excipients
(sucrose, Polysorbate 80, sodium phosphate buffer) was prepared as per
instructions in the ibing ation sheet. uently, the aqueous
drug product was purified, buffer exchanged, concentrated, dried,
reconstituted, and analyzed as described in Example 1, except that isotonic
amounts of d hydrophobic compounds were added.
Results
As demonstrated in Table 40, isotonic amounts of both CSAA and
CSAAPMI are capable of substantially reducing the Viscosity of
concentrated solutions ofREMICADE®, in some cases by up to about 10-
fold.
Table 40. Viscosities of ons of
REMICADE® in the presence of isotonic (0.3
molal) viscosity-lowering excipients
Salt [RIiEgrfigEqa] Viscosity (GP)
PB 171 432 :l: 30
CSAAPMI 167 41.4 :1: 0.7
PB 131 175 d: 15
CSAAPMI 124 16.4 :I: 1.2
CSAA 128 25.8 :I: 0.8
Unless sly defined otherwise above, all technical and scientific
terms used herein have the same meanings as commonly understood by one
of skill in the art. Those skilled in the art will recognize, or will be able to
ascertain using no morehthan routine mentation, many equivalents to
the specific embodiments ofthe invention described herein. Such
equivalents are intended to be encompassed by the following claims.
Claims (26)
1. A liquid pharmaceutical formulation for ion comprising: (i) at least about 100 mg/ml of an antibody; (ii) thiamine or a pharmaceutically acceptable salt f; and (iii) a pharmaceutically able solvent; wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an te viscosity of from about 1 cP to about 100 cP at 25°C as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute ity of the liquid pharmaceutical formulation is less than the absolute viscosity of a control formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the thiamine or a pharmaceutically acceptable salt thereof; wherein the absolute viscosity is an extrapolated zero-shear viscosity.
2. The liquid pharmaceutical formulation of claim 1, wherein the antibody is a monoclonal antibody.
3. The liquid pharmaceutical formulation of claim 1 or 2, wherein the antibody has a molecular weight of from about 120 kDa to about 250 kDa.
4. The liquid pharmaceutical formulation of any one of the previous claims, comprising from about 100 mg/ml to about 300 mg/ml of the antibody.
5. The liquid pharmaceutical formulation of any one of the previous claims, comprising from about 178 mg/ml to about 245 mg/ml of the antibody.
6. The liquid pharmaceutical ation of any one of the us claims, wherein the pharmaceutically acceptable solvent is s.
7. The liquid pharmaceutical formulation of any one of the previous claims, wherein the ne or a pharmaceutically acceptable salt thereof is present at a concentration of from about 0.01 M to about 1.0 M.
8. The liquid pharmaceutical formulation of any one of the previous claims, wherein the thiamine or a pharmaceutically acceptable salt thereof is present at a concentration of from about 0.15 M to about 0.25 M.
9. The liquid pharmaceutical formulation of any one of the previous claims, further sing one or more pharmaceutically acceptable excipients sing a sugar, sugar l, buffering agent, preservative, carrier, antioxidant, ing agent, natural polymer, synthetic polymer, cryoprotectant, lyoprotectant, tant, bulking agent, izing agent, or any combination thereof.
10. The liquid pharmaceutical formulation of claim 9, wherein the sugar alcohol is sorbitol or mannitol.
11. The liquid pharmaceutical formulation of claim 9, wherein the one or more pharmaceutically acceptable excipients comprise a polysorbate, mer 188, sodium lauryl sulfate, a polyol, a poly(ethylene glycol), ol, a propylene glycol, or a poly(vinyl alcohol).
12. The liquid ceutical formulation of any one of the previous claims in a unitdose vial, multidose vial, cartridge, or pre-filled syringe.
13. The liquid pharmaceutical formulation of any one of the previous claims, wherein the liquid pharmaceutical formulation is reconstituted from a lyophilized composition.
14. The liquid pharmaceutical formulation of any one of the previous claims, wherein the liquid pharmaceutical formulation is isotonic to human blood serum.
15. The liquid pharmaceutical formulation of any one of the previous , wherein the absolute viscosity is measured at a shear rate of at least about 0.5 s-1 when measured using a cone and plate viscometer, or a shear rate of at least about 1.0 s-1 when measured using a microfluidic eter.
16. Use of the liquid pharmaceutical formulation of any one of the previous claims in the manufacture of a medicament for administering to a subject a therapeutically effective amount of an antibody, wherein the medicament is formulated for subcutaneous or intramuscular injection.
17. The use of claim 16, wherein the medicament is formulated for injection with a syringe.
18. The use of claim 17, wherein the syringe is a heated syringe, a self-mixing syringe, an auto-injector, a pre-filled syringe, or combinations thereof.
19. The use of claim 18, wherein the syringe is a heated syringe and the medicament is formulated to have an administration temperature between 25°C and 40°C.
20. The use of any one of claims 16-19, wherein the medicament is formulated to produce a primary irritation index of less than 3 when evaluated using a Draize scoring system.
21. The use of any one of claims 16-20, n the medicament is formulated to be administered with an ion force that is at least 10% less than an injection force for a control composition comprising the antibody and the ceutically able solvent, but without the thiamine or a pharmaceutically acceptable salt thereof, when administered in the same way.
22. The use of any one of claims 16-20, wherein the medicament is formulated to be administered with an injection force that is at least 20% less than an injection force for a control composition comprising the antibody and the pharmaceutically acceptable solvent, but without the thiamine or a pharmaceutically acceptable salt thereof, when stered in the same way.
23. The use of any one of claims 16-22, wherein the medicament is ated for administration with a needle between 27 and 31 gauge in diameter and with an injection force less than 30 N with the 27 gauge needle.
24. A method of preparing the liquid pharmaceutical formulation of any one of claims 1- 15, comprising the step of combining the dy, the pharmaceutically acceptable solvent, and the thiamine or a ceutically acceptable salt thereof.
25. A lyophilized composition comprising: (i) an antibody; (ii) ne or a pharmaceutically acceptable salt thereof; and (iii) a pharmaceutically acceptable excipient.
26. The lyophilized composition of claim 25, wherein, once reconstituted, the antibody has a concentration of at least 100 mg/ml.
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361876621P | 2013-09-11 | 2013-09-11 | |
US61/876,621 | 2013-09-11 | ||
US201461940227P | 2014-02-14 | 2014-02-14 | |
US61/940,227 | 2014-02-14 | ||
US201461943197P | 2014-02-21 | 2014-02-21 | |
US61/943,197 | 2014-02-21 | ||
US201461946436P | 2014-02-28 | 2014-02-28 | |
US61/946,436 | 2014-02-28 | ||
US201461988005P | 2014-05-02 | 2014-05-02 | |
US61/988,005 | 2014-05-02 | ||
US201462008050P | 2014-06-05 | 2014-06-05 | |
US62/008,050 | 2014-06-05 | ||
US201462026497P | 2014-07-18 | 2014-07-18 | |
US62/026,497 | 2014-07-18 | ||
US201462030521P | 2014-07-29 | 2014-07-29 | |
US62/030,521 | 2014-07-29 | ||
NZ717944A NZ717944B2 (en) | 2013-09-11 | 2014-09-11 | Liquid protein formulations containing viscosity-lowering agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ756260A NZ756260A (en) | 2021-06-25 |
NZ756260B2 true NZ756260B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202407B2 (en) | Liquid protein formulations containing viscosity-lowering agents | |
US20240181063A1 (en) | Liquid Protein Formulations Containing Viscosity-Lowering Agents | |
NZ756260B2 (en) | Liquid protein formulations containing viscosity-lowering agents | |
RU2782765C2 (en) | Liquid protein compositions containing viscosity-reducing agents | |
NZ717944B2 (en) | Liquid protein formulations containing viscosity-lowering agents | |
NZ717918B2 (en) | Liquid protein formulations containing ionic liquids | |
BR112016005309B1 (en) | LIQUID PHARMACEUTICAL FORMULATION COMPRISING CIMETIDINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND USE THEREOF | |
NZ756401B2 (en) | Liquid protein formulations containing ionic liquids | |
BR122021023271B1 (en) | LIQUID PHARMACEUTICAL FORMULATION COMPRISING THIAMINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND USE THEREOF | |
BR122021023267B1 (en) | LIQUID PHARMACEUTICAL FORMULATION, ITS USE AND ITS PREPARATION METHOD |